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1 Abstract 
The design of innovative medical device requires extensive and hard efforts to reach good 
results in terms of safety, efficacy and cost effectiveness. First of all the idea has to be set and 
a wide search of state of the art, both technological and academic, has to be developed. Then 
the materials, manufacturing processes and design constraints have to be understood. In this 
work three examples of innovative surgical devices for minimally invasive surgery and 
assistance have been presented. 
The Muneretto Beam catheter is a new device for atrial defibrillation. Starting from a catheter 
produced by Estech1 company for the treatment of atrial fibrillation by ablating cardiac tissue 
during surgery, a system for the magnetic guidance of the same has been implemented. 
Thanks to finite element analysis of various configurations of magnets and to several in vitro 
tests, a final configuration which allows a good balance between the sliding of the catheter on 
the tissues and the magnetic interaction and adhesion to tissues has been found. Further 
attention has been taken to the development of the cover and the right configuration and  
method of use of the device. 
The VideoDrain system is a new catheter for the monitoring of post-operative wound. After 
critical surgical procedures it is necessary to monitor the status of the surgical wound for 
avoiding second look surgical interventions. Therefore a new balloon catheter for allowing the 
vision of the abdominal cavity has been produced. Several in vitro and in vivo trials have been 
conducted and the device is at the pre-industrial stage. 
The FloSeal GI cath. is a new device for the gastrointestinal release of an haemostatic 
substance of the Baxter2 company: the Floseal thrombin matrix. It consists in a balloon 
catheter suited for the use in the lower and upper gastrointestinal tract in the occurrence of 
bleedings during endoscopic procedures. This device has been CE labelled and is now on the 
market. 
All the devices described in this work come from ideas of surgeons leader in innovation in the 
field of minimally invasive interventions. Their collaboration has been fundamental for the 
several phases of design and tests of the devices.   
This Ph.D. thesis is divided into five chapters. In the Introduction chapter the process of 
research and development of innovative MDs for minimally invasive surgery has been 
illustrated. The second chapter shows the efforts done to find a working configuration for the 
Muneretto Beam catheter and the subsequent first prototypes developed. The progress in the 
design of VideoDrain has been explained in the third chapter; the whole process goes from 
the idea to the animal test on prototypes and a preliminary risk analysis. The development of 
the Floseal GI Catheter is depicted in the fourth chapter; all the details of the materials used 
and tests done to ensure a CE mark have been reported. Finally, in the Conclusion chapter I 
have reported some lessons learned from the work in the field of MDs, as a student, 
researcher and engineer at close contact with the world of surgery and minimally invasive 
technologies. Some papers about a preliminary research activity in the field of minimally 
invasive surgery and robotic interventions have been also enclosed. These works have been 
very useful to start the understanding of the complex and amazing world of MIS.  
                                                     
1
 http://www.estech.com/ 
2
 http://www.baxteritalia.it/ 
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3 Research and Development of medical devices 
3.1 Design for Minimally Invasive Surgery 
The medical practice is constantly being qualified through technological advances brought 
about by new Medical device (MD). Bringing a MD to the marketplace can be a long and hard 
road. In this Ph.D. thesis, a strategy to develop innovative MDs for various applications in 
minimally invasive surgery will be analyzed and implemented in few case studies. 
 
Figure 1 Minimally invasive surgery (MIS) procedures 
Using laparoscopic techniques, specialized equipment and at times robotic assistance, the 
expert surgeons are able to make tiny, precise movements through very small incisions. These 
innovative techniques cause minimal trauma to the body. Minimally invasive surgery can offer 
the following advantages to the patients: 
 Smaller incision, which reduces pain and shortens recovery time, as well as 
resulting in less post-operative scarring  
 Reduced hemorrhaging, which reduces the chance of needing a blood transfusion. 
 Less pain, leading to less pain medication needed 
 Although procedure times are usually slightly longer, hospital stay is less, and often 
with a same day discharge which leads to a faster return to everyday living 
 Reduced exposure of internal organs to possible external contaminants thereby 
reduced risk of acquiring infections. 
The various step (see Figure 2) through a valid development of MD starts from the 
specification of an idea, born from a real need of improvement of patients’ quality of life. 
Anatomical and physiological knowledge and a full medical literature research are necessary 
to implement that idea. Many of these devices are invented by the physicians who foresaw 
the potential benefits the new device would have on their own practice and that of their 
colleagues. After a specific market analysis and a feasibility study a first prototype is made in 
order to assure some initial critical aspects. Thanks to the close cooperation with surgeons 
and observation of clinical practice, a phase of co-invention starts. Engineers and surgeons 
cope to find a common language and define strict specification for a prototype which become 
a “proof of concept”. Around this tangible idea active business and feasibility plans are 
compiled. The device must respect some fundamental issues in order to be acceptable for 
production. First of all the marketability and effectiveness. They must assure a reduced 
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recovery and hospitalization time. With the use of the new device the abilities of the surgeon 
should be increased and the procedures simplified. Ergonomics and usability must be pursued 
in the design. 
 
Figure 2 The rules of safe and effective Innovation 
Protecting and licensing commercial rights for a new MD could mean the difference between 
success or failure. A patent protects against the unauthorized use of an idea and the inventor 
of a MD should take advantage of the available intellectual property rights to protect and 
defend against the unlawful infringement or theft of valuable intellectual property associated 
with a new MD.  
In conjunction with protecting the idea, it is necessary to develop a strategic business plan. It 
has several purposes. First, it will help to identify a "roadmap" for how the MD can be 
successfully marketed and define benchmark objectives and realistic dates to achieve those 
goals. Second, the strategic business plan is imperative if the company will need to raise 
equity or borrow money to fund the business venture. 
The cost and the safety are key issues for a MD. The material, the technologies and the 
processes used must be compliant with regulations. The device must be approved, certified 
and classified with existing legislation depending from the country of deployment of the 
device. 
The life of a MD can be divided in seven phases (1) from conception and development to 
disposal. The systems and devices described in this PhD work are enclosed in the first pre-
market phase through various level of examination (Figure 3). 
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Figure 3 Medical Device life span and subjects involved in each phase 
3.2 Methodologies for design and development of innovative devices 
TRIZ is a method and a set of tools developed in Russia in 1946; starting from the examination 
of a very large number of patents, it deducts the general laws underlying the evolution of 
technical systems and propose a system to develop innovative solutions. The search of 
solutions is methodical and is obtained overcoming the technical and physical contradiction 
which comes with the search of improvement. In Figure 4 3it is represented the process of 
development of new innovative products. All the main activities (violet) are surrounded by 
sub-activities (green) which contribute to clarify and analyze the work in a systematic way.  
                                                     
3
 JOC- Job Outcomes and Constraints 
CAM-Computer Aided Manufacturing 
CAE- Computer Aided Engineering 
CIM-Computer Integrated Manufacturing 
FEM-Finite Element method 
MRP-Material Requirements Planning 
MKTG-Marketing 
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Figure 4 Development of new products 
The design process followed in this work represents an implementation of the above scheme 
and it can be summarized in the following phases: 
 Clear Identification of the intended use 
 Analysis of the medical background 
 Market analysis 
 State of the art and patent search 
 Analysis of potential configurations and associated CAD4 
 Analysis and search of materials, components 
 Realization of Prototypes 
 Preliminary tests and FEM 
 Choice of final configuration 
 Deployment of the device 
 Mechanical strength tests 
 In vivo tests 
 Study and editing of technical file and Instruction of Use 
 CE mark, labelling, packaging 
 Post market surveillance. 
Some characteristics (2) in healthcare device design can be identified and Each of them is 
briefly described below: 
                                                     
4
 CAD Computer Assisted Drawing 
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 Functionalism refers to the belief that the intended function of something should 
determine its design, construction, and choice of materials. It is also seen as a 
philosophy which emphasizes on practical and utilitarian concerns 
 Ergonomics is the scientific discipline concerned with the understanding of 
interactions among humans and other elements of a system, and the profession 
that applies theory, principles, data, and methods to design in order to optimize 
human well-being and overall system performance. In medical design, the domain 
of ergonomics mainly refers to physical ergonomics, which deals with the human 
body's responses to physical and physiological loads 
 Technology can refer to the development and application of techniques for 
manufacturing and productive processes; a method of applying technical 
knowledge, and a sum of practical knowledge with regards to material culture 
 Appearance and Aesthetics refers to product qualities such as smoothness, 
shininess/reflectivity, texture, pattern, curviness, color, simplicity, usability, 
velocity, symmetry, naturalness, and modernism 
 Universal Design is related to "inclusive design" and "design for all," is an approach 
to the design of products, services and environments to be usable by as many 
people as possible regardless of age, ability or situation 
 User experience and Emotional Design is about improving people psychologically to 
feel that they are recuperating better overtime.  
During the design phase the principles of Human Factor Engineering has been followed; its 
application to system design improves ease of use, system performance and reliability, and 
user satisfaction, while reducing operational errors, operator stress, training requirements, 
user fatigue, and product liability. In Medical device design it is very important not to forget 
that the beneficiary of the invention and its user are the patient and the medical professional, 
so all the efforts of the designer must be focused on these subjects’ needs. 
Addressing use-related hazards should be undertaken within the context of a thorough 
understanding of how a device will be used.  Essential components of this understanding 
include: 
 Device users, (e.g., patient, family member, physician, nurse, professional 
caregiver) 
 Typical and atypical device use 
 Device characteristics 
 Characteristics of the environments in which the device will be used 
 The interaction between users, devices, and use environments. 
Following a thorough understanding of device use, specific ways that devices could be used, 
that are likely to result in hazards, should be identified and investigated through analysis and 
testing. In addition to investigating known or suspected problems with device use, testing 
prototype devices with users can identify ways of using devices that could be hazard-related, 
that were not anticipated. This is important because it is extremely difficult to identify all 
significant device use problems in advance. 
After use-related hazards are understood, the hazards are mitigated or controlled by 
modifying  the device user interface (e.g., control or display characteristics, logic of operation, 
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labelling) or the abilities of users to use the device (e.g., training, limiting use to qualified 
users).  
3.3 Design of medical components 
3.3.1 Microtubes 
The main sub components used for minimally invasive devices are catheters, available in 
different configurations and materials. Catheters are medical devices, typically in the form of 
a tube, that are inserted into the body to remove fluid, create an opening, or deliver a drug. 
All the device described in the current work rate catheters of different shapes and dimensions 
between their main components. 
Among the main design qualities of tubings (3), the profile or form factor as well as its 
trackability, pushability, and torqueability can be mentioned. Trackability means the ability of 
a catheter to go through tortuous paths to its ultimate destination. It depends on: 
 Shaft flexibility 
 Friction between a catheter and its surrounding environment 
 Column strength, which is the capacity of the tube to withstand axial forces 
without compression or stretch. 
Catheter torqueability describes the behaviour of a tube when a moment of torque is placed 
about its longitudinal axis (Figure 5).  
 
Figure 5 Torque or moment (M) applied to a tube. 
For small deflections, the tube's mechanical properties approximate a spring system, in which 
torsional stiffness is determined such that: 
           
where      is the torsional spring constant, G is the shear modulus, J is the polar moment of 
inertia, and L is the length of the catheter shaft. 
Tube flexibility can be modelled as a clamped beam system subject to a downward force at 
the beam, as shown in Figure 6. 
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Figure 6 Flexibility (F) or bending force applied to end of tube 
For small deflections, the tubing approximates a spring system, with the flexural stiffness 
determined by: 
             
where       is the flexural spring constant, E is the modulus of elasticity, I is the moment of 
inertia, and L is the length of the catheter shaft. In many cases, it is desirable to minimize the 
flexural stiffness of the catheter (6.5.2) and it’s possible by : 
 Minimizing the moment of inertia 
 Minimizing the modulus of elasticity by using a soft material 
 Increasing the overall part length. 
The pushability is the response of a tube when a longitudinal force is applied along its axis 
(Figure 7). 
 
Figure 7 Force applied on the longitudinal axis of a tube 
For small deflections, the tubing properties can be considered to approximate a spring 
system, in which the longitudinal stiffness of the spring is determined by the equation: 
      
  
 
 
Where       is the longitudinal spring constant, E is the modulus of elasticity, A is the cross-
sectional area, and L is the length of the catheter shaft. In order to maximize pushability, it’s 
necessary to maximize the parameter      : 
•By maximizing the cross-sectional area of the tubing 
•By maximizing the modulus of elasticity using a stiffer material 
•By decreasing the overall part length. 
In minimally invasive surgery, often it is very important not to augment the diameter of the 
tubing, so there is a wide search of new materials which offer a good compromise between 
stiffness, flexibility and biocompatibility.  
Commonly, composite tubing designs are used for catheter delivery systems. These include 
designs consisting of one or more plastic materials (6.5.4) as well as wire-reinforced (braid or 
coil) designs (VideoDrain device 5.5.1). 
3.3.2 Materials 
In designing a medical tube, it is important considering four basic physical properties of 
materials, which are critical to function (in Table 49 some properties of the most common 
materials for medical use): 
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 durometer (the hardness of the resin) 
 flex modulus (the flexibility of the resin) 
 ultimate tensile (the force it takes to break the tube) 
 elongation (how much the material will stretch before breaking). 
Two other important criteria are biocompatibility of the resin and postextrusion 
processability. The biocompatibility of catheters, as with other medical devices, can be 
defined as the ability of the device to perform its intended function without eliciting 
undesirable side effects. Their biocompatibility is related not only to the basic polymers, but 
also to the various additives used.  
It is also important to understand if the materials, once processed, can be used without 
hazards. Infact accidental release of particles of materials can occure for several purposes: 
friction, temperature, wrong conditions of use, intrinsic features of the material. 
Polyvinylchloride (PVC)(4) is an inexpensive plastic material that is used in a wide variety of 
industrial and domestic applications. PVC is used in some situations with minimal additives, in 
which case it is a hard rigid material; most often, an additive described as a plasticizer is used, 
and the resulting plasticized, or soft, PVC finds extensive applications, especially in medical 
tubings. Many short-term catheters and drains are used in the clinic, including umbilical vessel 
catheters, wound drainage tubes and osteotomy shunts. 
Natural rubber latex (NRL) is a highly elastic, very-low-durometer material exhibiting high tear 
resistance and high elongation. It has long (5) been used to manufacture a wide range of 
healthcare products and components for medical devices. But as latex allergy has become a 
major occupational health problem for healthcare workers, non-allergenic alternatives to NRL 
are in greater demand to meet the needs of the medical device industry for latex-free 
materials. 
Silicones, one of the most thoroughly tested and widely-used groups of biomaterials, are well 
known for their intrinsic biocompatibility and biodurability.  These key characteristics have 
been attributed to the material’s inherent chemical and thermal stability, low surface tension 
and hydrophobicity. As a result of these properties, silicones have the benefit of extensive 
application in catheters and other medical products.  Silicones have been successfully applied 
in short- and long-dwelling catheters, drains, and shunts for over sixty years (6). Silicone 
elastomer is a thermosetting material, capable of being processed by various moulding, 
dipping, and extrusion methods. Like polyurethanes, silicones are excellent for low-
durometer applications—strong, resilient, stretchable, and more stable than latex. 
Silicone elastomers used in medical device applications normally include reinforcing filler; 
Incorporation of reinforcing filler into the cross-linked matrix reduces material stickiness, 
increases hardness, and enhances mechanical strength. Silicone catheter raw materials are 
more expensive than legacy materials such as latex and PVC, but when examining healthcare 
choices, possibility of infection should be taken into account.  
TPU is a thermoplastic Polyurethane (see VideoDrain materials) and has gained wide 
acceptance as an alternative to silicone. When employed as part of an invasive device, 
polyurethanes soften considerably within minutes of insertion in the body, reducing patient 
discomfort and the risk of vascular trauma. The high strength and ease of processing of 
polyurethanes make them an excellent choice for soft-elastomer applications. Advances in PU 
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formulations have made polyurethane a suitable replacement for latex in a variety of medical 
device applications. 
A prominent device application (5) for polyurethane and silicone is in low-pressure 
elastomeric balloons, as the ones used in the current work. These components are different 
from high-pressure medical balloons, which are made of non- or low-compliant materials such 
as PET and nylon and are generally used to apply force in a variety of diagnostic and 
therapeutic procedures, including angioplasty and other dilatation applications. 
Fluoropolymers (7) exhibit very good lubricity compared with other plastics. PTFE is the most 
lubricious polymer available, with a coefficient of friction (COF) of 0.1, followed by fluorinated 
ethylene propylene (FEP), with 0.2. These two polymers represent the vast majority of all 
fluoropolymer tubing used in medical devices. Fluoropolymers, especially PTFE, has an 
excellent biocompatibility 
PTFE (Teflon) is very difficult to extrude, due to its high viscosity and it needs particular 
material for the equipment because of its high corrosion in  the molten state. 
3.3.2.1 Disposal 
For several years, regulations (8) for the reduction of waste and minimization or elimination of 
hazardous substances have been enforced in the European Union (EU). Standards such as the 
Waste Electrical and Electronic Equipment (WEEE); Restriction on Hazardous Substances 
(RoHS); Registration, Evaluation, and Authorization of Chemicals (REACH); and the Energy 
Using Products (EuP) regulations have significantly altered the manufacturing processes of 
electronics at industrial and consumer products companies.  
The WEEE Directive requires the use of specific labelling, compliance with disposal 
restrictions, and creation of instructions for end-of-life management and recycling.  
Methods such as Six Sigma and lean manufacturing promote low defect manufacturing and 
encourage process flexibility. Lean manufacturing specifically targets and attempts to reduce 
seven waste streams, namely overproduction, waiting time, transportation, processing, 
inventory, motion, and scrap. These concepts, while originally developed to improve 
efficiency and reduce production costs, also align with many of the goals of sustainable design 
and production. 
Disposal of medical products made from PVC can be problematic.  The preferred biohazard 
waste disposal method for hospitals is often incineration. Incineration of used PVC medical 
devices such as catheters and tubing generates hazardous gases including hydrochloric acid 
(HCl), dioxins, and polychlorinated biphenyls (PCBs).  In addition to the environmental impact 
of such air population, the HCl shortens the life of the incinerator. 
With respect to disposable medical products, choosing materials that limit environmental 
damage during disposal and incineration can reduce toxic air emissions and reduce waste 
processing costs. In addition, products that have a durable or reusable component and 
smaller disposable components can minimize waste without damaging the lucrative nature of 
the disposable device business model. The critical factor in the durable or disposable product 
concept is to create a simple, repeatable interface between the two component sections so as 
not to impair the functionality or efficacy of the product. 
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3.3.3 Design for manufacturability 
Achieving an efficient catheter system figures among the fundamental design requirements in 
developing a novel medical procedure.  
Most specifications for medical tubing consist of a drawing of a tube with  the material, 
dimensions and tolerances. For single lumen tubing(9), the dimensions will usually include 
two of the following three dimensions; inner diameter (ID), outer diameter (OD) and the 
tubing wall thickness, along with their associated tolerances.  In addition, the tubing length 
and tolerance would be included unless the tubing is to be provided in a continuous length on 
a spool.  
One of the pressing issues for any new product(3) or process development project is the 
complexity of the required manufacturing process and its expected yields. Optimizing the 
manufacturability of the design from the beginning of the development process is a key issue 
for medical devices in particular. Oftentimes, the process parameters and the equipment used 
to extrude the tubing are as important or even more important than the actual dimensions of 
the tube. The tolerance requirements for metal instruments are completely different from 
those for plastic molded components. The device must be properly designed in order to have 
proper function in spite of these variations. 
The following sections summarize recent trends in catheter manufacturing, including 
assembly techniques, component outsourcing tactics, and sterilization methods. The most 
important manufacturing techniques for the industry of plastic sub components (also for the 
device developed in this thesis) are the extrusion, the moulding and the dipping. 
3.3.3.1 Extrusion process 
During extrusion, the billet, heated to the proper hot-working temperature, is placed in the 
chamber of an extrusion press. The horizontally mounted chamber contains a die at one end 
and a hydraulically driven ram at the other. The face of the ram is fitted with a dummy block 
that is slightly smaller in diameter than the billet. 
 
Figure 8 Extrusion of tubing from a hollow billet 
An extrusion line is a combination of several pieces of equipment. The major elements of a 
medical extrusion line include a resin drying system, the extruder, the die, the cooling tank, a 
take-up device (puller) and a cutter or winder. 
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Figure 9 A typical medical tubing extrusion line. 
Many polymers used in the medical device industry are “hygroscopic”, i.e. they absorb 
moisture readily from the environment. Hygroscopic polymers must be carefully dried prior to 
being melt extruded or compounded. All materials are not dried under the same parameters. 
Some require high temperatures for long periods of time while other materials may require 
low temperatures for shorter periods of time. Residual moisture in the polymer results in 
hydrolysis during extrusion. Hydrolysis is a degradation process that results in significantly 
lower molecular weight. Over-drying is another problem that can occur; If not properly 
monitored, this can result in over-drying which can cause thermal degradation in some 
materials. Many polymers, such as nylon and polycarbonate, can be sensitive to over-drying. 
The extruder is a melting and pumping machine. It converts solid pellets into a uniform, 
molten state and forces the material through the die at a constant rate. Melting is 
accomplished through frictional heat generated from the mechanical work of the screw and 
heat conduction from the heated barrel of the extruder. The design of the extrusion screw is 
critical in achieving uniform melting and pumping of the polymer without over-working (over-
shearing) the material. 
The extrusion die sits at the end of the extruder and is the point where the polymer exits into 
a cooling tank. The die forms the initial shape of the tube. A tubing die typically consists of 
two major components; a mandrel or tip that forms the tube ID, and a die, or ring, which 
forms the tube OD. The die and mandrel are typically contained inside the extrusion “head”. 
The design of these components plays a critical role in the extrusion process and the ability of 
the extruder to produce precise dimensions and maintain proper physical properties of the 
material. The relationship between the die and mandrel dimensions and the finished tube 
dimensions is typically referred to as the draw down ratio. 
3.3.3.2 Drawing  
Drawing simply involves pulling the hollow tube through a series of hardened steel dies to 
reduce its diameter. 
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Figure 10 Tube Drawing over Fixed Mandrel (left); tube Drawing over a Floating Plug Mandrel (right) 
A tapered plug mandrel, which may be either fixed or floating (Figure 10) depending on the 
process used, is placed inside the tube. Floating plugs are used with bull blocks. Stationary 
mandrels are used for relatively short lengths of tube that are drawn on linear drawbenches. 
As the tube is drawn onto the spinning bull block, the mandrel and die act together to reduce 
both the tube's outside diameter and its wall thickness. The mandrel also imparts a smooth 
surface to the tube's inside surface. The tube is drawn in several stages until the desired 
diameter and wall thickness is attained. Drawing work-hardens the copper, and the tube is 
now quite stiff. 
3.3.3.3 Moulding 
Plastic moulding is a very methodological and technical process. There are several plastic 
moulding process: 
 Injection Moulding 
 Blow Moulding 
 Multimaterial molding. 
In Injection Moulding, melted plastic is forced into a mold cavity. Once cooled, the mold can 
be removed. This plastic injection moulding process is commonly used in mass-production or 
prototyping of a product. Typically this process is used to produce plastic mouldings where 
the relatively high tooling cost can be justified by low unit costs and tolerances which cannot 
be achieved by other moulding processes. 
The process is divided into three steps: injection, blowing and ejection. Blow moulding is like 
plastic injection moulding except that hot liquid plastic pours out of a barrel vertically in a 
molten tube. The mold closes on it and forces it outward to conform to the inside shape of the 
mold. When it is cooled, the hollow part is formed. Equipments needed in setting-up a blow 
moulding business are relatively higher than injection moulding. 
Overmolding (10), or two-shot molding, results in parts in which it is clearly evident that more 
than one material is being used. In these processes, only part of a product is molded in one 
material, and that molded piece is manipulated so the second material can be molded around, 
over, under, or through it to complete the final part. This method is sometimes referred to as 
in-mold assembly, since the resulting part effectively acts as an assembly of two materials 
rather than as a layered structure. 
3.3.3.4 Dipping 
Dip molding of polyurethane and silicone is a relatively recent development. To dip mold a 
product, a mandrel in the shape of the object being molded is heated, dipped into the resin 
solution, then removed from the dipping tank. Mandrels can be machined from metal or 
formed from other materials. Metal is typically used for high-volume production. Glass 
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mandrels produce a very smooth surface but are challenging to use because of their fragility. 
The mandrel should be lowered gradually into the solution to avoid solvent gassing or bubbles 
in the solution, which can result in pinholes and weakness in the finished product.  
 
Figure 11 Dipping of medical balloons 
After dipping, the thin coating of the polymer that remains on the surface of the mandrel is 
allowed to cure, then is stripped off as a finished product. 
Dip moulding is a cost-effective process for low-volume production of thin-film products, 
offering consistent wall thickness and uniformity, relatively low tooling costs, and fast setup 
for new product development. 
3.3.4 Assembly Techniques 
Epoxies were commonly used in catheter assemblies thanks to their very high performance. 
However they require long cure cycles or elevated cure temperatures and additional facilities 
dedicated for thus use. As a result, the use of epoxies in catheter subassemblies has often 
been replaced by the next alternatives:  
 Adhesives that can be cured on demand through exposure to ultraviolet light 
 Thermal welding of mating parts. This is accomplished via localized heating of 
certain materials (for example, Pebax and urethanes), which causes them to reflow 
and create a integral adhesive bond for the surrounding parts 
 Elimination, in some cases, of the use of adhesives altogether through innovative 
processes. For example, variable-stiffness catheter products can be manufactured 
as a continuous process 
 Surface modification in the form of chemical etching is required for those non stick 
materials as PTFE.  
3.3.5 Component Outsourcing 
Many medical device manufacturers outsource more subassembly to component 
manufacturers. Additional operations, typically requested from component manufacturers, 
include:  
 Cutting to exact length tolerances of non-braided tubing products.  
 Cutting to length of braided components in which the tip is non-deformed and the 
braid wires are embedded in the tubing product (non-frayed).  
 Secondary operations such as flaring, tipping, hubbing, hole drilling/punching, 
curve forming, and ID/OD tube tapering.  
 Surface preparation of fluoropolymer materials for bonding (Teflon).  
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Problems with outsourcing subassembly operations can often be minimized by requiring that 
the component manufacturer have a good quality system in place. ISO certification of quality 
systems (ISO 13485) is fast becoming a requirement for medical component suppliers. 
3.3.6 Sterilization Methods 
 
The first step is deciding whether to design instruments to be reusable or whether to make 
them disposable. The material requirements for each instrument are quite different. Reusable 
instruments are most likely going to be steam sterilized. For this type of application, 
manufacturers should select plastic resins that can be autoclaved. It's important to note, 
however, that autoclavable resins are much more expensive than those that can be used for 
disposables. 
An important issue concerns the terminal sterilization method used for the finished catheter 
device. Many catheter manufacturers are tending to favor the use of E-beam or gamma 
irradiation over ethylene oxide gas. The preference for high-energy sterilization has the result 
of eliminating the use of some fluoropolymer materials, such as fluorinated ethylene 
propylene (FEP) or polytetrafluoroethylene (PTFE) in catheter assemblies. This can 
compromise the finished devices' performance, since equivalent substitutes have not been 
found that offer all of the performance attributes of these two materials.  
Once cross-linked into the desired configuration, silicone (6) catheters are thermally stable 
(reported operating range from -80 °C to +230 °C), remaining essentially unaffected by 
repeated autoclaving.  They can usually be dry-heat sterilized as well. 
Specific requirements for documentation and validation of processes for sterile medical 
devices are shown in the ISO 11137-1, 3 (Table 1). In Annex II, some tables of different 
materials with the associated possible sterilization methods are enclosed. 
3.4 Regulation 
 
The process of design of a MDs should work with certification proactively. The key 
determinant for approving a MD to be marketed is that it must be safe and effective. There 
are a variety of mechanisms to prove a MD is safe and effective and they will be investigated. 
When placing a MD on the market the manufacturer must have demonstrated through the 
use of appropriate conformity assessment procedures that the device complies with the 
Essential Principles of Safety and Performance of MDs (Table 1). Any of the phases in Figure 3 
can affect them. The scientific principles upon which a device is based are fundamental: the 
more complex the device, the higher the risk of user error. Soundness of concept and 
adequacy of design, construction, and testing (including verification, validation and clinical 
trials) require analysis to ensure that design parameters and performance characteristics do 
not impose unwarranted risks. 
Good, functional medical devices are produced when the manufacturing process is adequately 
managed. This consideration has led to the development of good manufacturing practice 
(GMP) for drugs, biological products and medical devices.  
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In Table 1 there is a short list of the principal regulations to follow in the design of MDs. The 
first is the generic EMDD, the primary approach to the world of MD development.  
Regulation Directive 
(EMDD) European Medical Device Directive 2007/47 
(AIMD) Active implantable 90/385/EEC 
(IVD) In vitro diagnostic 98/79 CEE 
Medical electrical equipment IEC 60601 
Application of risk management to medical devices ISO 14971 
Quality management systems - Requirements for regulatory purposes ISO 13485-13488 
ISO 14969 
Fundamental aspects of safety standards for medical electrical equipment IEC/TR 60513 
Biological evaluation of medical devices ISO 10993 
Clinical evaluation of medical devices for human subjects ISO 14155 
Guidance on the selection of standards in support of recognized essential principles 
of safety and performance of medical devices 
ISO 16142 
Packaging for terminally sterilized medical devices ISO 11607 
Sterilization of medical devices ISO 11135, 11137, 
11138, 11140 
Table 1 Principal regulations for MD design and development 
Clinical evaluation (Table 1) is the assessment and analysis of clinical data pertaining to a MD 
in order to verify the clinical safety and performance of the device . It is an ongoing process 
conducted throughout the life cycle of a MD. The Clinical Evaluation can be based on clinical 
data derived from literature or based on data related to the specific device. It’s mandatory to 
specify the criteria for the evaluation of the data (description of the methods). The clinical 
evaluation is required for all the classes of devices, Class I included. For active implantable 
devices, Class III and no active implantable devices clinical investigations are required. The 
absence of clinical data has to be duly justified. The clinical evaluation has to be updated on 
the basis of a post market surveillance plan. 
3.4.1 Certification aspects: definitions and classification 
MD means any instrument, apparatus, appliance, material or other article, whether used 
alone or in combination, including the software necessary for its proper application intended 
by the manufacturer to be used for human beings for the purpose of: 
 Diagnosis, prevention, monitoring and treatment of disease or disability 
 Diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap 
 Investigation, replacement or modification of the anatomy, or of a physiological 
process 
 Control of conception. 
In the classification and certification of a MD the manufacturer must follow the directions of 
Directive 2007/47. 
All the considerations summarized in Directive 2007/47/EEC are mandatory steps for the 
manufacturer to obtain the CE mark on devices manufactured on his behalf. There are many 
components that contribute in parallel with the release of the CE mark as in Figure 12. 
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Figure 12 Steps to CE mark 
A simple set of classification rules based on technical features of MDs existing now and in the 
future is impossible, because of the vast number and the changing nature of variables 
involved. The human body, however, is a relatively unchanging element of the equation. The 
European legislator established therefore a classification concept which is essentially based on 
potential hazards related to the use and possible failure of devices taking account of 
technology used and of health policy considerations. The classification rules (see ) are based 
on terms related to duration of contact with the patient, degree of invasiveness and the part 
of the body affected by the use of the device. These terms are defined in Section I of Annex IX 
of the directive 2007/47. 
Concepts of duration such as transient, short term and long term are defined in terms of 
continuous use. Continuous use must be understood as an uninterrupted actual use for the 
intended purpose. 
Any device which, in whole or in part, penetrates inside the body, either through a natural 
body orifice or through the surface of the body is an invasive device.  A surgically invasive 
device always implies that it enters through an artificially created opening. The concept “act 
by converting energy” includes conversion of energy in the device and/or conversion at the 
interface between the device and the tissues or in the tissues. 
The derived classes of MDs are: 
 Class I: non-invasive devices, i.e. those which do not come into contact or interact 
with the body; 
 Class IIa: invasive short-term devices, used through natural orifices of the body and 
invasive surgical for temporary use; 
 Class IIb: short term surgical invasive devices 
 Class III: includes devices which come into contact with vital organs. 
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3.5 Quality system 
Deming in the 1950's proposed that business processes should be analyzed and measured to 
identify sources of variations that cause products to deviate from customer requirements. He 
recommended that business processes be placed in a continuous feedback loop so that 
managers can identify and change the parts of the process that need improvements. This 
continuous process can be summarized in a diagram commonly known as the PDCA cycle for 
Plan, Do, Check, Act: 
 
Figure 13 PDCA diagram 
The law outlines general requirements for MD quality system management, covering issues 
such as design, production, installation, and sales. A Quality System is defined as the 
organizational structure, responsibilities, procedures, processes and resources needed to 
implement quality management. The international quality system standards for MDs are 
issued by the International Organization for Standardization (ISO) (ISO13485:1996 and 
ISO13488:1996). ISO13485:1996 includes all the elements of ISO9001:1994 plus a set of 
minimum supplementary requirements for MDs.  
Similar to the ISO 9001:2000 standard(11), ISO 13485:2003 standard for medical device 
manufacturers has a strong focus on customer satisfaction and improvement, but with an 
added focus on safety. This explains why ISO 13485:2003, unlike ISO 9001:2000 requires 
medical device companies to maintain a risk management system. 
MDs should be designed and manufactured in such a way that, when used under the 
conditions and for the purposes intended and, where applicable, by virtue of the technical 
knowledge, experience, education or training of intended users, they will not compromise the 
clinical condition or the safety of patients, or the safety and health of users or, where 
applicable, other persons, provided that any risks which may be associated with their use 
constitute acceptable risks when weighed against the benefits to the patient and are 
compatible with a high level of protection of health and safety. 
Manufacturers of MDs have to face many challenges to enter the global medical technology 
market(11). Growing competition requires frequent design changes, shorter time to market, 
assembly of small parts with complex geometry and tight tolerances, and difficult to work 
with materials such as titanium and silicone, just to mention a few. 
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The cost of fixing a single error in a device increases exponentially with the discovery time. 
Thus, the earlier a problem can be identified the more money a company will save; so the 
design and testing phases are crucial for saving costs.  
Design controls (Figure 14) are a component of a comprehensive quality system that covers 
the life of a device. Design control begins with development and approval of design inputs, 
and includes the design of a device and the associated manufacturing processes (12). A 
specific focus is mandatory on the controls in the work environment to ensure product safety 
: clean rooms, machines, including also the procedure for cleaning parts coming from external 
providers. 
 
Figure 14 Application of Design Controls to Waterfall Design Process 
The production of the developed devices has been prevalently outsourced but in all cases 
sufficient evidence has been given in the technical file about the competence of the 
subcontractor to undertake supply of some parts, material or service in relation to the 
medical device in question (as said in (13)).  
3.6 Risk Management 
Risk management principles should be applied throughout the life cycle of medical devices 
and used to identify and address safety issues. The current approach to device safety is to 
estimate the potential of a device becoming a hazard that could result in safety problems and 
harm. This estimate is often referred to as the risk assessment. 
In general, risk management(14) can be characterized by phases of activities: 
 Determination of levels of risk that would be acceptable in the device 
 Risk analysis 
 Risk evaluation 
 Risk control and monitoring activities. 
The procedures to determine risk acceptability criteria comes from an analysis of the 
experience with similar medical devices or research on what appears to be currently accepted 
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risk levels by regulators, users, or patients, given the benefits derived from diagnosis or 
treatment with the device. 
The risk analysis starts with identifying hazards that may occur due to characteristics or 
properties of the device during normal use or foreseeable misuse. The ISO 14971 is an 
international standard for manufacturers of medical devices. It specifies a process through 
which the manufacturer can identify hazards associated with a medical device, estimate and 
evaluate the risks associated with these hazards, control these risks, and monitor the 
effectiveness of that controls. 
The functional analysis is the starting point and can be carried out using the ISO 14971; 
questions that can be used to identify medical device characteristics that could impact on 
safety are presented (pg.83 and 119). 
Hazards typically considered in risk analysis include: 
 Chemical hazards (e.g., toxic chemicals) 
 Mechanical hazards (e.g., kinetic or potential energy from a moving object) 
 Thermal hazards (e.g., high temperature components) 
 Electrical hazards (e.g., electrical shock, electromagnetic interference (EMI)) 
 Radiation hazards (e.g., ionizing and non-ionizing) 
 Biological hazards (e.g., allergic reactions, bio-incompatibility, and infection) 
 Use related hazards. 
The comparison between estimated risks and risk acceptability criteria will determine an 
appropriate level of risk reduction, if necessary. The combination of risk analysis and risk 
evaluation is called risk assessment. 
Risk control activities should begin as early as design input and continue through the design 
and development process, manufacturing, distribution, installation, servicing and throughout 
the medical device life cycle. 
The objective of risk management is rarely to eliminate all risk, but rather to reduce risk to an 
acceptable level while maintaining feasibility and functionality. Risk management activities 
should begin as early as possible in the design and development phase, when it is easier to 
prevent problems rather than correcting them later.   
After release of the device to market, risk management activities should be linked to quality 
management processes, for example, production and process controls, corrective and 
preventive actions, servicing and customer feedback. In Annex III a flow chart for the risk 
management activities in design and development has been enclosed. 
The specific performance of the device must be analyzed for each conceivable failure, and 
ranked by probability and consequence of that failure. In order to identify the risk 
acceptability, existing criteria (i.e. already indentified for similar products) can be used or 
determined using the following methods: Failure Mode and Effect Analysis (FMEA5), Fault 
                                                     
5
 The FMEA analysis is a regulated process (ISO 13485 and 9001) detailing the failure mode, its causes, its effects, 
the frequency of occurrence, the severity of occurrence and the actions to mitigate the effects. 
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Tree Analysis (FTA), Hazard and Operability Study (HAZOP). When the risk is unacceptable, 
some additional methods cha be used: 
1. indirect methods (i.e., design modification), 
2. direct methods (i.e., in case of radiation, protections or screens) 
3. description methods (i.e., device application description or prescription) 
4. re-definition of the intended use. 
3.6.1 The methodology of ISO 14971 
The methodology for creating and updating the technological risk analysis for a general 
product can be summarised in the next steps, as parts in Analysis of Technological Risk: 
 identification of a “risk”, defined as the chance to have a negative outcome of the 
project or of one of its activities, related to events – “Unwanted events UE” - that 
may be foreseen. The name and a brief description of the impact related to the risk 
must be reported  
 for the identified risk, the probability of occurrence must be estimated according 
to the probability scale of the sub-table “Risk Assessment Criteria”. This value must 
be reported in column “Probability - P” (Annex III) 
 the negative “impact level – IP” that may affect the project outcomes in case the 
identified risk occurs must be estimated according to the impact level scale of sub-
table “Risk Assessment Criteria”. This value must be reported in column “Impact 
Level” 
 the probability and the impact level must be multiplied together in order to fill the 
column labelled “Risk Estimation” 
 once the risk has been estimated, the “Risk Estimation” value must be compared 
with the numerical values of table “Measures Assessment Criteria”. This will be 
useful in order to decide the need of proper measures for decreasing the risk. If the 
“Risk Estimation (RE)” value falls within the: 
 “red” zone (“Risk Estimation” ≥ 18), then measures must be introduced to 
decrease the “Risk Estimation” down to a value that falls within the green or, at 
least, the yellow zones; 
 “yellow” zone (5 ≤ “Risk Estimation” < 18), then measures may be introduced to 
decrease the “Risk Estimation” down to a value that falls within the green zone; 
 “green” zone (“Risk Estimation” < 5) then no measures are required. 
 according to point 5 (in cases 5.a or 5.b) measures must or may be introduced. The 
proper measures, once identified, must be described in the row named “Measures 
and contingency”. This has to be placed in the column corresponding with the level 
of probability of occurrence(EI).  
 if Measures have been introduced and applied, the new probability and impact 
level values named in the “Probability after Measures” respectively the Probability 
after Measures and the Impact Level after Measures must be multiplied together in 
order to fill the column , labelled “Risk Estimation after Measures or Residual Risk 
- RRE”. This value must fall within the green or, at least, the yellow zones 
 steps from 1 to 9 must be repeated for each risk that has been identified. 
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4 Muneretto6 Beam Navigation device 
A preliminary study for the development of a new device for minimally invasive intervention 
for the treatment of atrial fibrillation has been here reported. A proof of concept will be 
presented. 
4.1 Analysis of the medical background 
Normally with each heartbeat, the electrical impulse begins at the sinoatrial (SA or sinus) node 
in the right atrium. The SA node produces the electrical impulses that set the rate and rhythm 
of the heart beat. The electrical activity (Figure 15,left) spreads through the walls of the atria 
and causes them to contract. The electrical impulse then crosses the AV node and spreads 
down to the ventricles, causing them to contract. This generates the heart beat.  
Atrial fibrillation (AF, Figure 15 right) is a supraventricular tachyarrhythmia characterized by 
disorganized atrial electrical activity and progressive deterioration of atrial electromechanical 
function. Electrocardiographic manifestations(15) of atrial fibrillation include absence of sinus 
P waves (atrial impulse); rapid oscillations (or fibrillatory waves) that vary in amplitude, 
frequency, and shape; and an irregular ventricular response. AF may occur in isolation or in 
association with other arrhythmias, most commonly atrial ﬂutter or atrial tachycardia. In AF, 
various regions of the atrial wall pulse 400-600 times per minute and the ventricular rate is 
determined by the interaction between the atrial activity and the filtering function of the 
atrioventricular node. 
 
Figure 15 Electrical System of the Heart (left) Atrial Fibrillation (right) 
Abnormalities in the heart's electrical impulses in patients with AF cause blood to be pumped 
improperly, resulting in pooling or clotting. If a blood clot moves to an artery in the brain, AF 
can lead to stroke. AF is also associated with increased risk of congestive heart failure and 
cardiomyopathy (heart muscle disease). 
AF is the most common arrhythmia in clinical practice, accounting for approximately one-third 
of hospitalizations for cardiac rhythm disturbances. Most data regarding the epidemiology, 
prognosis, and quality of life in AF have been obtained in the United States and western 
Europe. It has been estimated that 2.2 million people in America and 4.5 million in the 
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European Union have paroxysmal or persistent AF. It is an extremely costly public health 
problem: the annual cost per patient is close to €3000. 
4.1.1 Clinical evaluation in patients with AF 
The minimum evaluation for the assessment of AF comprises: 
 History and physical examination to deﬁne presence and nature of symptoms associated 
with AF 
 Electrocardiogram to identify Rhythm (verify AF) 
 Transthoracic echocardiogram, to identify valvular heart disease 
 Blood tests of thyroid, renal, and hepatic function. 
 Additional test can be performed to identify the type of AF (Holter monitoring or event 
recording), to identify left atrium thrombus or to guide cardioversion (Transesophageal 
echocardiography), to identify a predisposing arrhythmia such as atrial ﬂutter 
(Electrophysiological study). 
4.2 Surgical treatments for atrial fibrillation 
The goals of treatment for atrial fibrillation include regaining a normal heart rhythm (sinus 
rhythm), controlling the heart rate, preventing blood clots and reducing the risk of stroke. 
Many options are available to treat atrial fibrillation. These include medications, lifestyle 
changes, procedures and surgery. Several surgical treatments for atrial fibrillation are 
available : 
 Maze procedure 
 Surgical pulmonary vein isolation (endoscopic and percutaneous) 
 Left atrial appendage (LAA) excision. 
The drive to make ablation procedures more acceptable to a wider group of patients, 
particularly those with lone atrial fibrillation who otherwise would not be having surgery, has 
led surgeons to develop minimally invasive methods by which these devices can be 
introduced into the chest and made to create lesions on the heart.  
4.2.1 The Maze Procedure  
The Maze III procedure is a surgical procedure that cures atrial fibrillation by interrupting the 
electrical impulses that cause the abnormal heart rhythm. The surgery involves the placement 
of incisions (Figure 16) in both atria. When the incisions heal, scar tissue forms and prevents 
the abnormal electrical impulses from passing through the heart. The procedure works 
essentially by creating blocks that the electrical impulses cannot cross. It corrects all the major 
problems associated with atrial fibrillation: it stops the atrial arrhythmia, it restores normal 
rhythm between the atria and the ventricles, and it preserves the ability of the atria to 
contract on its own. 
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Figure 16 Maze III incisions 
Surgery for the treatment of atrial fibrillation in isolation has not been widely adopted, 
however, because the procedure remains complex, time-consuming, and requires 
cardiopulmonary bypass. Recently a minimal access technique, derived from Maze, has been 
deployed: a catheter can be inserted through a small incision outside the heart. Instead of 
making surgical incisions, a radiofrequency device is used to create the lesions on the atria. 
Recent reported series (16) have demonstrated the feasibility of treating patients undergoing 
cardiac surgery for other structural heart disease with limited, left-atrial ablation lesion sets 
using alternative energy sources (radiofrequency, microwave, high focused ultrasound, laser). 
Experimental mapping studies have suggested the importance of a primary local generator, 
such as a single small re-entry circuit or ectopic focus. Collectively, these recent findings 
challenge the long held view that all AF results from multiple-circuit re-entry and support the 
rationale for developing surgical procedures for the treatment of AF that focus on the left 
atrium and pulmonary veins 
Catheter-based ablation of the left atrium is technically demanding, time consuming, and 
associated with a number of complications (16). However, the alternative lesion patterns used 
by these procedures, such as individual curcumferential and segmental pulmonary vein 
isolation, may serve as an important guide for modification of partial Maze procedure lesion 
sets. 
4.2.2 Circumferential pulmonary vein ablation (CPVA) 
This procedure is performed in the electrophysiology lab by a specially trained cardiologist. 
During the procedure, catheters are passed through the femoral veins (in the groin) and into 
the heart. Two catheters are inserted into the right atrium and two into the left atrium. The 
left atrium is accessed through a trans-septal puncture, and intracardiac echocardiography is 
used to visualize the atrium during the procedure. One catheter in the left atrium is used to 
map or locate the abnormal impulses coming from the pulmonary veins. The other catheter is 
used to deliver radiofrequency energy to ablate, or create lesions, outside the pulmonary 
veins. The procedure is repeated for all four pulmonary veins. The lesions heal and form a 
circular scar around the pulmonary veins within four to eight weeks. The scar tissue blocks any 
impulses firing from within the pulmonary veins, thereby "disconnecting" the pathway of the 
abnormal rhythm and curing atrial fibrillation. Catheter ablation should be considered to 
maintain sinus rhythm in selected patients who failed to respond to antiarrhythmic drug 
therapy.  
33 
 
 
Figure 17 Pulmonary vein ablation 
Ablating the openings of the pulmonary veins is technically much easier than making a series 
of linear ablations, and takes much less time (though it still takes up to 4 - 5 hours). 
Problems remain, however. This new approach works best in patients who have "paroxysmal" 
atrial fibrillation - that is, relatively brief episodes. It works less well in patients with persistent 
atrial fibrillation. Also, while it is much quicker than the "linear" approach, it is still a lengthy 
procedure. 
Complications(15) of catheter ablation include the adverse events associated with any cardiac 
catheterization procedure in addition to those speciﬁc to ablation of AF. Embolic stroke is 
among the most serious complications of catheter-based ablation procedures in patients with 
AF. Atrioesophageal ﬁstula may be more likely to occur when extensive ablative lesions are 
applied to the posterior LA wall, increasing the risk of atrial perforation. 
Further,(17), ablating in or near the pulmonary veins can cause partial obstruction of the 
veins, leading to pulmonary vein stenosis - a very serious and potentially life-threatening 
condition.  
4.2.3 Radiofrequency ablation endoscopic procedures 
Radiofrequency (16) energy uses an alternating current from 350 kHz to 1 MHz to heat tissue, 
resulting in thermal injury. There has been a significant experience accumulated using 
radiofrequency ablation to treat patients via catheter-based approaches. This success has led 
to the development of a number of radiofrequency energy probes that are useful for 
application to atrial tissue during cardiac surgery. These probes can be applied to either 
endocardial or epicardial (18) heart surfaces to create transmural linear lesions that block 
atrial conduction. Radiofrequency ablation by epicardial application holds promise for 
developing off-pump and minimally invasive procedures for AF. 
The majority of radiofrequency ablation procedures to date have been performed with 
unipolar systems in which the patient is grounded by an indifferent skin electrode. In such 
systems, current flows from the radiofrequency probe to contacted atrial tissue, where 
thermal energy is released as a result of resistance to conduction. 
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Bipolar radiofrequency probes, show great promise to develop truly minimally invasive 
approaches to surgical procedures for AF.  
The surgeon has the advantage of direct visualization of the left atrium and pulmonary veins, 
both on the endocardial side than on the epicardial and this allows to create lines of ablation 
on atrial side of the pulmonary veins in order to minimize the risk of complications such as 
stenosis of the same. By using bipolar catheters, in contrast to unipolar, the risk of esophageal 
injury is eliminated, since the ablation is carried out between the two jaws of the catheter and 
there is energy transmission, and then heat, to adjacent structures. For the same reasons, the 
risk of thromboembolism, resulting from excessive heating of the blood, that comes into 
contact with the catheter during the unipolar distribution of power, is virtually abolished by 
using bipolar instruments. In addition, the ability of the surgeon, to exclude the left atrial 
appendage, by suturing the same, virtually eliminates the risk of stroke, particularly in 
patients who fail to restore sinus rhythm. 
4.2.4 Left atrial appendage (LAA) excision 
This procedure has been proposed as a standalone treatment for chronic atrial fibrillation 
because it removes the most important thromboembolic source for patients with chronic AF. 
The left atrial appendage is a small, ear-shaped tissue flap located in the left atrium. This 
tissue is a potential source of blood clots in patients with atrial fibrillation. Physicians and 
researchers at Cleveland Clinic 7 have developed a ligation device (Figure 18, right) for 
isolating and removing the left atrial appendage during heart surgery. Following its removal, 
the tissue is closed with a special stapling device. 
 
Figure 18 The Watchman® Left Atrial Appendage Filter System (left); The Gillinov-Cosgrove Clip*(right) 
The Watchman Left Atrial Appendage Filter System (Figure 18, left) is under study as an 
alternative solution to removing the left atrial appendage. It consists of a rounded, self-
expanding device that isolates the left atrial appendage and prevents clots from dislodging. It 
can be implanted through a catheter into the ostium of the left atrial appendage in 
combination with other interventional procedures such as pulmonary vein antrum isolation. 
Studies are under way to test the safety and effectiveness of this device. 
4.2.5 Robotically Assisted AF surgery 
(19) have recently developed a new technique (Niobe II, Stereotaxis, Stereotaxis, Inc., St. 
Louis, MO, USA) for remote ablation using a soft magnetic catheter. The operator is 
                                                     
7
 http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/atrial-fibrillation/ 
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positioned in a separate control room at a distance from the X-ray beam and the patient’s 
body. A 4mm magnetic catheter (NaviStar-RMT) is integrated with a newly developed electro-
anatomical mapping system (CARTO-RMT mapping system). Additional magnets in the distal 
portion of the device can be deﬂected in any desired direction and steered by the magnetic 
navigation system. 
Remote circumferential pulmonary vein ablation (CPVA) is usually performed with a target 
temperature of 65°C and a power limit of 50W. Magnetic ﬁeld vectors for each navigation 
target are stored and, if necessary, they are reapplied at any time while the magnetic catheter 
is navigated automatically. Electrical disconnection even of challenging targets can be 
achieved remotely with relatively few ablation lesions. 
At present, remote CPVA technology requires expensive equipment, and signiﬁcant beneﬁts 
over conventional catheters must be demonstrated to justify its purchase.  
The Columbia team has developed a totally endoscopic, beating heart version of surgical atrial 
fibrillation ablation. In this minimally invasive, robotic operation, the ablation is performed 
through small puncture wounds in the chest and without stopping the heart or using the 
heart-lung machine. 
 
Figure 19 Totally endoscopic, beating heart atrial fibrillation ablation 
4.3 Technological state of the art 
4.3.1 Magnetically guided systems 
A lot of groups have used magnetic force to control devices inside human body. It can be 
applied to control microforceps internally in assistance with EMR (20) and to control 
endoscopic cameras(21) and laparoscopic instruments  inside the abdomen without additional 
scars (22). 
Magnetic actuation can be used for minimally invasive control of medical devices such as 
robotic catheters. A device, that actuates pieces of high-permeability metal to redirect 
magnetic lines of ﬂux, is used to regulate the attractive force exerted by a large controlling 
magnet on a smaller moving magnet(23). (24) demonstrated accurate catheter navigation 
using a magnetic guidance system (MGS) to create RF lesion on canine atria. 
A new guidance system (25) for intramyocardial therapy utilizes magnetic ﬁelds and catheter-
tip sensors to locate a position in space and reconstruct three-dimensional left ventricular 
electromechanical maps without using ﬂuoroscopy. 
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4.3.2 Robots for atrial fibrillation 
The Sensei™ Robotic Catheter System uses computed catheter technology to provide stable 
and predictable control of catheter movement. This innovative technology is designed to 
provide fine guide catheter control in three dimensions, to enhance the physician's ability to 
access hard to reach anatomy, repeat procedure steps, and maintain stability during 
interventional procedures. The safety and effectiveness of this system for use  with cardiac 
ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation, have 
not been established, but studies are under development.  
Niobe robotof Sterotaxis has been used in several cases (26)(19) for the treatment of atrial 
fibrillation with good results. 
The only drawback of these systems is the high cost so a device as Muneretto Beam catheter 
could be the right compromise between less invasiveness and reduction of costs. 
4.3.2.1 Patent Search 
A patent search for magnetically guided catheters for atrial fibrillation ablation has been 
conducted. The main results are two patents: 
 Magnetized electrode tip (27) 
 Magnetic catheter ablation device and method (28). 
 
Figure 20 Magnetized electrode tip 
The first patent resides in a method for ablating localized cardiac tissue by the use of two 
catheters with magnetized tips. Collectively, the catheters serve both mapping and ablating 
functions, permitting both a determination of the locus of an arrhythmia and the ablation of 
locus to correct the arrhythmia without the need to relocate the locus between these two 
functions. The magnetic attraction is across cardiac tissue and serves to secure the proper 
positioning of the ablation function.  
While the mapping and ablation functions can be either on a single catheter or divided among 
the two catheters, the preferred arrangement is the latter, i.e., with one catheter serving as 
the "targeting catheter" which performs the mapping function, and the other serving as the 
"ablation catheter" which performs the ablation. In either arrangement, since ablation is done 
without removal of the targeting catheter, this invention involves a lesser use of such 
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procedures as x-ray exposure and fluoroscopy than conventional methods, as well as a 
reduction in the risks associated with these procedures. Regardless of the arrangement, both 
catheters have magnetized tips and are preferably positioned on opposing sides of cardiac 
tissue.  
 
Figure 21 Magnetic catheter ablation device 
In the second patent a method and apparatus for ablation of a layer of tissue is achieved by 
providing first and second bodies on opposed sides of the tissue. The first body includes a first 
ablation member and a source of magnetic force adjacent one side of the tissue. The second 
body includes a second ablation member and a magnetically attractive element responsive to 
the magnetic force adjacent the other side of the tissue. The magnetic attraction between the 
source and the attractive element is adapted to align the first and second bodies in opposed 
relationship on the opposed sides of the tissue. One of the first and second bodies may 
include at least one expendable member for controlling the magnetic attraction between the 
bodies. 
4.4 Analysis and search of materials 
4.4.1 Permanent magnets 
Magnets function as transducers, transforming energy from one form to another, without any 
permanent loss of their own energy. General categories of permanent magnet functions are: 
 Mechanical to mechanical - such as attraction and repulsion 
 Mechanical to electrical - such as generators and microphones 
 Electrical to mechanical - such as motors, loudspeakers, charged particle deflection 
 Mechanical to heat - such as eddy current and hysteresis torque devices 
 Special effects - such as magneto resistance, Hall effect devices, and magnetic 
resonance. 
There are four classes of modern commercialized magnets, each based on their material 
composition. Within each class is a family of grades with their own magnetic properties. These 
general classes are: 
o Neodymium Iron Boron 
38 
 
o Samarium Cobalt 
o Ceramic  
o Alnico. 
NdFeB and SmCo are collectively known as Rare Earth magnets because they are both 
composed of materials from the Rare Earth group of elements. Neodymium Iron Boron 
(general composition Nd2Fe14B, often abbreviated to NdFeB) is the most recent commercial 
addition to the family of modern magnet materials. At room temperatures, NdFeB magnets 
exhibit the highest properties of all magnet materials (Table 2). Ceramic, also known as 
Ferrite, magnets (general composition BaFe2O3 or SrFe2O3) have been commercialized since 
the 1950s and continue to be extensively used today due to their low cost. A special form of 
Ceramic magnet is "Flexible" material, made by bonding Ceramic powder in a flexible binder. 
Alnico magnets (general composition Al-Ni-Co) were commercialized in the 1930s and are still 
extensively used today. 
Characteristic Ceramic alnico Bonded ND-
Fe-B 
Sm-Co Nd-Fe-B 
Highest energy 
product 
Bhmax(kJm-3) 
32 59 79 254 382 
Maximum 
operating 
temperature (°C) 
300 550 150 300 150 
Resistance to 
demagnetization 
Moderate Low High Very high High 
Corrosion 
resistance 
(uncoated) 
Excellent Excellent Good God Poor 
Mechanical 
toughness 
Moderate Tough Moderate Very brittle Brittle 
Relative cost Very low Moderate High Very high High 
Table 2 Comparison of key characteristics of commercially available magnetic materials 
Nd-Fe-B is an obvious example of a ferromagnetic material. In magnetic materials, a magnetic 
field is produced because of the movement of electrons within the material, which produces 
the field around the material and a magnetization effect within it. An electrical charge moving 
through a conductor will also produce a magnetic field; therefore the magnetic field strength 
H can be measured in A.  
When a material experiences a magnetic field, the individual atomic moments contribute to 
the overall response of that material to the field. This response is called the magnetic 
induction B and is an inherent property of the material; it is also known as the flux density and 
is measured in Tesla (T). The relationship between the applied field and the response of the 
material is known as the permeability of the material . In free space: 
      
and the permeability of free space is 4π10-7 WbA-1m-1. In any other medium, however, the 
permeability may not be a linear function of H; although B(H) may vary with the applied 
magnetic field, particularly in ferromagnetic materials. 
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4.4.2 The B-H Curve 
The basis of magnet design is the B-H curve, or hysteresis loop (Figure 22), which characterizes 
each magnet material. This curve describes the cycling of a magnet in a closed circuit as it is 
brought to saturation, demagnetized, saturated in the opposite direction, and then 
demagnetized again under the influence of an external magnetic field.  
  
Figure 22 Hysteresis loop 
The second quadrant of the B-H curve, commonly referred to as the "Demagnetization Curve", 
describes the conditions under which permanent magnets are used in practice. A permanent 
magnet will have a unique, static operating point if air-gap dimensions are fixed and if any 
adjacent fields are held constant. Otherwise, the operating point will move about the 
demagnetization curve, the manner of which must be accounted for in the design of the 
device.  
The three most important characteristics of the B-H curve are the points at which it intersects 
the B and H axes (at Br - the residual induction - and Hc - the coercive force - respectively), and 
the point at which the product of B and H are at a maximum (BHmax - the maximum energy 
product). Br represents the maximum flux the magnet is able to produce under closed circuit 
conditions. In actual useful operation permanent magnets can only approach this point. Hc 
represents the point at which the magnet becomes demagnetized under the influence of an 
externally applied magnetic field. BHmax represents the point at which the product of B and H, 
and the energy density of the magnetic field into the air gap surrounding the magnet, is at a 
maximum. The higher this product, the smaller need be the volume of the magnet. Designs 
should also account for the variation of the B-H curve with temperature.  
4.5 Design History 
The ideal non pharmacological treatment  for atrial fibrillation should: 
 Ensure an appropriate pattern of lesions; 
 Be performed in a minimally invasive manner, and therefore without 
cardiopulmonary bypass; 
 Minimize the risk of damage to structures adjacent to the heart; 
 Avoid as much as possible exposure to X-rays; 
 Ensure transmural lesions; 
 Allow for resection or exclusion, however, of left appendage. 
The idea of a new device is property of Prof. Muneretto, who decided to develop a new 
magnetic guidance system for a device for the ablation of atrial fibrillation. The surgical 
approach can be defined linear magnetically guided endoscopic ablation. 
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4.5.1 Muneretto approach 
The design started from the study of two devices of Estech8 company: the COBRA® Adhere XL 
and the COBRA® Bipolar Surgical System. 
The COBRA® Adhere XL (Adhere) (Figure 23) is a device which allows the surgeon to easily 
create a complete epicardial box lesion using standard open surgical technique or through 
minimally invasive approaches. 
 
Figure 23 COBRA Adhere XL: probe(left), adhering mechanism (right)  
It is comprised of two components, the Cobra Adhere XL Surgical Probe with integrated 
Suction Stabilizer and the Cobra Adhere XL Introducer. The stabilizer is designed to engage 
tissue under negative pressure such that constant contact between probe and tissue to be 
coagulated is maintained throughout the procedure. The Introducer is designed to facilitate  
introduction and advancement of the Probe/Stabilizer to the desired anatomical position.  
The surgical Probe has a flexible distal section. This probe is designed to conform to the 
specific anatomy of the tissue area to be coagulated. The distal section of the probe can have 
from two to fourteen 15 mm electrodes spaced 2mm apart along the body. Any linear 
combination of coagulating electrodes may be used. 
The COBRA® Bipolar Surgical System (Bipolar) is intended for the coagulation of soft tissue 
using radiofrequency energy during general surgery, creating rapid reproducible transmural 
lesions.  The System may also be used to coagulate blood and soft tissue to produce 
hemostasis. It is comprised of two components (Figure 24), the COBRA Bipolar Inserts and the 
COBRA Bipolar Clamp. The Clamp is designed to fit over the Inserts and engage tissue such 
that constant contact between Inserts and tissue to be coagulated is maintained throughout 
the procedure. The Inserts have a flexible distal section. They are designed to conform to the 
specific anatomy of the tissue area to be coagulated, according to the chosen clamp. The 
distal section of the Inserts has two RF electrodes spaced 2mm apart and one return 
electrode. The Inserts fit into the groove of each clamp jaw. 
                                                     
8
 www.estech.com 
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Figure 24 Clamps (left), Bipolar inserts (right) 
The initial specifications were to modify the previous Estech devices enabling a magnetic 
guidance of the same. The new device will have features coming from both the unipolar and 
bipolar instruments. 
Linear or focal radiofrequency(29) ablation with the magnetic catheter is not compromised by 
the magnetic field. The critical (19) purpose of navigation and ablation is a stable contact of 
the catheter tip with the endocardium at the time of RF applications. Hence a magnetic 
coupling between an internal and an external catheter can be a good solution for a good RF 
ablation. 
4.5.2 Analysis of potential configurations 
In a first configuration analyzed, (config. A, Figure 25), it has been decided to use the two 
inserts of the Bipolar device and to obtain the alignment and the guidance of the same with 
some small magnets on both inserts. The idea is to introduce one insert, thanks to endoscopic 
guidance, on the external wall of the hearth, and the other insert internally by means of a 
trocar of 8 Fr (2.7mm). Once inserted the catheter would be guided by the external one 
thanks to the magnetic coupling. 
 
Figure 25 Configuration A 
The main issue has been to understand the type of magnets to use, their position, 
magnetization (Annex IV) and material (4.4). A series of shapes and dimensions have been 
designed. Spherical, cylindrical, U-shapes (Figure 26) mainly due to the configuration of the 
catheter for atrial fibrillation. 
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Figure 26 U- shapes 
Cobra monopole silicone cover could be a good solution for the  envelop of the external 
catheter. In Figure 27 a possible configuration for the magnets inside the cover is shown 
(config. B). 
 
Figure 27 Cobra Monopolar cover modified 
Since magnets of such shapes are difficult to reach on the market (non customized), the 
design has moved to a simpler form of magnets (cylinders diametrically magnetized, see also 
section 4.5.5). 
Therefore a third configuration (config. C) has been evaluated. The external catheter would be 
inserted pericardially, the internal one (Ø2.7mm) intracardially by means of a 8 french trocar. 
Both catheters are sliding. 
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Figure 28 Configuration C 
In order to guarantee the sliding of the external catheter into its silicone cover a system of 
inserts has been designed (Figure 29). Both magnets and platinum electrodes are embedded 
in a dacron cover for ensuring the thermal contact between electrodes and biological tissues. 
 
 
Figure 29 Config. C: External catheter(up), Dacron cover (down) 
The only drawback of this configuration is the high curvature which the internal catheter is 
subjected. It could be reason of decoupling inside the atrium, because the curvature inside 
the organ are very small. Professor Muneretto provided some dimensional indications about 
the curvature , by means of two test benches (Figure 30). 
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Figure 30 Test bench for catheter curvature 
Clinical efficacy (30) has driven the use of larger electrodes (7F, length > or =4 mm) for 
radiofrequency ablation, which reduces electrogram resolution and causes variability in tissue 
contact depending on electrode orientation. With active cooling, ablation electrode size may 
be reduced. The Estech Cobra device has an internal circuit for cooling. Thus a length of 1 cm 
for each electrode would be enough for a good action. 
Therefore a last configuration with smaller electrodes and magnets has been developed 
(config. D). In this configuration the catheters are fixed. The internal catheter is inserted into 
the atrium by means of a plastic sheath and it is bended in two parts. When the catheter is 
inserted, the front magnet couple with the frontal one of the external catheter and then the 
other two magnets are released from the oversheath. 
 
Figure 31 Final configuration (D) 
The best magnetic coupling is obtained by configuration1 (October tests): magnets in 
neodymium with dimensions of 2 and 3.5 mm in diameter and length 10 mm. The length, both 
of magnets and electrodes, has been reduced due to the change in the specification for the 
curvature that Prof. Muneretto provided. 
4.5.3 Finite Element Analysis  
Basic problems of permanent magnet design revolve around estimating the distribution of 
magnetic flux in a magnetic circuit, which may include permanent magnets, air gaps, high 
permeability conduction elements, and electrical currents. Exact solutions of magnetic fields 
require complex analysis of many factors, although approximate solutions are possible based 
on certain simplifying assumptions. Obtaining an optimum magnet design often involves 
experience and tradeoffs. 
Finite Element Analysis (FEA) modelling programs are used to analyze magnetic problems in 
order to arrive at more exact solutions, which can then be tested and fine tuned against a 
prototype of the magnet structure. Using FEA models flux densities, torques, and forces may 
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be calculated. Results can be output in various forms, including plots of vector magnetic 
potentials, flux density maps, and flux path plots.  
The software used in this work in Comsol Multiphysics 3.5. Several attempts has been made in 
order to establish the right parameters for our purposes. First of all the definition of the 
problem: at first it has been decided to study only the interaction between the magnets, 
without the thermal and electrical effect of the ablative electrodes. 
In magnetostatic problems, where no currents are present, the problem can be solved using a 
scalar magnetic potential. In a current free region, where  
        
Equation 1 
it is possible to define the scalar magnetic potential,   , from the relation  
        
Equation 2 
This is analogous to the definition of the electric potential for static electric fields. Using the 
constitutive relation between the magnetic flux density and magnetic field  
          
Equation 3 
together with the equation: 
     
Equation 4 
It is possible to derive an equation for   : 
               =0 
Equation 5 
The force on the magnet is calculated by integrating the surface stress tensor over all 
boundaries of the magnets. The expression for the stress tensor is, 
      
         
 
        
  
Equation 6 
where n1 is the boundary normal pointing out from the magnet and T2 the stress tensor of 
air. The integration gives the actual force on the magnet. 
4.5.3.1 Modeling Using the Graphical User Interface 
When COMSOL Multiphysics starts, the first window that appears is the Model Navigator 
(Figure 32) in which the main application is chosen: the Space dimension (3D and 2D) and the 
Application Modes (Magnetostatics, No Currents) are selected. 
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Figure 32 Comsol Model Navigator interface 
Then the constants are set (Table 3) and the geometry is drawn or imported from another Cad 
Software (Pro-engineer 5.0). 
NAME   EXPRESSION  DESCRIPTION 
mur μ tissue~ μ air = 1 Relative permeability of air 
Br(N/(mm*A) 0.0017 Residual magnetic flux 
Table 3 example of the main constants used 
4.5.3.2 PHYSICS SETTINGS - Boundary Conditions 
Magnetic Insulation 
Along the boundaries far away from the magnet, the magnetic field should be tangential to 
the boundary as the flow lines should form closed loops around the magnet. The natural 
boundary condition is 
                     
Equation 7 
Thus the magnetic field is made tangential to the boundary by a Neumann condition on the 
potential.  The magnetic insulation boundary condition sets the normal component of the 
magnetic flux density to zero. This boundary condition is useful at boundaries confining a 
surrounding region of air. 
Magnetic Potential 
The magnetic potential boundary condition 
       
Equation 8 
allows specifying the potential at the boundary. 
Zero Potential 
Along the symmetry boundary below the magnet, the magnetic field should also be 
tangential, and therefore the same Neumann condition can be applied there. The zero 
potential boundary condition 
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Equation 9 
sets the magnetic potential to zero at the boundary. 
Continuity 
The continuity boundary condition  
            
Equation 10 
is the natural boundary condition ensuring continuity of the normal component of the 
magnetic flux density. 
POINT CONDITION 
To obtain a unique solution, the potential at (at least) one point must be provided. If the 
magnetic insulation boundary condition is used everywhere, the potential has to be fixed 
using a point condition (i.e. Equation 8 where Vm0 is a given constant). 
Hence from the Physics menu, in Boundary settings of the models studied, magnetic 
insulation is set on the air around the magnets and the continuity on the magnets.  
4.5.3.3 PHYSICS SETTINGS - Subdomain Settings 
For the various configurations analyzed the relative permeability for the magnet, the 
magnetization vector, and constitutive relations and force variables are set in this module.  
 Constitutive relation 
air B=µoµrH 
magnets B=µoµrH+Br 
Table 4 Constitutive equations used 
4.5.3.4 MESH GENERATION 
To resolve the field a mesh generation is necessary. Mainly Free Mesh has been used, but in 
some cases, when the size of the model is too big, the mesh has been mapped. In the region 
of interest (i.e. area between 2 magnets) the mesh size was smaller, while in other areas it 
had bigger elements (thus coarse calculation).  
4.5.3.5 Computing the SOLUTION and POSTPROCESSING 
In the Solver Parameters dialog box, the Adaptive mesh refinement check box underneath the 
Solver list is sometimes selected. When modeling, it is important to select a mesh that 
minimizes the errors in the quantities of interest. However, it is not easy to minimize the error 
in a desired quantity by manually specifying a mesh. In many applications, the algorithm must 
resolve the solution in great detail only on small portions of the domain. Adaptive mesh 
generation identifies the regions that require a high resolution and produces an appropriate 
mesh. 
In the Plot type area it is possible to choose the type of visualization and  the quantities for 
the solution (Slice, Arrow, Contour, Surface..). 
4.5.3.6 Force Calculation 
To calculate the force on a magnet, the surface stress tensor has been used (see Equation 6). 
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The electromagnetic force variable is defined on one magnet in the Sub domain Settings 
dialog box; it generates the variables forcex_emnc, forcey_emnc, and forcez_emnc, which are 
the forces on the magnet in the x, y, and z directions, respectively. 
4.5.4 Model validation 
The simulation activities, especially with a program of electromagnetic simulations, must start 
with a validation of the mathematical model. Therefore the results of the first simulations 
have been compared with the datasheets of the first available magnets. In Annex V the 
complete comparative data are reported. From the data obtained it results that the FEA 
model works enough good to understand the magnitude of the forces interested by the 
magnetic coupling. 
 
Δx(mm) 0.11 0.3 1 2 
F(N) 4.52 3.53 1.53 0.46 
Fdatasheet 3.34 2.44 1.11 0.53 
Table 5 d22-d22 (axially magnetized) interaction 
These simulations are then also compared with the experimental data of the interaction 
forces between the magnets available. In Table 6 there is a list of the features of the first 
magnet used for the validation of the model. Magnetic force at a distance of s for the magnets 
used is: 
                  
Equation 11 
 
Figure 33 Force between magnets and an iron plate 
The holding force Fh decreases with the distance s exponentially. 
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Ø (mm) H (mm) Mdir Grade Brmax(T) 
Sphere s3 4.76 - 
 
N42 1.32 
Cylinder D22 3.175 3.175 
 
N52 1.48 
Cylinder D24 3.175 6.35 
 
N50 1.45 
Disk S09 9 2.50 
 
N52 1.45 
Table 6 First magnets used: features 
It is particularly necessary using a program like Comsol, extremely complicated, with lots of 
boundary conditions to be set correctly to understand if the used model is trustable. In this 
case, the final comparison was made between the SW model and mechanical tests carried out 
with a load cell (that determines the strength of interaction between the two magnets in 
various configurations choices). 
 
Figure 34 Load cell and test bench  
As of the comparisons of forces obtained from simulations and first tests, it is possible to 
understand that the model, excluding some exceptions (see red value in Table 60), is enough 
trustworthy for the purpose, even if, in some cases, a refinement in term of mesh 
construction is necessary. 
Therefore a new comparison has been made between the model of a cylindrical magnet and a 
iron plate has been done and the results from the FEA compared with forces obtained from 
the datasheets. A good correspondence has been found (see Annex V and Table 7). 
Δx(mm) 0 1 
F(N) 1.3  0.59  
Fdatasheet  1.26 0.63  
ΔF 0.04 0.04 
Table 7  
4.5.5 Main FEA results  
As a result of the first session of simulations and tests one of the configuration chosen is a 
d22-d22 diametrically magnetized, because these magnets allowed more stability without 
damaging tissues (the spheres and the disc perforated the tissue). This coupling could be good 
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for the configuration A (section 4.5.2) but the local forces are a little bit low comparing them 
with the results of the first tests (section 4.6). 
 
 
Figure 35 d22-d22 Interaction diagram; on the y axis the force in N and on the x axis the distance between magnets 
Δx (mm) 0.11 0.41 1 2 
F (N) 3.62 2.5 1.35 0.52 
Table 8 interaction forces 
These results helped in the purchase of new diametrically magnetized magnets (Validation 
tests with hkcm magnets) 
Another useful use of the simulation has been in the evaluation of forces deriving from drilling 
of magnets for the embedding into the final catheter (to allow the passage of the platinum 
electrodes). In Figure 36, two Magnets (3.5x10mm) has been drilled to make holes of Ø2mm 
coaxially (2) and eccentric (3). The calculation has been done with Magnetic insulation 
condition  on all surfaces, Vm=o in one extreme point and a standard mesh. Air volume is a 
cube of 40x40x40mm. 
 
Figure 36 Comparison between cylindrical magnets and drilled ones 
Δx (mm) F1(N) F2(N) F3(N 
1 7.61 3.49 2.02 
Table 9 Forces comparison 
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From this first simulation it has been decided to reduce the holes (Table 10) and to allow only 
electrical wires to pass through the magnets. 
 
Figure 37 Magnets 3.5x10mm, smaller holes 
Ø holes (mm)  1  0.4  
F      (N)  6.34  7.5  
Δx   (mm)  1  1  
Volume air  40x40x40  40x40x40  
Table 10 Force with smaller holes 
Finally simulation of the magnets chosen from the last test (config. 1, October 2010) have 
been done in order to understand the acting forces on magnets and drilled one (Ø 0.4mm). 
  
Figure 38 Magnets with diameters:2 and 3.5 mm  
No holes 
F on z3.5 (N) 0.096 0.18 0.27 0.70 1.58 3.9 
F on z2     (N) -0.16 -0.26 -0.39 -0.76 -1.56 -4.10 
Distance Δx   (mm) 5 4 3 2 1 0 
With holes 
F on z3.5 (N) 0.0666 0.19 0.38 0.68 1.50 3.92 
F on z2     (N) -0.16 -0.24 -0.37 -0.7 -1.54 -3.92 
Table 11 Results of FEA on the final configuration (with and without holes) 
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As from Table 11 holes of such diameter don’t influence magnetic force in a wide way. 
Therefore a decision about the design can be taken and in the last configuration D electrical 
wires can be passed through the magnets without reducing the force value.  
4.6 Prototypes and Tests 
Several tests have been conducted: 
1. To validate the FEA model (1 session) (see 4.5.4) 
2. To understand the forces required for the magnetic coupling (4 sessions). 
A preliminary in vitro test with the magnets in Table 6 on a pig atrium have been made on the 
24/02/2010 in order to have a preliminary idea about the feasibility of Prof. Muneretto 
design. 
As in Figure 39 it has been shown that a certain coupling and sliding with magnets could be 
achieved. Therefore a consequent work could be done. 
 
Figure 39 Test session 24/02/10 
The first session of in vitro trials with a pig hearth has been conducted in Pontedera 
(14/03/2010) with the assistance of Prof. Muneretto and under the supervision of Estech R&D 
personnel. Some home - made prototypes with magnets have been tested (see Figure 40) in 
order to understand the level of forces (Table 12) needed to do the task (magnetic guidance 
of the internal catheter by means of the external one). 
 
Figure 40 First prototypes 
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 Ft(N) Fn(N) 
Case A: d22-d24 
 Cylinder Ø 3- cylinder Ø 6 
3 1.1 
Case B:s09-d24 
Disc Ø 9mm-Cylinder Ø 6 
2.85 3.89 
Table 12 Test session 14/03/2010 
As predicted and from the results of these first two sessions, balance between friction and 
magnetic force is a key issue in the design of the Muneretto Beam Device. 
A new series of prototypes have been manufactured using new magnets (Tests results-
September 2010) with more appropriate dimensions and magnetization direction. 
The magnets have been embedded in  many types of moulding silicone. In Table 13 their main 
features are shown. 
Name Type of application Viscosity (MPa) Hardness Shore A Elongation at Break 
GLS 50 (Prochima) Casting 30000 18-20 400% 
CRISTAL RUBBER 
(Prochima) 
Casting 28000 33 320% 
RTV 4411 (Silbione) Casting 7500 11 800% 
Table 13 Silicones 
As a results a series of new prototypes have been manufactured and tested with chicken 
tissue (5 mm thick). In Annex VI the main results are reported. 
 
Figure 41 Silicone embedded prototypes  
The intermediate results from these tests are: 
 Silicone is not good for sliding  
 Frosted PVC can be the solution for the catheter 
 The handling, layout and coupling of the magnets during manufacturing are key 
issues. 
Therefore a new series of prototypes have been manufactured and tests with chicken tissue 
(5mm thick) are made (see October 2010). 
The best results are achieved with configuration 1 (see Figure 42), with magnets Z03.5x10GD-
N35 for the external catheter and Z02x10ND-N35 for the internal one. 
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Figure 42 Configuration 1, October 2010 tests (left); Pig-tail (right) 
Therefore the catheters with materials like pellethane and frosted PVC offer a good sliding 
and magnets of config. 1 are chosen for the integration in the device. Another important issue 
is the shape of the tip (a round shape is suggested for improving the sliding, see pig-tail in 
Figure 42) and the flexibility of catheters has to be increased: 
 Reducing tube thickness 
 With a modular catheter. 
The magnets will be integrated on the device like a necklace. This will enhance flexibility and 
the magnetic coupling will not be invalidated by the stiffness of the wall. Moreover during the 
insertion of the internal catheter inside the atrium (4.5.2), it would be possible to reduce the 
diameter of the oversheath, thus reducing the scar on the wall of the heart tissue. 
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5 Video drain 
5.1 Analysis of the medical background: Anatomy and Complications of 
abdominal surgical wounds 
5.1.1 Anatomical district 
The abdominal cavity is the largest hollow space of the body. Its upper boundary is the 
diaphragm, a sheet of muscle and connective tissue that separates it from the chest cavity; its 
lower boundary is the upper plane of the pelvic cavity. It is vertically enclosed by the vertebral 
column and the abdominal and other muscles. The abdominal cavity (Figure 43) contains the 
greater part of the digestive tract, the liver and the pancreas, the spleen, the kidneys, and the 
adrenal glands located above the kidneys. 
 
Figure 43 Abdominal Organs 
The abdominal cavity is lined by the peritoneum, a membrane that covers not only the inside 
wall of the cavity (parietal peritoneum) but also every organ or structure contained in it 
(visceral peritoneum). The space between the visceral and parietal peritoneum, the peritoneal 
cavity, normally contains a small amount of serous fluid that permits free movement of the 
viscera, particularly of the gastrointestinal tract, inside the peritoneal cavity. The peritoneum, 
by connecting the visceral with the parietal portions, assists in the support and fixation of the 
abdominal organs. The diverse attachments of the peritoneum divide the abdominal cavity 
into several compartments. 
Some of the viscera are attached to the abdominal walls by broad areas of the peritoneum, as, 
for example, the pancreas. Others, such as the liver, are attached by folds of the peritoneum 
and ligaments, usually poorly supplied by blood vessels. 
The peritoneal ligaments are actually rather strong peritoneal folds, usually connecting viscera 
to viscera or viscera to the abdominal wall. Their name usually derives from the structures 
connected by them(e.g., the gastrocolic ligament, connecting the stomach and the colon; the 
splenocolic ligament, connecting the spleen and the colon) or from their shape (e.g., round 
ligament, triangular ligament). 
The mesenteries are folds of peritoneum that are attached to the wall of the abdomen and 
enclosing viscera. They are richly supplied with vessels that carry blood to or from the organs 
that they enfold. The three most important mesenteries are the one for the small intestines; 
the transverse mesocolon (which attaches the transverse portion of the colon to the back wall 
of the abdomen) and the mesosigmoid (which enfolds the sigmoid portion of the colon). 
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The omenta are folds of peritoneum enclosing nerves, blood vessels, lymph channels, and 
fatty and connective tissue. There are two omenta: the greater omentum hangs down from 
the transverse colon of the large intestine like an apron; the lesser omentum is much smaller 
and extends between the stomach and the liver. 
5.1.2 Ethiology and Pathophysiology 
Common afflictions of the abdominal cavity include the presence of fluid in the peritoneal 
cavity (abscess) and peritonitis, an inflammation of the peritoneum. Intra-abdominal 
abscessess are an important and serious problem in surgical practice. Appropriate treatment 
is often delayed because of the obscure nature of many conditions resulting in abscess 
formation, which can make diagnosis and localization difficult. Associated pathophysiologic 
effects may become life threatening or lead to extended periods of morbidity with prolonged 
hospitalization. Delayed diagnosis and treatment can also lead to increased mortality rates. 
Therefore, the economic impact of delaying treatment is significant. 
A better understanding of intra-abdominal abscess pathophysiology and a high clinical index 
of suspicion should allow for earlier recognition, definitive treatment, reduced morbidity and 
mortality. 
Although multiple causes of intra-abdominal abscesses exist, the following are the most 
common:  
 Perforation of a diseased viscus, which includes peptic ulcer perforation  
 Perforated appendicitis and diverticulitis 
 Gangrenous cholecystitis  
 Mesenteric ischemia with bowel infarction  
 Pancreatitis or pancreatic necrosis progressing to pancreatic abscess. 
Other causes include untreated penetrating trauma to the abdominal viscera and 
postoperative complications, such as anastomotic leak or missed gallstones during 
laparoscopic cholecystectomy.  
Intra-abdominal abscesses are localized collections of pus that are confined in the peritoneal 
cavity by an inflammatory barrier. This barrier may include the omentum, inflammatory 
adhesions, or contiguous viscera. The abscesses usually contain a mixture of aerobic and 
anaerobic bacteria from the GI (Gastro Intestinal) tract. 
Surgical site infections (SSIs) are not an extinct entity; they account for 14-16% of the 
estimated 2 million nosocomial infections affecting hospitalized patients in the United States 
(31). Infections are caused by bacterial contamination mostly contracted during surgical 
operation (see Table 14 ) and, more rarely, by contamination in the postoperative period.  
clean intervention  1-3% 
clean-contaminated intervention    5% 
contaminated intervention 15-30% 
dirty intervention  20-40% 
Table 14 Percentage of infection per grade of cleanliness of intervention 
Local Signs of infection are erythema, tenderness, hardening of margins and pus that leaks 
from the wound. It becomes clinically manifest between the V and VII day. Some slow onset 
infections occur with skin erythema, partial wound dehiscence, and streaming days after 
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removal of points. The main complications can be dissemination of local or general infection, 
wound dehiscence with possible gutting and incisional hernia. The prognosis of wound 
infection is generally favourable if the treatment is appropriate. Only exceptionally a poor 
evolution occurs for the incidence of complications later (e.g. dehiscence, peritonitis, septic 
shock). In Table 15 there is a list of risk factors in surgical wound infections. 
 Risk factor 
Patient’s status Age, nutrition, diabetes, tabagism 
Intervention Duration of surgical washing 
Failure in the obliteration of dead 
space 
Preoperative shower 
Preoperative skin preparation 
Duration of the intervention 
Right antibiotic prophylaxis 
Operating room ventilation 
Not accurate Surgical device 
sterilization 
Surgical drainage 
Surgical technique 
Poor haemostasis 
tissue trauma 
Table 15 List of risk factors in surgical wound infections due to patient’s status and intervention 
Today the only way to monitor surgical wounds are: 
 To monitor the patient several times during the day in order to avoid immediate 
local complications 
 To check color and amount of drainage in the post operative period  
 Daily inspection and palpation of the wound 
 Medication of the wound on the 5th day 
 Partial removal of suture knots ,total removal on the 9th day 
The use of drainage reflects the need for the surgeon to maintain a "Spy" on what happens in 
the outbreak surgery after skin closure. The drainages have the primary objective to promote 
the evacuation of any collecting blood, serous fluid or other. The abdominal cavity generally 
doesn’t require aspiration, because the abdominal pressure is enough to convey the collected 
blood or other liquids outside. There are several kind of drainage tubes for each application. 
The endo-abdominal draining tubes are used for emptying the peritoneal cavity from: 
 Normal substances present in the post operative phase: serositis, poor bleedings 
 Residual not totally removed during intervention: blood, bile, pus, necrotic 
substances secondary to infectious or hemorrhagic complications occurred 
postoperatively 
VideoDrain is a ''warning'' endoscopic system that allows the monitoring of abdominal cavity 
in the postoperative course. It allows for viewing inside the abdominal cavity and can be used 
by nurses and by the physician. With direct and real-time visualization of the abdominal cavity 
it will be possible to find the potential danger before the leak of liquids. 
VideoDrain must be positioned parallel to a drainage tube placed after any abdominal surgery. 
It can be placed in the laparoscopic wounds or in an abdominal incision depending on the 
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organs / tissues to inspect. VideoDrain is designed to be used in post-operative course after 
resection of the stomach, intestine and rectum (in hazardous, both intestinal and vascular), 
anastomosis (special kind of suture that joins two hollow viscera thus making them 
communicate ). In presence of ischemia, the use of VideoDrain is highly recommended, 
especially where there is a need to reopen and verify the result of the intervention. It is a valid 
alternative to "second look" interventions.  
5.2 Market Analysis 
A precise market analysis has been conducted thanks to the use of national hospital discharge 
records for the particular surgical application of the device. The SDO (schede di dimissione 
ospedaliera9) is the tool used in all Italian hospitals to document the hospitalization of each 
patient. The national database of hospital admissions has been established in 1994 and it 
carries the information of all admissions registered in Italy. It has gradually expanded both 
quantitatively and qualitatively. Completing the form, the hospital identifies the service 
offered to the patient, which can be a surgical procedure or a diagnostic intervention, with a 
code: ICD, International Classification of Diseases. 
Regularly reviewed, the present version is ICD9CM (International Classification of Diseases, 
9th Revision, Clinical Modification) whose main objective is to classify morbidity data. 
The main surgical applications regarding the post-operative use of VideoDrain are listed in the 
Table 16. 
Description of the intervention ICD9-CM 
Discharged –Italy 
(2005) 
Discharged –USA 
(2005) 
Esophageal interventions 42 2710 45.292 
Incision and removal of the stomach 43 15347 267.547 
Other interventions on the stomach 44 5816 174555 
Incision, removal and anastomosis of the intestine 45 57510 628.661 
Other interventions on the intestine 46 3738 57.255 
Interventions on the rectum, rettosigmoid and rectal 
peripheral tissues 
48 24135 110.528 
Other interventions on the abdominal region 54 2943 96.162 
Transplantations 
Liver 
Pancreas 
Kidney 
 2740 21.218 
50,5 935  
52,8 72  
55,6 1733  
TOTAL  114.939 1.401.218 
Table 16 Comparison of principal DRG (Diagnosis Related Groups ) for VideoDrain application between Italy and Usa 2005 
5.3 State of the art: Commercial systems 
The objective of VideoDrain is to monitor the abdominal cavity after a surgical intervention 
creating, through the insufflation of a balloon, a cavity between the organs; introducing a 
fiberscope inside a tube until the cavity, it allows the control of the post–operative course of 
the patient. 
In Table 17 there is an economic comparison between some devices similar in terms of 
structure or components and sometimes in intended use to VideoDrain. 
                                                     
9
http://www.salute.gov.it/ricoveriOspedalieri/paginaInternaRicoveriOspedalieri.jsp?menu=rilevazione&id=1232
&lingua=italiano 
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Product Price (€) 
Companies Annual 
sales Italy 
(pcs) Italy Europe World 
Drainage catheters 
1-4 (the catheter) 
20-80(the whole 
set depending 
from the type) 
Chimed
10
, 
Gps 
11
 
Mediberg
12
 
Anderseneurope
13
 
Astratech
14
 
 
Boston
15
 
Merit
16
 
Angiodynamics
17
 
+500 K 
Endoscopic covers 9-15 
Service 
2001
18
 
Xmed
19
 
Endoclarix
20
 
Storz
21
 
Insight
22
 
Scopeguard
23
 
Medtronic
24
 
 
1.5 M 
Balloon dissectors 580  Covidien
25
 Bbraun
26
 ≈8.000 
Balloon systems for 
diagnosis and 
intervention 
193  Pajunk
27
   
Table 17 Analysis of competitors: market evaluation 
The annual sales have been calculated starting from information on national hospital public 
databases, regarding the annual purchases of each institute and the number (32)of Italian 
public and private institutes of Health (approx 1600). 
Below there is a description of each concurrent device and also of alternative diagnostic 
techniques for post operative diagnosis of abdominal surgery complications. 
5.3.1 Abdominal drainage tubes  
The drainage system is generally a tube whose inner diameter can vary from about 1 mm to 
over 15 mm with thicknesses ranging from 1 to 6 mm and should be designed to allow easy 
flow of materials in the main channel of collection. In general, in the distal portion it has a 
variable number of side holes to facilitate the conveyance of the drainage material toward the 
external sterile containers. 
                                                     
10 http://www.chimed.it/ 
11 http://www.gpsmedical.com 
12 http://www.mediberg.it/prodotti-medicali-monouso.html 
13 http://www.anderseneurope.com/ 
14 http://surgery.astratech.it/ 
15http://www.bostonscientific.com/procedure/ProcedureLanding.bsci/,,/navRelId/1000.1002/method/Procedure
/id/10001061/seo.serve 
16 http://www.merit.com/products/productdetail.aspx?id=654 
17 http://www.angiodynamics.com/products/total-abscession 
18 http://www.service2001surgyline.it/ 
19 http://www.xmed.it/ 
20 http://www.endoclarix.com/ 
21 http://www.karlstorz.com/cps/rde/xchg/karlstorz-en/hs.xsl/146.htm 
22 http://www.insightmedical.net/product.asp?ID=58 
23 http://www.scopeguard.co.uk/products/urology/cystoscope-sheath/ 
24 http://www.medtronic.com/italy/ 
25 http://www.covidien.com/hernia/pages.aspx?page=Catalog/Access 
26 http://www.bbraun.com/cps/rde/xchg/bbraun-com/hs.xsl/products.html?prid=PRID00005099 
27 http://www.pajunk.com/ 
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Thanks to the monitoring of drainage fluids (33), it is possible, but not in all cases, to prevent 
post operative complications such as pancreatic fistulas, hematomas etc. 
 
Figure 44 Example of systems for drainage 
5.3.2 Endoscopic covers 
The endoscopic covers  (i.e. ENDOSHAFT-COVER® and ENDOSHAFT-COVER® PLUS) are sterile 
and disposable protective coatings for flexible and rigid endoscopes. They are easily placed on 
the fiberscope and usually equipped with a lens on the tip of the device in order to avoid 
blurring. The device provides a fast and effective way to increase the productivity of 
endoscopes, it provides sterility for each procedure and it is an effective barrier to 
microorganisms. 
 
Figure 45 Example of fiberscopic covers 
5.3.3 Trocar for extraperitoneal dissection (Balloon dissectors) 
The balloon dissectors separate the layers of fascia from the peritoneum and access the site of 
the hernia, they promote relaxation leading to the creation of an extraperitoneal cavity in 
which it is possible to operate. It consists of a reusable part (Blunt cannula and mandrel) and a 
disposable part (rod with balloon distension and hand pump). 
 
Figure 46 Balloon dissectors 
5.3.4 Balloon systems for diagnosis and intervention without insufflation 
Diagnostic balloon is a valid "gas-less" alternative to pneumoperitoneum. It allows the 
examination of the cavity during the distension of tissue through a rigid endoscope. The 
unique system, LapVision by Pajunk , consists of an optical trocar tip which gives the vision, 
once introduced the endoscope, throughout the operation of abdominal distension. The 
balloon has a second chamber in the distal part and the two balloons are blown 
simultaneously. This ensures greater stability in handling maneuvers during the surgical 
dissection. The diameter of the balloon reaches only 3 cm. 
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Figure 47 Pajunk LapVision 
5.3.5 Abdominal ultrasound 
Sonography of the abdomen is commonly requested for patients who have recently 
undergone abdominal surgery. Abdominal sonographic examination is often inadequate or 
impossible in the patient who has recently had abdominal surgery. Dressings, sutures, drains, 
raw areas, discharging sinuses, and tenderness interfere with the study. Hence the examiner 
has to scan between the wounds or intercostally. In addition to these limitations, scanning is 
impossible directly over the wound when sutures or clips are present(34). 
Incisional hernias, which are hernias that occur through a surgical scar in the anterior 
abdominal wall, are serious complications of abdominal surgery (35) and Ultrasound 
examination can help the diagnosis of such complications. In post-operative patients, large 
hematomas may often be seen in the vicinity of the surgical scar (36). 
In (37) ultrasound examinations were carried out on women on day 4 after surgery to assess 
the presence of abdominal wall or pelvic ﬂuid collections.  
 
Figure 48 Abdominal Ultrasound examinations 
5.3.6 Diagnostic Laparotomy 
Diagnostic laparoscopy is a minimally invasive surgical procedure that allows the visual 
examination of intra abdominal organs in order to detect pathology. The video image of the 
liver, stomach, intestines, gallbladder, spleen, peritoneum, and pelvic organs can be viewed 
on a monitor after insertion of a telescope into the abdomen. Manipulation and biopsy of the 
viscera is possible through additional ports. 
The indications (38) for diagnostic laparoscopy can be divided into four main groups: 
3. Non-traumatic, non-gynecological acute abdominal pain like: 
 Appendicitis 
 Diverticulitis 
 Duodenal perforation 
 Mesenteric adenitis 
 Intestinal adhesion 
 Omental necrosis 
 Intestinal infarction 
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 Complicated Meckel’s diverticulum 
 Bedside Laparoscopy in the Intensive care unit 
 Torsion of intra-abdominal testis 
4. Gynecological abdominal emergencies  
5. Abdominal trauma, abscesses and disease 
6. “Second look” procedure or cancer staging. 
There is some risk of infection. However, antibiotics are usually given to prevent this 
complication. 
There is a risk of puncturing an organ, which could cause leakage of intestinal contents or 
bleeding into the abdominal cavity. Such a complication could lead to immediate open 
surgery. 
5.3.7 Abdominal radiography and computer tomography scan 
When an abdominal X-ray is taken, radiation is momentarily applied to the abdomen. The 
image that is produced is the result of passing X-rays through the abdomen to the film. 
Structures like bone or calcification, which are dense and have a high atomic number, absorb 
a lot of radiation, so that fewer X-rays reach the film, and appear white. Structures like bowel 
gas, which are full of air and have a low atomic number and density, appear black because 
most X-rays pass through without being absorbed. Liver, fat, tumor, and fluid absorb less X-
rays than bone, but absorb more than air and, consequently, appear gray on the film. 
Abdominal radiography uses X-rays, a type of ionizing radiation that can potentially change 
chemical and genetic structures in the human body. Plain abdominal X-rays can render 
important clues in evaluating one's condition. But in many cases, it does not provide any 
specific information, and only functions as a gateway examination to the next step. In the case 
of abdominal trauma, abdominal CAT (computer axial tomography) scan is the examination of 
choice because it can demonstrate internal bleeding, organ injury, or bowel perforation 
specifically, in an early stage. 
Abdominal CT for postoperative abscess can be expected to be diagnostic in a substantial 
proportion of cases (39) in the ﬁrst week after an abdominal intervention, the majority of 
which lead to percutaneous or operative drainage. Postoperative CT for intra-abdominal 
abscess should be obtained as clinically indicated, regardless of interval from surgery. 
CT helps identify ﬂuid collections(40), differentiate them from hernia recurrence (which may 
have a difficult physical examination, especially in obese patients), and conﬁrm their 
resolution. 
5.3.8 Analisys of competitors features 
In Table 18 there is a comparison between the main features of  concurrent devices and 
system of diagnosis of abdominal organs and wounds in the postoperative period. 
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System 
Feature 
Drainages Covers 
Balloon 
dissector 
LapVision US Laparotomy 
TC, 
Xrays 
VideoDrain 
Visual 
monitoring of 
the surgical 
wound 
 X X X  X  X 
Space creation 
in the 
abdomen 
  X X  X  X 
Diagnosis of 
post-operative 
complications 
X X  X X X X X 
Difficult use for 
lacking of 
necessary 
accessories in 
the hospitals 
 X   X X X X 
High cost (both 
disposable and 
reusable parts) 
  X X X X X  
Invasiveness    X  X X  
Diagnostic 
efficiency 
Medium, 
sometimes 
a second 
look 
intervention 
is necessary 
Not 
applicable 
for 
abdomen, 
due to 
the 
collapse 
of organs 
Not 
applicable, 
different 
intended 
use 
No data 
available 
Low, 
lack of 
direct 
vision 
of the 
wound 
x x Tbd 
Disposable X X 
X 
(partially) 
X    X 
Flexibile X X  
Flexible 
trocar 
sleeves 
with flat 
closures 
remains 
in the 
patient 
without 
being 
disturbed. 
   X 
Additional 
scars needed 
   X  X   
Anestesia 
needed 
   X (LOCAL)  X   
Hazardous      X X  
Table 18 Analysis of competitors: comparison of main feature 
As seen in the previous table there is not a real direct competitor for VideoDrain because the 
systems differ for many reasons. The TC scan and X-rays exams are very effective but very 
dangerous for health and the ratio cost/efficacy is very high; ultrasound is not dangerous but 
not very effective in case of visualization of pus, bile, blood. The balloon dissectors are 
fabricated with a different intended use and cannot be released in the patient for the entire 
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length of the postoperative period. The endoscopic covers cannot allow the inflation of the 
abdominal cavity and the drainage tubes are only intended for draining liquids but they 
cannot show the condition between the organs. 
Only LapVision allows the visual monitoring of abdominal site but there are some structural 
and economic differences compared to VideoDrain. 
The shaft is in stainless steel (Table 19) and only a flexible trocar is left into the scar on the 
patient for further monitoring, thus the surgeon has to reuse the entire kit in order to 
evaluate the patient’s conditions. The cost of the kit, as reported in Table 17, is very high 
compared to the one of Video Drain, which will be approximate around 15-20 €. 
Product Spacemaker™ Dissection Balloon Herloon Pajunk LapVision 
Material Silicone balloon, latex body o the trocar (not 
in contact with the patient). The oval 
dissection balloon is rigid; the round 
dissection balloon is elastic. 
Stainless steel 
shaft, plastic 
balloon 
Stainless steel shaft, plastic 
balloon 
Shape Different shape of the ballon depending 
upon the intervention 
Unique Unilateral and bilateral balloon. 
Double balloon for enhanced 
stability and for guaranteeing a 
minimal space between the 
optic 
Sterilization 
method 
The entire device is disposable Partially 
disposable 
Partially disposable 
Dimensions The round dissection balloon is 4.5 
(114.3mm) inches in Ø when inflated with 
1000cc. The oval dissection balloon is 7.5 
inches wide, 4.5 inches tall and 4.5 inches 
deep when inflated with 1000 ccs of air. 
Vmax=40 hand pumps of air (syringe up to 
20cc) 
Lenght 300 
mm 
Tube Ø 10 
mm 
Tube Ø 11 mm 
Balloon Ø 30 mm 
 
Valve   One way tap valve for 
insufflations of the balloon 
Accessories 
needed 
  scopes Ø 3,5 mm 
Table 19 Analysis of structural features of the main concurrent and similar  device 
5.4 Patent Search 
A search of pre-existing patents has been conducted on free databases like: 
 http://www.freepatentsonline.com 
 http://www.wipo.int/pctdb/en/ 
 http://www.espacenet.com/index.en.htm7 
 www.patentstorm.com 
Taking into account only the class A61-Medical or veterinary science; hygiene- of the 
International Patent Classification (IPC)- in Table 20 there are the main results of a wider 
patent search. 
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Keywords 
Search engine Relevant results among the first 
200 1 2 3 4 
post-operative diagnosis device abdominal 
vision 
154 293 0 425 
(41) 
(42) 
patient abdominal vision system cover 547(3) 0 0 1438(0) 
(43) 
(44) 
Drainage Endoscope 4237 0 17 3464 0 
Balloon Dissector 1075 195 9 877 
(45) 
(46) 
(47) 
(48) 
Multilumen drainage tube 395 63 0 260 0 
Balloon Wound Surgical Tube 5776 4219 0 8816 0 
Endoscopic balloon Cover 4778 2236 2 7306 
(49) 
(50) 
(51; 52) 
(53) 
(54) 
Scope sheath balloon diagnosis 2066 1314 0 1000 (55) 
drainage  endoscope  monitoring  post-oper 391 109 0 279 0 
Wound scope observation  post-oper 1730 2447 0 3676 0 
Expanding balloon abdomen monitoring 
device 
803 1347 0 1954 
(56) 
(57) 
Table 20 Results of patent search 
The main patent found is (43) described as follows: 
It is directed towards a medical scope guide for use in viewing the internal body tissues of a 
patient. The scope guide comprises an elongated hollow tube having opposite inner and outer 
ends. A transparent balloon is secured to the inner end of the tube. The tube serves as a 
conduit of air for inflating and deflating the balloon. A scope device is slidably received in the 
tube and extends into the balloon for viewing internal body tissues. 
In use, the scope guide is inserted through a surgical incision into a patient's body. During 
such insertion, the balloon is retracted into the inner end of the tube. The balloon is inflated, 
and preferably engages the body tissue to be viewed. After the tube is in place, the scope 
device is inserted into the tube such that the end of the scope device is positioned within the 
transparent balloon. Thus, with the balloon inflated and the scope device positioned in the 
balloon, the internal body tissue can be easily viewed. The scope guide can remain in position 
with the inner end thereof located within the patient's body and the outer end located 
outside the patient's body, so that the internal tissues can be viewed at a later time. In such a 
situation, the incision can be closed around the tube and then closed completely after the 
scope guide is finally removed. 
Preferably, the scope guide is made of a flexible plastic material and is disposable. Also, 
aspiration and irrigation passages may be provided on the scope guide. 
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Figure 49 Patent Images 
As described, the patent refers to a device very similar to VideoDrain but it is expired due to 
failure to pay maintenance fee, as seen on (58).Thus it is not possible to patent again the 
device but the production is free of any legal or economic constraint. 
Thanks to the advice of an expert in patenting, it has been stated that it may still be possible 
to submit an application for patent as an invention, applying some changes to the intended 
use (restricted to a certain series of risk interventions) and other technical changes. At the 
same time as an alternative, it is also possible to submit a request of Utility Patent. 
5.5 Design of the device 
Initial specifications of the Product are: 
 Biocompatibility, both in the materials and in the design 
 Minimal invasiveness into the abdominal cavity and outside 
 No incision / trauma to the patient more than the one reported after the 
intervention 
 Rapid diagnosis in cases of post-operative problems in the abdominal cavity. 
VideoDrain must be able to see organs placed inside the abdominal cavity and interconnected 
between them in order to keep the physiological balance of the body. Each dimension is well 
defined and the spaces between the various tissues are minimal. It is necessary an 
enlargement of the field of vision for a precise diagnosis and, hence, the need for a system 
able to create volume in the area concerned.  
The tools that perform a separation of tissues and membranes inside the human body are 
known as dissectors. In no way the system can damage bodies which it comes into contact 
with and then a balloon dissector has appeared to be a minimally invasive solution because it 
is able to: 
 Apply mechanical action of rapid and temporary separation 
 Adapt to the surrounding organs without damaging 
 Allowing for a clear view of the abdominal cavity 
 Protect the vision system 
 Maintain microbial insulation and protection from external agents in the abdomen. 
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5.5.1 Analysis of potential configuration and Computer assisted design 
The main components discussed below are: 
 A plastic tube 
 A balloon 
 A one-way valve system 
 A vision system. 
In the design of the device several configurations have been examined, evaluating whether 
each of them met the basic specifications. 
The potential versions can be: 
1. Multi-lumen (M): the catheter incorporates the collection of drained fluid and 
visualization of internal organs. 
2. Single-lumen (S): the catheter allows the endoscope to visualize organs within the 
abdominal cavity. 
The first approach has been adopted to consider the integration of the drainage system and 
the vision system in order to reduce the number of tubes to bring inside the patient at the end 
of the intervention. Therefore, the completion of the postoperative tasks results simplified.  
Two different (M) versions containing drainage and vision system in one device (see Figure 50 
) have been designed. An external diameter of the tube of 10 mm has been established for 
both versions for minimal invasive purposes. The internal channel for the commercial 
fiberscope varies from 3 to 5 mm (see 5.5.4). 
In the first version (A) there is a single channel for the collection of drainage fluids coming 
from the lateral holes and the channel for the fiberscope is eccentric compared to the tube. In 
version B, four channels have been designed in order to allow an easier flow of drainage 
fluids, due to the symmetrical order of the holes. The main disadvantage of the second 
solution is the thickness of the tube wall (0.45 mm versus 1mm of the version A, see Annex 
VII), which is too low for a good result of the process of extrusion (3.3.3.1). For further 
information about drawings see Annex VII) 
 
Figure 50 Distal end of multilumen (M) tubes: version A on the left and version B on the right 
Other two (M) versions have been investigated (Figure 51): 
3. C version, which has a channel for the fiberscope and one for the sliding of a guide 
wire  
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4. D version, with a lumen for the introduction of a commercial drainage tube and one 
for a commercial fiberscope 
 
Figure 51 Multi-lumen version C (left) and D (right) 
Because of the difficulty to find a fiberscope in the hospitals, another draft (E version, Figure 
52) has been made in order to embed an economic mini vision system. The system consists of: 
1. A miniature camera 
2. A lighting system using LEDs. 
After careful concerns regarding the resolution, size and cost, the chosen camera is the model 
MO-BS802-105 of MISUMI (Figure 52 on the right); its specifications are shown in Table 21. 
Video system NTSC 
Effective Number of pixels 320x240 
Image Sensor 1/18” Color CMOS Camera 
Resolution 240 TV Lines 
S/N Ratio >48dB 
Minimal illumination 2 Lux/F1.2 
dimensions 3.5X5.2 mm 
Table 21 Misumi MO-BS802-105 specifications 
This solution has two main disadvantages: the external diameter of the whole device results 
too big (15mm) and the device too expensive for the DRG which it has been thought to. 
 
Figure 52 Multilumen (E) with embedded vision system 
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The major benefit of the multi-lumen solution is that the device integrates drainage and 
diagnosis (solution A,B,D,E),thus the introduction of a single tube causes less discomfort to 
the patient. 
There are many disadvantages: 
 Assembly and manufacturing are more complex, thus the cost is higher 
 Need of additional evidence to assess the power of drainage system 
 The size of the outer diameter increases 
It is more difficult to find the proximal end connector between standard connectors because it 
has to be also a collection system for drained liquids: it cannot be commercial, thus the cost 
increases. 
Another configuration (S) provides a tube with an internal channel for the endoscope and for 
insufflation of a distal balloon for the monitoring. In order to reduce the wall thickness, whilst 
maintaining the integrity and mechanical flexibility of the tube, a steel spiral has been 
included during the extrusion in the wall of the tube (Figure 53).  
 
Figure 53 Single lumen(S) braided reinforced tube 
The single-lumen configuration has many advantages: 
 Construction and manufacturing are relatively simple 
 Lower overall costs 
 Meets the specification on the maximum external dimension: <<10mm 
 One-way valve system for the connector part already commercially available. 
The only disadvantage is that it must be parallel to a commercial drainage catheter, thus 
causing less comfort to the patient during the insertion of two tubes. 
5.5.2 Analysis of materials 
Biocompatibility plays a key role in the development of medical devices and is an important 
input requirement for its design. In order to take into account the biocompatibility (59) one 
must not only consider the applied materials, but especially the complete medical device as a 
whole and its intended use in the human body. In addition one should keep in mind that 
biocompatibility of a medical device depends on the time that it is exposed to the human 
body and the location in the body where it is applied or implanted. 
Apart from the materials and its intended use, the biocompatibility of a medical device is also 
influenced by its production process. During this process the quality of materials may decline 
and, as a consequence, the applied materials must be judged in their final state. Degradation 
can be caused by heat, temperature or contact with other materials. Cleaning, packaging and 
sterilization may alter the quality of materials. Therefore, the complete production process 
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has to be taken into account when the biocompatibility of a medical device is established. In 
the ISO 10993-1 there is a flow chart (see Figure 54 in yellow circles VideoDrain evaluation) 
which guides selecting the tests to evaluate the biological response to medical devices. 
Either directly or through the release of their material constituents, the device materials 
should not: 
 Produce adverse local or systemic effects 
 Be carcinogenic 
 Produce adverse reproductive and developmental effects. 
Therefore, evaluation of any new device intended for human use requires data from 
systematic testing in order to ensure that benefits provided by the final product will exceed 
any potential risks produced by device materials. 
In general, the tests include: acute, sub-chronic and chronic toxicity, irritation to skin, eyes 
and mucosal surfaces, sensitization, hemocompatibility, genotoxicity, carcinogenicity and 
effects on reproduction including developmental effects.  However, depending on varying 
characteristics and intended uses of devices as well as the nature of contact, these general 
tests may not be sufficient to demonstrate the safety of some specialized devices. Additional 
tests for specific target organ toxicity, such as neurotoxicity and immunotoxicity, may be 
necessary for some devices.  
There are devices which are made of materials that have been well characterized both 
chemically and physically in the published literature and that have a long history of safe use. 
For the purposes of demonstrating the substantial equivalence of such devices to other 
marketed products, it may not be necessary to conduct all the tests suggested by the ISO 
10993 standard.  
A systematic analysis of biological risks can be found in the general principles set out in clause 
3 of ISO 10993-1 (see Table 22, in red the indications about the minimal tests for the materials 
of VideoDrain components). 
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Figure 54 Annex B ISO 10993 Flow chart for the selection of toxicity tests 
Device Categories Biological Effect 
Nature of Body Contact 
Contact duration 
A-limited 
(24h) 
B-prolonged 
(24h to 30 days) 
C-permanent 
(>30days) 
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Surface  
devices 
Skin 
A x x X      
B x x X      
C x x X      
Mucosal 
membrane 
A x x X      
B x x X      
C x x X  x x   
Breached or 
compromised 
A x x X      
B x x X      
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C x x X  x x   
External  
communicating 
devices 
Blood path, 
indirect 
A x x X x    x 
B x x X x    x 
C x x  x x x  x 
Tissue/bone/ 
dentin 
communicating 
A x x X      
B x x    x x  
C x x    x x  
Circulating 
blood 
A x x X x .  . x 
B x x X x  x  x 
C x x X x x x  x 
Implant 
devices 
Tissue/ 
bone 
A x x X  . . .  
B x x    x x  
C x x    x x  
Blood 
A x x X x . . x x 
B x x X x  x x x 
C x x X x x x X x 
Table 22 ISO 10993-1 Biocompatibility Matrix  
In the prototyping phase, several kind of materials have been used in order to choose the 
right characteristics (stiffness for the tube, transparency and elongation for the balloon). 
Silicone is among the most extensively tested materials used in medical device applications, in 
particular in tubing for minimally invasive devices. Chemical analysis demonstrate a low loss of 
residues and the absence of plasticizers and additives. The majority of medical devices made 
in silicone show: 
•Low bacterial adhesion 
•Low thrombogenicity. 
Therefore, silicone is the ideal material for creating VideoDrain, considering its repellent and 
excellent stability both from a chemical and a mechanical point of view. In fact, silicone is 
used in a context similar to VideoDrain as surgical drainage, urethral probes and all 
applications in which there is prolonged contact with the body (60). Indeed is flexible, elastic, 
resistant and can be autoclaved repeatedly. 
The main mechanical specification for VideoDrain are: 
 For the catheter: flexibility and stiffness ( shore A between 30 and 80) 
 For the balloon: transparent, expandable (max. pressure 20mmHg, external  
diameter  from 30 to 90 mm so an high elongation to break is needed)  
Mechanical characteristic Rtv 4411 Rtv4440 
Hardness Shore A 11 37 
Tensile Strength [N/mm ] 3.0 5.5 
Elongation [%] 800 400 
Tear strength 12 22 
Colour Transparent Transparent 
Table 23 Materials for the prototyping phase 
The first prototypes designed to assess the feasibility of the system were produced using the 
line of Silbione® Bluestar Silicones (Table 23), respectively RTV 4411 for the balloon and RTV 
4440 for the catheter. Both the silicones are certified for medical products. For the 
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manufacturing of the balloon various attempt  have been done. At first, a mould has been 
designed and realized with a 3d printer, and a casting has been done. The results have been 
not so encouraging, due to the high number of air bubbles (see Figure 55, left) depending to 
lack of openings for air. The technique of dipping showed better results (Figure 55, right). 
 
Figure 55 Balloon prototyping 
A manual immersion does not allow the control of the thickness and for the tube the results 
obtained were very bad, due to presence of air bubbles and bad dimensional tolerances.  
5.5.3 Final configuration and prototype 
After the analysis of all the possible configurations for the tube, the S version has been chosen 
as the solution which better matches the intended use of the device and better optimizes the 
potential manufacturing costs and quality parameters. A search for commercial components 
has been completed in order to produce the device drawn in Figure 56 (see Annex VII for 
further details), fulfilled with auxiliary systems (valves, balloon, connectors). 
 
Figure 56 Final CAD drawing of VideoDrain 
The Lateral Valve(61) is a one way valve which utilizes a female luer lock compatible 
connector and a male luer lock adapter. It mates securely with all standard luer syringes and 
connectors providing a hermetic seal between syringe luer tip and valve. 
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Figure 57 Lateral valve: cad drawing and commercial component 
The single lumen tube is reinforced (Figure 58) with an helical metal wire coextruded with the 
tube. 
 
Figure 58 Braided reinforced tube 
The distal balloon (Figure 59) is made by medical grade silicone. It allows an expansion from 
35mm of diameter to 90mm. 
 
Figure 59 Balloon: deflated (left) and inflated (right) 
The connector is made by three parts (see Figure 60 left image): 
1. One bonded with the single lumen reinforced tube 
2. One attached to the first part with a thread, it contains a silicone membrane (4 in 
Figure 60 right ) 
3. One laterally glued to the second part, it has a luer lock attachment to fit the lateral 
one-way valve 
 
75 
 
Figure 60 Exploded view of the connector (left) and the adapter (centre). Commercial adapter (right) 
At the proximal end of the connector there is a red cap which allows the regulation of the 
opening of the silicone membrane, thus allowing the insulation for fiberscope of different 
diameter. 
The commercial component chosen for the device is a Tuohy Borst Adapter (Figure 60) (62) 
which allows the regulation of internal diameter for the entrance of the fiberscope with an 
external diameter from 2.2 to 5.6 mm. 
 
Figure 61 Final Prototype of VideoDrain 
In Table 24 we report all components of the pre-industrial prototype (Figure 61) . VideoDrain 
final prototype (Figure 61) has been manufactured by a company which applies the new 
quality standards and safety for the medical device sector (ISO13485, MDD 2007/47). 
Component (Figure 61) Critical dimensions material 
1-Balloon External diameter 35mm 
Thickness: 0.3-0.4mm 
Silicone 
2-Reinforced tube 23Fr (7.59 mm) Body: PU AISI 304 
3-Thuohy Borst adapter for catheters Internal diameter from 7 to 17 Fr  
(2.33 to 5.66 mm) 
Body: PC 
Membrane: Silicone 
4-Sleeve T.B. adapter-catheter body  PVC 
5-Female luer lateral connector  PVC 
6-Connector between adapter and 
lateral luer 
 PVC 
7-Anti-reflux luer lock valve  Body: PC 
Valve: silicone 
Table 24 Components of the final prototype 
5.5.4 Accessories 
In order to insufflate the distal balloon, an inflation device is needed. It must have a male luer 
lock attachment in order to fit the female luer of the one way valve. A commercial syringe 
with a big volume (50 ml,(63)) has been chosen.  
Alternatively another way to control the insufflation can be an inflation device like the one in 
Figure 62 (left)(64) which allows a monitoring of the pressure inside the balloon. 
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Figure 62 Inflation device (left); flexible endoscope (right) 
For the monitoring of wounds, a vision system is needed. It must be flexible and the outer 
diameter must be between 2.3 and 5.6mm. In the healthcare facilities there are a lot of 
flexible endoscopes, available for various applications (see Table 25), which can be used with 
VideoDrain. 
Scope External diameter(mm) Length(mm) 
Broncoscope 3.6-5 550 
Rhinolaryngoscope 3.4-5.2 250-300 
Cystoscope 3.3-5.1 350 
nasopharyngoscope 3-5 300 
Choledochoscope 3.7-4.5 300-1880 
Hysteroscope 3.1-4.9 200 
Fiber Intubation Scope 3.4-4 600 
Uteroscopes 3.3 700 
Table 25 Medium values of dimensions of commercial flexible endoscopes 
5.6 Tests 
5.6.1 Mechanical tests 
Some mechanical tests has been done on the connections of the final prototype in order to 
ensure their resistance to break. 
The UNI EN 1617 (Sterile Drainage Catheters and Accessory Devices for Single Use) refers to 
drainage catheter and auxiliary disposable devices. Catheters of external diameter below 
2mm, suction catheters for the respiratory tract and tracheal tubes are excluded. Therefore, 
VideoDrain can be included. The regulation provides information on various made tests 
indicating what should be the minimum strength at break between connections of the 
components of the device. 
External nominal diameter Tensile strength at break (N) 
From 2 to 4 5 
>4 15 
Table 26 UNI EN 1617; minimum force needed to break connections 
The UNI EN 1618 (Catheters Other than Intravascular Catheters - Test Methods for Common 
Properties) indicates the test methods to ensure an uniform assessment of the characteristics 
of catheters, such as resistance to corrosion of metal components, determination of the 
traction, resistance to leakage of fluid under pressure, determining the water flow in catheter 
and tests for safe connections.  
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The useful data extrapolated from this standard is the speed to be imposed during the tensile 
test (Figure 63) on the connections of VideoDrain: 
20mm * L / min 
where L is the length exposed to tension. 
 
Figure 63 Tensile test on the connection between tube and sleeve 
On the device the tensile strength test of the connection between the adapter 4 in Figure 61 
has been carried out. The expected minimum value of breaking stress for the connection is 
0.288 N/mm2 (calculated starting from the data in Table 27). As depicted in Figure 64 the 
breaking value of stress is much higher than the limit imposed by the UNI EN 1617, so the 
connection is safe. 
Sample Length 15 mm 
Speed trial 300 mm/min 
Sample Section 52 mm2 
Minimum strength to break UNI EN 1617 15 N 
Minimum allowed break limit for connections 0.288 N/mm2 
Table 27 Connection break test parameters 
 
Figure 64 Stress Strain curve for the tensile test of connection 
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5.6.2 Animal trials 
A device as VideoDrain doesn’t need preclinical testing to enter the EC market, because its risk 
class is IIa (see Certification aspects). However in order to test the usefulness of the device 
before its possible marketing, the device has been tested in vivo.  
The significance of the results derived from animal testing is highly dependent on the choice 
of a suitable animal model. The pig is a scientific model suitable for subsequent mining results 
in humans. Moreover, it is ease of use for the assessment of VideoDrain properties, such as 
transparency of the balloon, ease of use. Organs like stomach, liver, bowels and kidneys from 
an anatomical point of view in the pig are very similar to those of man. 
Clinical trials with medical devices are subject to the following harmonized standards: 
 UNI EN 540: Clinical Investigation of Medical Devices for Human Subjects 
 UNI EN ISO 14155-1: Clinical investigation of medical devices for human subjects. 
General requirements, november 2005 
 UNI EN ISO 14155-2: Clinical investigation of medical devices for human subjects. 
Clinical investigation plans, dicember 2004. 
Video Drain has been tested in vivo in four sessions to verify the visualization of the 
abdominal organs through the prototype and to chose the protocol for its clinical use. To 
protect animal welfare, the prototype has been ETO sterilized and provided in a sterile 
packaging. The tests were conducted with the animal under general anesthesia, monitoring its 
physiological activities and under the supervision of a veterinarian and a surgeon, following 
the requirements of Decree 609/86 (EU Directive on animal experiments). 
 
Figure 65 Experimental session: set-up phase 
The tested version, with all its components, is shown in Figure 65: 
1. The connection between the video input of the optical fiberscope and the surgical 
workstation; 
2. Fiberscope; 
3. Syringe for the expansion of the balloon; 
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4. One-way valve system; 
5. VideoDrain catheter; 
6. Expanded balloon (the end of the fiberscope with the lighting system is also shown). 
5.6.2.1 Test procedure 
Once the device is placed into a scar in the abdomen, the fiberscope is inserted into the red 
connector on the device. After making sure that the Thuohy Borst adapter closes properly the 
endoscope (to avoid the loss of air), the syringe for the expansion of the balloon should be 
connected through the lateral luer-lock attachment. Particular attention should be paid to all 
the auxiliary channels of the endoscope. In fact, they must be closed otherwise the balloon 
will not be inflated. VideoDrain user can directly view the expansion (see the sequence in 
Figure 66) of the balloon once it has been introduced into the abdominal cavity. 
 
Figure 66 Insufflation of the balloon 
Test 1 2 3 4 
Place San Piero a Grado CNR Pisa San piero a grado Roma-Tor vergata 
Date  04/06/2009  20/07/2010 
Partecipants 
Troia, Lencioni, 
Burchielli,Menciassi,Magnani 
Troia, Doc. Peri, 
Lencioni 
Magnani, Doc. 
Basili 
Troia, 
Prof. Scozzarro, 
Menciassi 
Device VideoDrain VideoDrain VideoDrain VideoDrain 
Required 
equipment 
Fiberscope, syringe 60 ml, 
luer lock stopcocks to close 
aux channels 
Fiberscope, 
syringe 60 ml, 
luer lock 
stopcocks to 
close aux 
channels 
Fiberscope, syringe 
50 ml, luer lock 
stopcocks to close 
aux channels 
Fiberscope, syringe 
50 ml, luer lock 
stopcocks to close 
aux channels 
Animal Pig Pig Pig Pig 
objective 
Evaluation of vision through 
the balloon 
Evaluation of 
vision through 
the balloon 
Evaluation of 
device ease of use 
and impact on 
surgeons 
Evaluation of device 
ease of use and 
impact on surgeons 
Short 
description of 
procedure 
Insertion fiberscope 
insertion of the tube through 
the scar 
Insufflations 
Further insertion of 
fiberscope 
vision 
Insertion 
fiberscope 
insertion of the 
tube through the 
scar 
Insufflations 
Further insertion 
of fiberscope 
vision 
Insertion 
fiberscope 
insertion of the 
tube through the 
scar 
Insufflations 
Further insertion of 
fiberscope 
vision 
Insertion fiberscope 
insertion of the tube 
through the scar 
Insufflations 
Further insertion of 
fiberscope 
vision 
Position of 
the scar 
Lower lateral abdomen 
Higher lateral 
abdomen 
Lower lateral 
abdomen 
Lower lateral 
abdomen 
Target organs Abdominal cavity Abdominal cavity Abdominal cavity Abdominal cavity 
Estimated 15-20 15-20 15-20 15-20 
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procedure 
time (min) 
Results Good view Good view 
Good idea for the 
surgeon 
Good but see after 
for details 
Problems   
Air loss due to 
fiberscope 
channels 
Buorst adapter 
broken,balloon 
cannot be insufflated 
due to air loss in the 
proximal part 
Table 28 VideoDrain animal lab sessions 
For creating an anatomical volume three complete injections are necessary. After each pump, 
the syringe has to be unscrewed from the luer-lock, recharged and connected again to the 
blue valve. The maximum number of injections is seven. 
5.6.2.2 Test results 
As soon as the balloon is expanded, the user will have a view similar to Figure 67. 
 
Figure 67 Image obtained through VideoDrain 
Slightly rotating the catheter and directing it to the right, left, up and down, detailed images 
of the organs surrounding the insertion point of the device can be obtained. 
The first test was carried out by inserting the fiberscope in a scar on the abdomen (Figure 68) 
charged by the veterinarian and the device was positioned to be the end of the balloon on the 
wall of kidneys. 
 
Figure 68 Insertion of VideoDrain in vivo testsm; first trial (right), second (left). 
The vision (Figure 69) is distorted compared to a normal 2D acquisition but the view of the 
organs is quick and easy to understand. The images contain information about physiology and 
pathology of the cavity explored with details and color immediately comprehensible to 
doctors and nurses.  
81 
 
 
Figure 69 View of viscera from VideoDrain 
In the second test, the protocol was similar but the scar was in the higher part of the 
abdomen thus liver and gallbladder could easily be seen.  
The system successfully creates an anatomic volume within the abdominal cavity and it adapts 
easily to the surrounding organs allowing for the monitoring. As a results of the first two trials, 
as follows, there is the definition of the experimental protocol which has been used in the 
subsequent trials with surgeons: 
 Remove VideoDrain from the sterile packaging 
 Remove the protection in the distal part of the system 
 Insert the device into the abdominal cavity through the laparoscopic incision  
 Insert  the fiberscope into the device adjusting the red adapter to the diameter of 
the vision system 
 Advance the fiberscope to the distal end of the catheter in order to have an image 
of the expanded balloon  
 Press the plunger of the syringe (60ml recommended) inflate the balloon 
monitoring the dilatation on the image on the screen to avoid damaging the 
surrounding organs. Unscrew the syringe and proceed to the next expansion. 
 Push and position the fiberscope within the expanded balloon and keep on with 
the inspection. 
The fourth test has been carried out in Rome with the assistance of two expert surgeons. At 
first they have performed a colecistectomy before, thus the VideoDrain has been inserted 
through a laparoscopic hole left by the trocar in the lower left side of the abdomen. 
There were problems with the inflation of the balloon, probably because of air leakage from 
the bronchoscope channel. The vision appeared satisfactory. Prof Scozzaro28 was impressed 
by the idea of the device but he suggested some further improvements for product marketing. 
                                                     
28
 Endoscopist of University of Rome 
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First of all he suggested to keep the balloon with a plastic sheath before the use and during 
the insertion into the wound. Prof. Scozzarro also suggested to include the device in a higher 
market segment, changing a little bit its intended use (restricting from the case of post-
operative complications to the one already advanced after the hint of complications such as 
bile). Thanks to a guidewire insertion (0,035") with a-traumatic tip (type TERUMO), the device 
can be inserted after the removal of the drainage tube in the same area, ready for the 
inspection. For the previous design the VideoDrain should have an additional lumen for 
inserting the guidewire externally (C tube in Figure 51). 
5.7 Risk Managment 
5.7.1 VideoDrain intended use 
Starting from the definition of medical device, VideoDrain falls within the scope of Directive 
2007/47 EEC and its guideline has been followed both in its design and implementation. 
The acronym VideoDrain derives from Video monitoring of a Drainage site after surgery; the 
device doesn’t need any additional scar because it is introduced through a surgical hole for a 
maximum of seven days. It is designed to accelerate the identification of potential bleeding or 
complications that may arise as a result of an operation. 
The device, inserted Following the annexed IFU (Instruction of Use), introduces a balloon 
inside the collapsed cavity; once positioned the catheter following anatomical knowledge, the 
endoscope is introduced, later the balloon is expanded. The doctor can conduct the inspection 
moving the endoscope to reach the desired point inside the inflated balloon. Once positioned 
the catheter remains in place, and periodically re-inserting endoscope and reconnecting the 
expansion of the balloon it is possible to monitor the abdominal cavity. VideoDrain is 
indicated for the detection of post-operative bleeding, it is recommended  
 after anastomotic dehiscence; the suture might yield causing an hazardous 
situation, for example when esophagus and rectum are involved, 
 to control the plenty visceral perfusion for example in the post-operative course 
after a mesenteric ischemia, 
 to control the pulsation of the arteries, especially after vascular interventions and 
transplantations. 
VideoDrain can be an alternative to the so-called "second look " interventions (operations 
carried out shortly after the primary to control its outcome); for example, after visceral 
ischemia where it is necessary  to reoperate the patient to check the status of the suture after 
the removal of the infarcted section. In these cases the device can be inserted into the patient 
after the first intervention so that it can represent an "eye" for the entire post-surgery. The 
use of the device is associated with a system vision (max 5 mm) that the manufacturer does 
not provide; it is possible to use any endoscope present in intensive care units (Table 25). 
5.7.2 Classification 
The device VideoDrain, in accordance with Directive 2007/47 which scope covers medical 
devices and precisely with the Art. 8 and Annex IX, belongs to the class IIa, because it is a 
Surgically invasive device the use of which is to be classified in the short time term. The device 
has been classified (Table 29) as mentioned in 3.4.1. 
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Duration Short term 
Invasiveness Invasive surgical device 
Risk class Class IIa 
Table 29 VideoDrain classification 
5.7.3 Functional Analysis 
The manufacturer must identify the hazards associated with analyzing characteristics of MD 
that could affect patient safety. In ISO 14971 there is a questionnaire (Table 30) that can help 
the functional analysis of a MD in understanding the potential hazards associated with its use. 
Probing the phases of manufacturing and planning the use of the device, manufacturer can 
deduce what are the potential dangers of MD. 
Question Answer 
What is the intended 
use and how is the 
medical device to be 
used? 
VideoDrain has been designed for the monitoring of the abdominal cavity in the post-
operative phase. The distal balloon is inflated through a syringe and a fiberscope in 
inserted through the tube; the device has a non-return valve and an adapter for the 
scope, which make the system perfectly sealed 
Is the device 
intended to be 
implanted? 
no 
Will the device be in 
(direct) contact whit 
patient or other 
persons? 
Yes, it can be inserted into the scars left in the abdomen after laparoscopic surgery. Also 
the medical people can touch the device during the follow-up. 
What are the 
materials or 
components used ? 
See Table 24 
Is Some kind of 
energy given or 
detracted to the 
patient? 
No 
Is Some kind of 
matter given or 
detracted to the 
patient? 
Yes: blood, bile, pus, etc. 
Does the device 
manage some 
biological material 
for a subsequent 
use? 
No 
Is the device sterile 
or is it sterilised by 
the end user? 
Yes, It is sterilized with ETO 
Is the medical device 
intended to be 
routinely cleaned 
and disinfected by 
the user? 
No 
Does the device 
modify the 
environmental 
conditions of the 
patient? 
It applies some pressure to the abdominal cavity organs when the balloon is inflated for 
the monitoring 
Is a measurement No 
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device? 
Can the device make 
an interpretation? 
No 
Can the device 
control or is it in 
connection with 
other devices?  
Yes, it is connected to a fiberscope 
Can the device be 
subject at 
unexpected leak of 
energy or matter? 
No 
Can the device be 
subjected by 
ambient conditions?  
Yes, during storage and transport the temperature must not exceed room temp. 
Does the medical 
device influence the 
environment? 
No 
Are there some 
consumables or 
accessory associated 
to the devices?  
Yes, a syringe for insufflation of the balloon and a fiberscope. 
Are periodical set-up 
or re-conditioning 
necessary? 
The medical personnel should check the positioning inside the patient 
Does the device use 
a software? 
No 
Has the device an 
expiration date? 
Yes, Max 5 years in a sterile condition and kept as close to delivery 
Can the device 
produce some delay 
effects due to the 
long-term use? 
No 
To what mechanical 
forces will the 
medical device be 
subjected? 
VideoDrain is subject to mechanical pressure at one end and the control is performed by 
the user with a syringe on recommendation of the manufacturer; a maximum pressure 
of 20 mmHg can be applied 
What determines the 
lifetime of the 
medical device?  
For a new device, the lifetime of the medical device is driven by the sterilization process 
and its level of Bioburden; during use, life span depends on the need of medical / other 
person carrying the protocol, in any way is a limited time. 
Is the medical device 
intended for single 
use? 
Yes 
Is safe 
decommissioning or 
disposal of the 
medical device 
necessary? 
Yes 
Does installation or 
use of the medical 
device require 
special training or 
special skills? 
The installation and use of the device requires specialized knowledge and the following 
of IFU 
How will information 
for safe use be 
provided? 
Through the label and the IFU leaflet 
Will new No 
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manufacturing 
processes need to be 
established or 
introduced? 
Is successful 
application of the 
medical device 
critically dependent 
on human factors 
such as the user 
interface? 
No 
Does the medical 
device use an alarm 
system? 
No 
In what way(s) might 
the medical device 
be deliberately 
misused? 
Not following the IFU 
Does the medical 
device hold data 
critical to patient 
care? 
No 
Is the medical device 
intended to be 
mobile or portable? 
no 
Does the use of the 
medical device 
depend on essential 
performance? 
no 
 
  
Table 30 Questionnaire for functional analysis 
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6 Floseal GI (Gastro Intestinal) catheter 
6.1 Analysis of the medical background: bleedings in upper and lower 
gastrointestinal tract 
6.1.1 GI Endoscopy 
GI endoscopy is a minimally invasive diagnostic and therapeutic procedure used to evaluate 
the interior surfaces of any organ in the gastrointestinal (GI) tract by inserting a small scope in 
the body, generally through a natural body opening (mouth/anus).  
Through the scope, one is able to see lesions; an instrument may not only provide an image 
but also enable taking small biopsies and perform a surgical procedure. Many endoscopic 
procedures are relatively painless and only associated with mild discomfort, though patients 
are sedated for most procedures. Complications are rare but may include perforation of the 
organ under inspection with the endoscope or biopsy instrument. If this occurs, surgery may 
be required to repair the injury. 
All GI organs can be inspected and treated with an endoscopic procedure; an Upper GI 
endoscopy is a test that allows the vision of oesophagus, stomach, duodenum (the first part of 
the small intestine). The lower gastrointestinal tract includes most of the small 
intestine(duodenum, Jejunum, ileum) and all of the large intestine (Cecum, Colon, Rectum, 
Anus)(see Figure 43). 
 
Figure 70 Gastrointestinal tract: anatomy and endoscopy 
6.1.2 Ethiology and Pathophysiology 
GI bleeding can be spontaneous (due to an underlying condition or disease) or surgical (due to 
a resection of tissue to treat a disease).Upper gastrointestinal (UGI) and lower gastrointestinal 
(LGI) spontaneous bleeding is a very common disorder which has many different causes. 
Bleeding is generally severe and patients present to the Emergency Room and then undergo 
an endoscopy after resuscitation and stabilization. 
GI bleeding can originate anywhere from the mouth to the anus and can be overt or occult. 
The manifestations depend on the location and rate of bleeding. 
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Hematemesis (65) is vomiting of red blood and indicates upper GI bleeding, usually from an 
arterial source or varix. Coffee-ground emesis is vomiting of dark brown, granular material 
that resembles coffee grounds. It results from upper GI bleeding that has slowed or stopped, 
with conversion of red Haemoglobin to brown haematin by gastric acid. Hematochezia is the 
passage of gross blood from the rectum and usually indicates lower GI bleeding but may result 
from vigorous upper GI bleeding with rapid transit of blood through the intestines. Melena is 
black, tarry stool and typically indicates upper GI bleeding, but bleeding from a source in the 
small bowel or right colon may also be the cause. About 100 to 200 ml of blood in the upper 
GI tract is required to cause melena, which may persist for several days after bleeding has 
ceased. Black stool that does not contain occult blood may result from ingestion of iron, 
bismuth, or various foods and should not be mistaken for melena. 
GI bleeding is not a disease, but a symptom of a disease. GI bleedings can be characterized in 
two major groups: spontaneous bleedings and surgical bleedings. 
There are many possible causes for spontaneous bleedings (Table 31), which are divided into 
upper GI (above the ligament of Treitz), lower GI, and small bowel. Bleeding of any cause is 
more likely, and potentially more severe, in patients with chronic liver disease (e.g., from 
alcohol abuse or chronic hepatitis), in those with hereditary coagulation disorders, or in those 
taking certain drugs. 
Upper GI tract (70%) Duodenal ulcer (20–30%) 
Gastric or duodenal erosions (20–30%) 
Varices (15–20%) 
Gastric ulcer (10–20%) 
Mallory-Weiss tear (5–10%) 
Erosive esophagitis (5–10%) 
Angioma (5–10%) 
Arteriovenous malformation (< 5%) 
Gastrointestinal stromal tumors 
Lower GI tract 
(percentages vary with 
the age group 
sampled≈24%) 
Anal fissures  
Angiodysplasia (vascular ectasia) 
Colitis: radiation, ischemic, infectious 
Colonic carcinoma 
Colonic polyps 
Diverticular disease 
Inflammatory bowel disease: ulcerative proctitis/colitis, Crohn's disease 
Internal haemorrhoids 
Small-bowel lesions 
(rare)(5%) 
Angiomas 
Arteriovenous malformations 
Meckel's diverticulum 
Tumors 
Table 31 Main causes of spontaneous Gastrointestinal bleeding (66) 
For surgical bleeding the main and fastest growing procedure is EMR (Endoscopic Mucosal 
Resection), which can be performed in the UGI (Barrett's oesophagus, early gastric cancer 
etc.) or LGI tract (flat adenomas, polyps etc.). 
Upper gastrointestinal haemorrhage (UGIH)(67) is an urgent disease that is often encountered 
in daily medical practice. Endoscopic hemostasis is currently indispensable for the treatment 
of UGIH. Many methods of endoscopic hemostasis are in wide use, including hemoclip, 
injection and thermo-coagulation methods. Although UGIH develops from a wide variety of 
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diseases, such as oesophageal varices and gastric and duodenal ulcer, hemostasis is almost 
always possible. Identification of the causative diseases, primary treatment and characteristic 
features of endoscopic hemostasis are needed to allow appropriate treatment. 
Gold standard therapies are available for hemostasis of ulcers and varices. Other causes of GI 
bleeding are generally treated with combination therapies. Surgical bleeding during an EMR is 
managed the same way as ulcer bleeding. Hemostasis is of critical importance during all 
surgical procedures. A fundamental principle of good surgical technique is minimization of 
blood loss, and gastroenterologists have a wide variety of agents and tools to aid them in this 
endeavour. Although used less frequently than simple electro cauterization, topical 
haemostatic agents are useful in minimizing blood loss and in turn surgical morbidity. 
Ulcer bleeding is an arterial, spurting, difficult to manage type of haemorrhage where Floseal' 
s strong efficacy profile could make a difference and innovate endoscopic hemostasis 
management. Preclinical works confirmed this hypothesis(68); gelatin matrix hemostatic 
agents are considered to be very effective to control bleedings that occur during surgical 
operation.  
6.2 Market Analysis 
GI bleeds are a growing phenomenon and the incidence rate trend has been going up 
dramatically over the past decades. Epidemiologic data from Europe indicated an UGI annual 
incidence of 48 to 145 per 100.000 population in the 1960's and 1970's (69).Despite recent 
advances in the therapeutic approach, mortality associated with UGI bleeding remains 
significant at 5% to 11 %, and it is the highest in patients with liver disease and oesophageal or 
gastric varices (70). A list of possible intervention which allow the use of Floseal GI catheter is 
shown in Table 32. The data are taken from Italian29 and American30 database of hospital 
discharged in year 2005.  
Description of the intervention ICD9-CM Discharged –Italy 
(2005) 
Discharged –USA 
(2005) 
Closed Biopsy Of Esophagus 42.24 206 654 
Closed Gastric Biopsy 44.14 1142 956 
Suture Peptic Ulcer Nos 44.40 233 * 
Suture Gastric Ulcer Site 44.41 1143 4.051 
Suture Duodenal Ulcer Site 44.42 1287 7.701 
Endosc Control Gast Hemorag 44.43 2651 46.263 
Transcath Embo Gast Hem 44.44 89 334 
Other Control Gast. Hem. 44.49 107 211 
Proctosigmoidosc Thru natural orifice 48.22 7 * 
Closed Rectal Biopsy 48.24 702 11.904 
Radical Electrocoag-Rectal Lesion 48.31 103 * 
Other Electrocoag Rect Les 48.32 90 499 
Laser Destruc Rectal Les 48.33 103 * 
Cryosurg Destruction Rect Les 48.34 9 * 
Local Excision Rectal Lesion 48.35 1504 2.587 
Polypectomy Of Rectum 48.36 986 6.575 
TOTAL  10362 81736 
                                                     
29
 http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/sceltaint.jsp 
30
http://hcupnet.ahrq.gov/HCUPnet.jsp?Id=FCB06E8AF5B3E88A&Form=SelDXPR&JS=Y&Action=%3E%3ENext%3E
%3E&_DXPR=PR1 
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Table 32 Comparison of principal DRG (Diagnosis Related Groups ) for Floseal GI Catheter application between Italy and 
Usa 2005 
6.3 State of the art: Commercial systems and therapies 
The aim of Floseal GI Catheter is to introduce and apply an Haemostatic matrix (Floseal) which 
is the gold standard in the field of surgical Hemostasis. 
Endoscopic therapy (71) can be broadly categorized into injection therapy, thermal 
coagulation, and mechanical hemostasis. When analyzed separately, injection therapy, 
thermal-contact devices, and laser treatment all decrease the frequency of recurrent bleeding 
and rate of surgical intervention. 
Mechanical method Injection method Thermo-coagulation Hemostyptic sprays 
Hemoclip Ethanol APC Thrombin 
Balloon tamponade Epinephrine Heater prove Sodium alginate 
Ligation (EVL, detachable 
snare) 
Monoethanolamine oleate Hemostatic forceps Fibrin glue 
Polymer Polidocanol Microwaves  
 N-butyl-2-cyanoacrylate Laser (Nd-YAG, diode)  
Table 33 Summary of methods of endoscopic hemostasis 
Clips, cauterization, APC, and injection therapy have been useful with good efficacy. Using 
principles established by these tools future devices may better address current limitations by 
enhancing tissue capture and providing greater compressive forces. Several novel endoscopic 
devices are under development may lead to improved endoscopic outcomes. These include 
memory clips, flexible suturing devices, high compression cauterization, injectable polymers 
and telecommunicating biosensors(72). 
Below there is a description of each concurrent device and also of alternative diagnostic 
techniques for post operative diagnosis of abdominal surgery complications. 
6.3.1  Endoscopic injection needles   
Endoscopic sclerotherapy, a well-established treatment for bleeding GI varices, accomplishes 
vascular obliteration by injection of a sclerosing agent. Sclerosants are tissue irritants that 
cause vascular thrombosis and endothelial damage, leading to endoﬁbrosis and vascular 
obliteration when injected into or adjacent to blood vessels. To control bleeding from a varix, 
a sclerosant is dispensed with a sclerotherapy needle passed through the working channel of 
an endoscope. Sclerotherapy needles consist of an outer plastic sheath and an inner core 
channel attached to a needle at the tip. The conventional sclerosants, ethanolamine oleate, 
polidocanol, sodium tetradecyl sulfate, sodium morrhuate, and absolute alcohol, are indicated 
for acute endoscopic hemostasis and elective obliteration of bleeding esophageal varices. 
They have also been used alone or in combination with ligation or cyanoacrylate for the 
treatment of bleeding esophageal or junctional (esophagogastric) varices. The sclerosants are 
not indicated for primary prophylactic treatment of varices that have not bled. 
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Figure 71 Injection needle hemostasis 
The use of sclerosants (including absolute alcohol) in injection therapy (Figure 71) for bleeding 
ulcers should, however, be discouraged: extensive and uncontrolled tissue necrosis caused by 
sclerosants injected to the ulcer base can result in ulcer perforation and complications relating 
to adjacent tissues. 
EUS (Endoscopic Ultrasound) directed polymer injection may allow temporary hemostasis in 
massive haemorrhage when visualization is not possible. Thermo-sensitive reverse phase 
polymers rapidly transform from a liquid into a gel-plug at body temperature. This new 
endoscopic method of temporary hemostasis does not require direct visualization of the 
bleeding site and may provide more time for thorough endoscopic evaluation and definitive 
treatment. 
6.3.2 Thermo coagulation 
Thermal devices can be divided into contact (heater probe, monopolar and bipolar electro 
coagulation) and noncontact types (Figure 72,laser treatment, argon plasma coagulation 
[APC]). Heating leads to edema, coagulation of tissue protein, and contraction of vessels, 
resulting in a haemostatic bond.  
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Figure 72 Laser hemostasis (YAG) on the left; Argon Plasma hemostasis (right) 
While the haemostatic effects of contact probes are well established by clinical trials, the use 
of APC in the treatment of peptic ulcer bleeding has only recently been reported. There has 
been only one randomized, controlled study comparing APC with heater-probe coagulation, 
and it suggested that APC is equally as safe and effective (73). 
Tissue coagulation requires a temperature of approximately 70˚C. Repeated application of 
these devices can result in the build-up of coagulum at the tip, which can impede conductivity 
and necessitates removal of the probe and cleaning the tip (74). 
Another flexible (75) device under development for hemostasis are high compression 
endoscopic bipolar forceps. Insulation between conductive plates and jaws prevent radiation 
of heat and allow for trans-endoscopic sealing of large blood vessels. Applicable to future 
natural orifice surgery, this device may prove useful for advanced intraluminal procedures. 
6.3.3 Mechanical Devices 
Mechanical devices have been used for the treatment of variceal haemorrhage (71), but rarely 
in the treatment of peptic ulcer disease. Hemoclips (Figure 73) have gained popularity in the 
past few years. The deployment of hemoclips on fibrotic ulcer floors can be difficult, however, 
particularly when they are used tangentially or with the endoscope in a retroflexed position. 
The efficacy of hemoclips seems to be limited by difficulty of successful application. With 
improvements in design, this technical problem might be overcome. More studies are 
required to give a fair verdict on the effectiveness of hemoclips. 
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Figure 73 Endoclips 
Nitinol clips like OTSC are the newer device for hemostasis of non-variceal bleeding(76). These 
are cut by electrical discharge machining and are mounted in a loaded position on the 
endoscope tip. They capture large amounts of tissue and achieve compression with serosal 
apposition.  
Other developments have lead to flexible sewing(75) tools. This device has 4 degrees of 
freedom with articulating jaws that pass a barbed one-way locking suture preventing tissue 
from moving retrograde once acquired. This trans-oral device could find clinical application for 
hemostasis and closure of perforated ulcers.  
6.3.4 Combined Therapy 
The benefit of combination therapy has been evaluated in many trials (77) . 
In (73) patients with actively bleeding peptic ulcers, ulcers with adherent clots, or ulcers with 
no bleeding visible vessels were randomly assigned to epinephrine injection plus heat probe 
coagulation or epinephrine injection plus argon plasma coagulation. The primary outcome 
measure was recurrence of bleeding. Secondary outcome measures were initial hemostasis, 
endoscopic procedure duration, number of patients requiring surgery, mortality within 30 
days, and ulcer status at 8 week follow-up endoscopy. Epinephrine injection plus argon 
plasma coagulation is as safe and effective as epinephrine injection plus heat probe 
coagulation in the treatment of patients with high-risk bleeding peptic ulcers. 
Currently, the standard therapy most widely used is injection with diluted epinephrine, 
followed by thermo coagulation with a 3.2 mm heater probe. 
6.3.5 Hemostyptic sprays  
Preparations containing collagen play a prominent role among local hemostyptic agents in 
surgery (78). The combined application of a sheet of collagen with fibrin glue improved local 
hemostasis to a great extent. Large areas of capillary bleeding can be treated successfully with 
this method. Despite the very good results, this method has not been applied on a broad 
scale. This is due to the necessary skill and experience and the relatively cumbersome 
preparation required at the operation site. 
6.3.6 Analysis of competitors features 
Following (Table 34) there is a comparison of prices between the main competitor techniques 
of the Floseal GI cath. even if due to the variety of treatment modalities, often combined, it is 
very difficult to estimate an average cost of treatment. 
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Product Price (€) Companies 
Endoscopic injection needle cath 
40-60 
(disposable cath.) 
Olympus
31
 
TeleMed Systems
32
 
Boston Scientific
33
 
Electrosurgical haemostatic devices 200-300 (disposable) 
Olympus
34
 
ConMed 
35
 
Cook Medical
36
 
Endoscopic clip fixing devices 100-200 
Olympus
37
 
Boston Scientific
38
 
Ovesco
39
 
Floseal GI cath. 50 MicroTech 
Table 34 Analysis of competitors: market evaluation 
In Table 35 there is a comparison ((79) (74)) between the main features of concurrent devices 
and system for the treatment of peptic ulcer disease. 
                                 System 
Evaluation 
parameter 
 
Injection 
therapy 
Thermo 
coagulation 
Clips 
Hemostyptic 
sprays 
Floseal GI cath. 
(results of first 
trials) 
Good Initial hemostasis
40
 xx xxx xx xxx x 
Difficult Maintaining of front 
view 
  xxx x  
Risk of perforation xxx xx xx   
Rate of recurrent bleeding xxx xxx xx   
Requirement for emergency 
surgery 
xx xx xx   
Mortality within 30 days  xx xx   
Ulcer status at 8 week follow-
up endoscopy 
x x x   
Length of hospital stay  x x   
Transfusion requirements  xx x   
Ease of use xx xx x  xxx 
Hazard  xxx    
Table 35 Analysis of competitors: comparison of main feature (x=low, xx=medium, xxx=high). 
                                                     
31 http://objects.olympus-europa.com/endo/documents/injector_force_max.pdf 
32
 http://www.telemedsystems.com/sclerotherapy_needles.htm 
33http://www.bostonscientific.com/Device.bsci?page=HCP_Overview&navRelId=1000.1003&method=DevDetailH
CP&id=10074442&pageDisclaimer=Disclaimer.ProductPage 
34 http://www.olympuskeymed.com/index.cfm/page/products.index.cfm/id/754/navid/754/parentid/752 
35 http://www.conmed.com/EndoTech_SuperConductor.php 
36 http://www.cookmedical.com/esc/dataSheet.do?id=698 
37 http://www.olympusamerica.com/presspass/press_pass_cut/documents/QuickClip2%20Long%20brochure.pdf 
38 http://www.cookmedical.com/esc/dataSheet.do?id=700 
39
 http://www.ovesco.com/ 
40 endoscopically verified cessation of bleeding for at least 5 minutes after the first endoscopic treatment 
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All of the current standard treatments for endoscopic hemostasis, although effective to a 
certain extent, have some relevant drawbacks and limitations: 
 Failure rate (intra-op or delayed re-bleeding is very common) 
 Necessity to do open surgery in case of persisting untreatable haemorrhage (e.g. 
gastrectomy) 
 Not easy to adopt (injection therapy, ligation etc. may turn out to be difficult due to lack of 
viable tissue, poor vision through the endoscope in the blood, application of devices on 
the scope) 
 Safety (tissue damage). 
 Floseal, if used with appropriate delivery devices which allow easy and fast application 
through a scope, have the potential to perform hemostasis and bleeding prophylaxis in an 
effective, safe and innovative way in GI endoscopy. 
Recently in parallel with the development of the Floseal GI cath. a new similar device has been 
designed and an in vivo animal study has been deployed (80). This device (Figure 74) is a 
catheter of 2mm in diameter and length 1350mm.It can be used only with gastroscope, while 
the Floseal GI cath. can be used in colonscope too (see 6.5). From these first in vivo tests , it is 
easy to understand that the original IFU of Floseal are not followed. In fact they use 5 ml of 
thrombin (instead of the indicated 4) and saline solution to help the extrusion of the 
hemostatic agent into the channel. The hemostatic efficiency results invalidated; in fact  the 
quantity of Floseal they have to use (from 1 to 4 doses of 2,5 cc each), in order to achieve 
some reasonable results, is much higher than the maximum four applications of 0.5cc of the 
Floseal GI cath. (indications from a validation protocol of Doc. Spera). Moreover the cost of 
each package of Floseal is very high and the healthcare system recommend a wise use of the 
hemostatic drug. 
 
Figure 74 Floseal endoscopic applicator by Maslanka 
6.4 Intellectual property 
The Floseal GI Cath. is the development of a patented idea (81) of a “Gastrointestinal 
applicator and Method of using the same”. The patent is related to methods and apparatuses 
for applying therapeutic compositions having viscosities too large to be pushed through an 
entire length of a relatively long and thin catheter, such as one configured to reach the inside 
a person's gastrointestinal track.  
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Figure 75 Patent principal drawing 
One of the claim regarding the catheter is the 10th: 
“A medical catheter assembly comprising: an outer tube having a proximal end and a distal 
end; and a balloon catheter located within the outer tube, the balloon catheter moveable 
within the outer tube so as to create an open space within the outer tube at the distal end 
thereof, the open space sized to hold a composition configured to be applied to an internal 
wound site of a mammalian body in an amount sufficient to cover the wound site; and an 
applicator configured to seal to a distal end of the outer tube to deliver the composition to 
the open space.” 
6.4.1 Accessory device: Floseal Matrix 
Floseal Matrix 41consists of a bovine-derived Gelatine Matrix component mixed with a human-
derived Thrombin component. Floseal Matrix is indicated in surgical procedures  as an adjunct 
to hemostasis when control of bleeding by ligature or conventional procedures is ineffective 
or impractical. 
The device is not intended as a substitute for meticulous surgical technique and the proper 
application of ligatures or other conventional procedures for hemostasis.  It  is effective on 
surgical bleeding, from oozing to spurting, and is not intended to be used as a prophylactic 
haemostatic agent. 
Floseal is the gold standard in the field of haemostatic agents; it is proven(82) to stop bleeding 
in two minutes (median time to hemostasis) in patients undergoing cardiac, vascular, or 
spinal/orthopedic surgery. A prospective, randomized, controlled, multi-centre, multi-
specialty study was conducted using a formulation of Floseal Matrix containing bovine 
thrombin. Patients were randomized only after it was determined that the bleeding could not 
be controlled using conventional approaches (e.g. direct pressure, sutures and/or 
cauterization) because of their ineffectiveness or impracticality.  Success at achieving 
hemostasis was defined a cessation of bleeding within 10 minutes following application of the 
agent.  The primary endpoint was hemostasis success for the first treated bleeding site. A 
                                                     
41
 Baxter Biosurgery 
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secondary endpoint was time to hemostasis for the first treated bleeding site. Although 
multiple bleeding sites in the same patient were treated, only the first treated bleeding site 
was used to determine primary effectiveness, as this was the only site that was truly 
randomized. 
The Floseal Mechanism of Action is the Biophysical Hemostasis: 
 It is applied to the tissue surface at the base of the lesion. Its granules ﬁll the wound and 
conform to its shape 
 the granules expand approximately 20%  within 10 minutes and physically restrict the ﬂow 
of blood. Blood percolates through the spaces and is exposed to thrombin 
 A clot forms around the mechanically stable matrix provided by the granules. The 
structural integrity of the gelatin ﬁbrin matrix enables it to remain in place at the tissue 
surface 
 Floseal granules not incorporated in the clot can and should be removed with gentle 
irrigation without disrupting the hemostatic seal 
 FLOSEAL is resorbed by the body within 6–8 weeks, consistent with the time frame of 
normal wound healing. 
 
Figure 76 Floseal action 
A gauze sponge must be applied to approximate the Floseal Matrix against the bleeding 
surface, conforming it to the lesion. In the case of the Floseal GI cath. the gauzes are 
represented by the balloon because it is not possible to introduce gauzes in gastroscopic 
procedures. 
6.5 Design History 
6.5.1 Initial Specification 
A reverse engineering process on a “0” prototype provided to MicroTech by Baxter and 
specification extrapolated from the analysis of the patent N. US 0106213- “Gastrointestinal 
applicator and method of using same”- of Baxter int., which authors are Prof. Spera and Doc. 
Ariano, created the design of Floseal CS GI cath. device. The device has been designed to 
release haemostatic drug (Floseal) in the cavity of the gastrointestinal tract. The prototype 
had following characteristics: 
 Primary corpus: catheter with distal latex balloon in part and luer proximal access  
 Plastic tubular oversheath (Teflon) 
 Cover 
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 Syringe to inflate balloon 
 Haemostatic valve 
 Syringe for Floseal. 
At first the Floseal dosage to inject was equal to 2 cc, for every delivery, for a total of two 
extrusions. 
First of all dimensional restraints of catheter have been fixed. Passing by operative channel of 
a gastroscope or colonscope, a first market survey about these last devices has been made to 
identify lengths and dimensions of the operative channels. 
Company Gastroscopes 
(operative channel) 
Colonscopes 
(operative channel) 
 Lenght (m) Diameter (mm) Lenght(m) Diameter (mm) 
Olympus  1.1 2-2.8 1.3-1.7-2.4 2.8-3.2-3.7 
Pentax  1.5 2-2.4-2.8-3.8 1.3-1.5-1.7 2.8-3.8-4.2 
Storz 1.1 2.2-2.8-3.8-4.2 2.2 2.8 
Table 36 Commercial scopes features 
It has been made a survey among endoscopists to have a further indication about lengths and 
possible versions of the device to make available. 
 
 
Surgeon Spera
42
, 
Cipolletta
43
 
Repici
44
 Occhipinti
45
 Zambelli
46
 De Pretis
47
 
Indications Two versions 
for  gastric 
and 
colonscopic 
procedures  
One version One version One version One version 
Lenght(m) 1.80 e 2.40 1.80 1.80 2.10 2.10 
Table 37 Survey on possible length device 
For most of surgeon the gage length is 2.10m both for gastro applications and colon; some of 
them think that an excessive length of  the catheter could make more difficult the procedure, 
beyond the fact that most of bleedings is in the superior gastrointestinal tract (in which 
lengths of 1.60m would be sufficient). 
6.5.2 Underlined problems 
The main complication to exceed during the design of device is the hard extrusion of the 
haemostatic fluid. Due to its viscosity, administration of Floseal, through a device that fits 
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47
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working channels of therapeutic and diagnostic scopes, is only possible if the distal end of a 
catheter is preloaded. 
Increases in the viscosity(83) of a fluid causes increases in the maximum pressure required 
during passage in a catheter. This can be explained by increased resistance in the catheter, as 
represented by Equation 12: 
  
     
    
 
Equation 12 Fluid resistance in a catheter 
This equation was derived from Hagen–Poiseuille’s law (Equation 13): 
              
Equation 13 Poiseuille law 
where: ΔP is the pressure drop, L is the length of the tube, η is the dynamic viscosity, Q is the 
volumetric ﬂow rate, d is the diameter, and π is the mathematical constant. As electricity was 
originally understood to be a kind of ﬂuid, this hydraulic analogy is still conceptually useful. 
Then Hagen–Poiseuille’s law corresponds to Ohm's law for electrical circuits (V = IR), where 
the pressure drop (ΔP) is analogous to the voltage (V), and the voluminal ﬂow rate (Q) is 
analogous to the current (I). The resistance, then, is represented by Equation 12. Although 
Floseal is a suspension (ie, not completely homogeneous) and the ﬂow may not be steady, the 
Hagen–Poiseuille equation was used for simpliﬁcation. This means that the resistance (R) is 
proportional to the viscosity of the Floseal (η) and the length of the catheter (L), and is in 
inverse proportion to the inner diameter of catheter (d) raised to the fourth power. Lower 
ﬂuid viscosity (η) can result in easier injection which can also be inﬂuenced by its temperature 
and dilution ratio, and the concentration of particles. Microcatheters with shorter lengths (L) 
and larger inner diameters (radius [a]) are recommended for easier injection, but this is not 
the case of Floseal GI cath. because it has to be inserted in a scope working channel . 
The most probable causes for a weak pushability, analyzed after the production and test on 
prototypes of different type (see Annex VIII), divide themselves between the high friction to 
interface of oversheath-catheter and a weak thrust of fluid. Analyzing with greater detail, the 
efficiency absence of some of first prototypes can be given to: 
 Floseal seeping 
o Friction between external sheath and catheter 
o Friction between balloon and external sheath  
o Sheath material 
o Balloon material 
o Catheter material 
o Dimensions gap between internal and external catheters  
o Balloon folding in the subsequent deliveries 
99 
 
 Buckling 
o Shape of the tip 
o Tip dimensions  
o Catheter and sheath length 
o Material and dimensions of metal guide-wire 
 Required dosage of Floseal 
 Fluid rheology linked to conservation temperature. 
 
Figure 77 Floseal lateral infiltration 
In order to reduce the friction between the lateral surfaces of sheath and catheter caused by 
sliding, different hypothesis and system configuration have been analyzed. 
 
Figure 78 A possible solution to avoid friction between balloon Floseal and sheath 
In the solution in Figure 78, a further catheter, in the blue one, has been used to realize the 
thrust of Floseal avoiding the friction between balloon, Floseal and oversheath. This solution 
was more expensive because of the additional micro-catheter, less effective, for the fact that 
the lumen available for the Floseal had a very inferior volume. More applications of the drug 
would be necessary, because the diameter of tip of micro-catheter was of 1mm and the 
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efficiency of the thrust would be so certainly weak, thus this configuration has been 
dismissed. 
Another important characteristic to be considered is the material of different components 
that, in spite of it has characteristics of biocompatibility and safety, it must guarantee the 
correct working of the device. 
With regard to oversheath, surface sliding has a particular importance. Teflon is one of plastic 
materials with less surface friction. Making tests with sheath of this kind of material, extrusion 
of fluid is favorite. The only PTFE(Teflon) hitch is economic; it is quite difficult to extrude micro 
catheters in this material, due to its high viscosity when molten. Moreover Teflon is a material 
with lowest adhesive properties, so it is hard to paste it to others materials. In the device 
considered, a Teflon tract would have pasted to a luer connector in PVC. A three layer 
material with surface low friction strata is preferred (see 6.5.4). 
The material of the balloon, in the initial prototype of Baxter, is latex, inactivity material in the 
sector because it could create allergy in particular subjects. Actually that material has surface 
characteristics of friction better than materials now in business for the fabrication of balloons; 
in agreement with supplier, it has been chosen a material which can offer the right 
compromise between workability (extrusion) and low surface friction, a synthetic 
polyisoprene. As well, the particular balloon setup could cause difficulties in the extrusion of 
the fluid, especially in the second delivery, in case of missed return to zero of the balloon after 
the first inflation. 
 
Figure 79 Setup balloon image 
Another solution to be considered has been to lower the diameter of the balloon to be not in 
contact with sheath, but the particular setup would have been still more difficult. 
We tried to accent the inclination of the only one taper (Figure 79) corresponding to ligature 
of the balloon, or to increase the length of taper, to allow that the balloon in pause does not 
extend the diameter of catheter (obviously from both extremities of the balloon) but, during 
the phase of prototyping, for a mechanical matter, the tube cannot be tapered more than that 
obtained with the first prototyping. 
Maybe the material of the catheter is the least important to lower the total friction but also 
this element could invalidate the quality of relative movement among parts. Consideration 
made before for the sheath about Teflon, also are worth for the catheter. An option can be a 
micro milling to lower the effective of contact, thus augmenting the sliding between catheter 
and sheath (in Figure 80 see the cause of a bad sliding between surfaces); but this idea has not 
been investigated till now. For the material chosen during the prototyping, refer to 6.5.4. 
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Figure 80 Expanded roughness 
Another instability cause in the extrusion is the instability of buckling. Buckling is a stress of 
pressure applied to the head of a pivot. It is practically impossible that pivot is stressed by this 
pressure with a normal pure stress; the stress will be probably a force applied to distance 
from the barycentre axis and this creates a bending moment. For the device in question, 
stress is represented by the resistance of the volume of fluid to be pushed. 
 
Figure 81 Image of  buckling applied to our cat  
To protect oneself from this phenomenon, it is important to forecast the project loadings and 
the stressed actions in a correct way, modifying the parameters of the project. For example: 
 Reducing the pressure 
 Lowering the eccentricity of loading 
 Increasing the cross sectional area 
 Reducing the length of the object 
 Adding restraints with other near axis or with the ground 
 Reducing the free deflection length of the beam. 
The only way to reduce this effect in the catheter is to increase the surface of the tip and 
make it as flat as possible because the pushing force is transmitted in the best way without 
dispersion on the borders due to tangential force component (see Figure 82). 
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Figure 82 Pushing force distribution on different shape for the tip of the catheter 
Different made tests show the tip as a crucial element for the push. Tips with different 
diameter and shape have been taken as prototype and soldered in the distal part of the 
catheter for thermoplastic fusion. Some different tests (Annex IX) have been made with 
modified pits (Figure 83) and the concavity of pit is very important; it must be dimensionally 
calibrated with the whole lumen of the sheath. In fact the diameter which, from the tests, is 
right for an ideal extrusion of Floseal, is equivalent to 1.9 mm. 
 
Figure 83 Metallic tip 
Besides of the dimensions of the tip, the gap between external diameter of the catheter and 
internal diameter of the sheath is important. It is important to keep a least difference to avoid 
that an excessive quantity of haemostatic fluid seeps and creates a very viscous layer between 
the two main components of the device. It is necessary not to exceed a determined limit for 
the external diameter of the catheter (1.63mm) because of the thickness of balloon and its 
particular setup. It could be only increased in the proximal part but this would involve a 
further working. 
 
Figure 84 Inflated balloon Drawing 
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It is important to consider that the shape of the tip (Figure 84 and Figure 82) must be a-
traumatic to avoid damaging to the tissue during the use. 
Another possible cause of ineffectiveness in the thrust of the haemostatic is the shape, 
dimensions and material of metallic mandrel which is in the internal part of the balloon 
catheter. However it must be quiet flexible to play up the catheter in the bend made by 
gastroscope and anatomic ones; Hence, a right compromise between flexibility and rigidity, so 
a capacity of thrust is necessary. 
In the first prototypes of the device, the mandrel, a medical metallic wire in AISI 304 o 316, 
was too short or slim (see Annex VIII for the different prototypes manufactured ). Because the 
internal lumen of the blue catheter with balloon has an inferior diameter in the distal part, it 
is necessary to have a mandrel with a different diameter which can reach the tip. Several trials 
have been made to get the ultimate stage. At the beginning a 0.4mm wire has been bent in 
two parts, so one length was about 70cm and the other the entire length of the catheter. This 
solution was not very functional to thrust; even if for a length of 70cm the section was 
nominally doubled, with two of 0.4mm wires, their contribution to the “Pushability” of the 
catheter was bit superior than that of only one with the same diameter. 
 
Figure 85 Welded mandrel particular (left); drawing of a tapered mandrel (right) 
Successively guide-wires made up of two metallic wires have been created; in proximal and 
distal part there are different diameter wires (match proximal/distal part in mm: 0.8/0.5, 
0.75/0.55, 0.6/0.4 o 0.4/0.3) welded with laser (Figure 85). Actually, this solution has taken an 
improvement in the extrusion of fluid but the technology of laser welding is expensive and 
hardly available for medical applications . Furthermore the welding was often not very 
resistant, already in the phases of prototypes assembly. The welded joint is very fragile, in fact 
from the SEM analysis in the welded zone (Figure 86) there is a very deep crack probably 
caused by formation of martensite. 
 
Figure 86 SEM analysis (scanning electron microscope) welded zone mandrel welding 
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Contextually the possibility to use metallic mandrel tapered in tip has been considered, but 
the sharpening of the tip is an expansive and hardly available process of production. If we 
consider a taper reduction equal to (see Figure 85, right) 
 
 
 
        
   
        
Equation 14 Taper reduction 
the price of 30 pieces of mandrel (smallest number of prototypes) is about 1600 euro (to 
make matrixes for rotary swaging which realizes plastic deformation of a 0.75mm AISI 304 
annealed wire. The annealing process consist of : 
1. An heating process with temperature major than the one in the critical range 
2. Permanency at that temperature for an appropriate time, 
3. Final cooling at ambient temperature; more or less rapid to allow a major cold 
workability, removing any possible internal tension. 
The final prototype has a solution similar to first one considered: only one 0.50mm diameter 
wire, bent in two. In this solution two wires are twisted for a length equal to 2120mm, starting 
from the proximal part and in the distal part there is only one  
The problem of hard friction and the following extrusion of the fluid could be partially 
overcome using silicone lubricants, nowadays used in gastroenterology, or physiological 
saline. 
Actually, after several trials and prototyping, also on different batches of Floseal, some 
anomalies has been found, also with the same initial geometrical and physical conditions. If 
the haemostatic fluid is kept under 4°C temperature, it is much more granular and less liquid 
and as a result, its extrusion is invalidated. The important indication about the preservation of 
the fluid has been introduced in IFU (instruction of use), even if it was already present in the 
Floseal package. Also the time of use is very important (given by American producer): the 
thrombin takes at least 10 minutes to hydrate itself. 
Besides, after consultancies with Doctor Spera, we got to a more detailed clinical algorithm 
which provides an inserting of following quantities of Floseal of 0.5 cc (against the initial ones 
of 2 cc); this change of quantities simplifies the problem of the seeping making the extrusion 
easier. 
The introduction of haemostatic valve was very difficult, so, for augmenting device 
effectiveness, the rounding (Figure 87 option 2), previously considered necessary for the 
atraumatic of the catheter, has been removed, to get an entrance for the metallic cylinder of 
the valve as easy as possible (number 1, Figure 87). Safety was not invalidated also with a 
distal cut sheath, because the introduction of the catheter would be gradual and even if this 
does not happen, the traumatic tip is irrelevant in this case. 
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Figure 87 Enlarged image of the tip of the oversheath and connection to haemostatic valve 
A pebbled grip for better catching the catheter has been considered but never realized 
because less pushing force is now needed due to the reduction in Floseal dosage. 
6.5.3 Connections  
Floseal GI catheter has several connections: 
 Non-return valve for pump of balloon 
 Haemostatic valve to connect Floseal syringe to distal part of sheath. 
Both valves and cocks to pump and deflate the balloon were in the first prototypes; first 
solution was chosen for a better ease of use. 
The two connections are provided with a Luer 6% mechanism. The Luer taper is a 
standardized system of small-scale fluid fittings used for making leak-free connections 
between a male-taper fitting and its mating female part on medical devices. Key features of 
Luer Taper connectors are defined in the ISO 594 standards.  
Some black notches on sheaths have been introduced in the final phase of the device: 
 One in distal part to indicate the shot of haemostatic valve  
 One to indicate the introduction of 0.5 cc. 
And a white notch on the blue catheter in the proximal part to indicate until where to shrink 
the catheter to 1 cc for the insertion of the sheath. 
In any case, the device in question, was developed in a way that does not provide connections 
to other medical devices, in addition to the components present in the device itself. 
6.5.4 Analysis of materials 
In the following section some considerations about the choices made for the materials. 
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6.5.4.1 Balloon 
Silicone, the main material in the balloon production for the medical, would be not suitable in 
the device considered; it must be as sliding as possible so it would be better to orient on: 
 Polyurethane 
 Latex 
 Polyisoprene (synthetic latex). 
Today Latex, as said in 3.3.2, is in disuse because of possible allergies of the personnel and of 
the patients. A polyurethane balloon is not so compliant, it shrivels up when it goes back to 
zero position. Floseal could penetrate and stick on it, so this solution hasn’t been considered 
useful. 
The material used is such a polyisoprene, a mixture between Chemiton and Tefabloc. 
Chemiton gives the right elongation about 700% (it should be at least 400%, because the 
balloon has to be inflated from 0 to 400cc), while Tefablock gives the right low friction 
properties. 
6.5.4.2 External sheath  
Oversheath material must be the right compromise not to invalidate the axial thrust 
(overstretch). The choice has been very difficult, due to the high viscosity of the Floseal. The 
right compromise between low friction and good extrudability has been a three layer 
material, an acetal resin Teflon loaded: 
1. Ely2694 (thermoplastic polyamide elastomer, flexible without the addition of 
plasticizers) 
2. 50%Ely+50%Hostaform 
3. Hostaform (POM, polyoxymethylene, a thermoplastic material with good friction 
behavior) 
A good solution would have been to use a cover in POM with PTFE, but it would not be easy to 
extrude for the chosen external manufacturer. Also coatings as parylene have been 
considered but, after the change of the dosage of Floseal, no further action has been 
necessary about the improvement of the sliding of the surfaces. 
6.5.4.3 Catheter 
From the analysis of the various tests done, friction is not the key issue in the choice of the 
material of the catheter, but it is very important its pushability and the avoidance of kinking 
(minimizing      and      , see 3.3.1).  
Also in this case a three layer material has been chosen (from internal to external): 
1. Ely2694 
2. grilamidTR90+SdB+white 
3. grilamidTR90+blue. 
Grilamid is a stiff thermoplastic polyamide, it offers a high flexural fatigue strength, good to 
avoid unwanted lateral bending (kink) of the catheter. 
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6.5.4.4 Biocompatibility evaluation 
Commonly, biocompatibility is a material’s lack of interaction with living tissues by not being 
toxic, injurious, or physiologically reactive, and not causing immunological rejection: this is not 
restricted to the chemical/biological response, but also to energy interaction (mechanical, 
thermal, electromagnetic,…. ). Basically, it means that “the material can be used with an 
appropriate and predictable response in a specific device application without patient harm”. It 
is important to underline that any material adopted is related with a specific application (time 
dependent). No single test may be sufficient to define biocompatibility: the same material can 
be perfect for a specific device/application, but not for a different one.  
To minimize any potential hazards to the patients, it’s essential that biocompatibility 
assessments be conducted for all materials which are used in a medical devices. That’s why 
it’s possible that multiple tests would be needed to determine the biocompatibility of the 
material.  
In the ISO 10993-1 there is a flow chart (see Figure 54 in yellow circles Floseal GI cath. 
evaluation) which guides selecting the tests to evaluate the biological response to medical 
devices. Due to the novelty of some materials used in the device, it has been necessary to 
conduct all the tests listed in Table 22.In paragraph 6.6.3.3 and 6.6.3.4 there is the complete 
list of chemical and biological test made to prove biological compatibility of materials both of 
the device and of the packaging. The biological tests has been conducted by an external 
certified laboratory.  
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Figure 88 Annex B ISO 10993 Flow chart for the selection of toxicity tests 
Device Categories Biological Effect 
Nature of Body Contact 
Contact duration 
A-limited 
(24h) 
B-prolonged 
(24h to 30 days) 
C-permanent 
(>30days) 
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Surface  
devices 
Skin 
A x x x      
B x x x      
C x x x      
Mucosal 
membrane 
A x x x      
B x x x      
C x x x  x x   
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Breached or 
compromised 
A x x x      
B x x x      
C x x x  x x   
External  
communicating 
devices 
Blood path, 
indirect 
A x x x x    x 
B x x x x    x 
C x x  x x x  x 
Tissue/bone/ 
dentin 
communicating 
A x x x      
B x x    x x  
C x x    x x  
Circulating 
blood 
A x x x x .  . x 
B x x x x  x  x 
C x x x x x x  x 
Implant 
devices 
Tissue/ 
bone 
A x x x  . . .  
B x x    x x  
C x x    x x  
Blood 
A x x x x . . x x 
B x x x x  x x x 
C x x x x x x X x 
Table 38 ISO 10993-1 Biocompatibility Matrix  
6.5.5 Final configuration and prototype 
Several following versions and production of so many prototypes was necessary to get an 
efficient and safe version of device. 
Floseal GI cath. final prototype has been manufactured by a company which applies the new 
quality standards and safety for the medical device sector (ISO13485, MDD 2007/47). The 
main characteristics of the final prototype, are the following: 
 Catheter length: 2270mm  
 Sheath length: 2200mm 
 1.2cc Luer female syringe 
 5 ml Balloon inflation syringe 
 Storage device  
 Haemostatic valve. 
In Figure 61 the 3D drawing of all the components of the device is reported. 
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Figure 89 Drawing of final prototype of Floseal GI cath.  
A detailed description of the components used in the production of medical device  Floseal GI 
cath., complete with technical drawings and specifications for materials, has been reported in 
Table 39 and in the technical file. 
Denomination Material  
External sheat E2694-(50%Ely+50%Hostaform)-
Hostaform 
luer lock 2.65 transp. ABS Terlux 
balloon 50% chemiton+50%tefablock 
tying wire for bonding Nylon 
catheter tube Ely2694-(GrilamidTR90+SdB+white)-
Grilamid TR90+blue 
guide wire AISI 316 
luer lock 1.75 blue transp. ABS Terlux +blue 
one way valve various 
haemostatic valve 7 Fr. various 
valve tube AISI 316 
valve tube reducer Grilamid E2694 
syringe 5cc various 
syringe 1.2cc various 
dispenser tube eraclene BC82-bynel CXA104-
Grilamid L25 
catheter stop ely2694+ orange 
3 channel clip politene 
shrink 3/16 politene 
Table 39 Components of the final prototype 
Starting from the analysis of the material chosen and their datasheet, it’s possible to declare 
that the products are free of phthalates. 
6.5.6 Manufacturing process 
The industrial prototype of the Floseal GI cath. has been made through different 
manufacturing process which have involved the transformation of plastic materials in 
different shapes and sizes. 
The first process to ensure has been the extrusion of the blue catheter, the external shaft and 
the balloon (Figure 90). The tolerances for the extrusion are very strict and depend on the 
dimension of the component and on the particular machine used by the manufacturer.  
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Figure 90 Balloon manufacturing tolerances 
The dispenser tube (Figure 91) is extruded, whirled and 3 channel clips are applied. 
 
 Figure 91 Dispenser tube 
The next steps are the extrusion of the orange stop for the catheter inside the external shaft 
(Figure 92) that will be thermoformed, cut to length and squashed with small forceps. 
 
Figure 92 Stop of the catheter 
In order to insert the commercial haemostatic valve to the oversheath the extrusion of a steel 
cylinder is necessary(Figure 93). 
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Figure 93 Dimensions the adapter cylinder for the haemostatic valve. 
Following the injection molding of the luer-lock adapter for the blue catheter (Figure 94, up)  
and for the external sheath (Figure 94, down). 
 
Figure 94 Luer lock adapters for the catheter (up) and the external sheath (down) 
In order to mount the balloon on the internal catheter it is necessary to taper the distal end of 
the catheter (Figure 95) from a diameter of 1.65mm to 1.2mm for a minimum length of 50mm 
and then to a diameter of 1mm for 25 mm. 
 
 
Figure 95 Tapered distal part  
A tube drawing machine has been used to reduce the diameters and the distal end is cut 
25mm from the point of the first drawing and closed by means of 2 consequent application of 
UV resin which polymerizes and leaves a round tip. 
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Figure 96 Balloon area manufacturing 
A 0.5mm hole for the inflation of the balloon is made at a distance of 10 mm by the end of the 
catheter, taking care not to perforate the opposite wall. Then the tubular balloon is mounted 
on its area by means of glue (Loctite 4011) and spirally bonded with a nylon wire of 0.5mm 
diameter. Then a check of the balloon is done as in 6.6.3.2. The cutting of the catheter to 
length (2280mm) is next realized with a blade. 
After that the blue luer connector is glued to the catheter and a check that there is not air loss 
is done. 
Starting from an AISI 316 steel wire of 0.5mm in diameter, a spiral (Figure 97) is obtained 
using the lathe chuck. Then the guide-wire is inserted into the catheter. 
 
Figure 97 Guide-wire manufacturing 
The cut of the oversheath (Figure 98) to length (2210mm) and a series of black notch is made: 
one for the limit of the hemostatic valve and one for the insertion of the right dosage of 
Floseal. The luer is glued to the oversheath. 
 
Figure 98 Oversheath 
The AISI 316 cilynder is cut to lenght (Figure 99 A), a UV resin is posed on one side and it is 
inserted into a 7Fr commercial hemostatic valve (Qosina48). 
                                                     
48
 http://www.qosina.com/catalog/part.asp?partno=80391 
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Figure 99 Hemostatic valve assembly 
The two syringes are equipped. A block is made in the big one to allow an insertion of 4 cc of 
air into the balloon and the Floseal one is labelled with an accurate discretization to allow a 
precise dosage of the hemostatic agent(Figure 100). 
 
Figure 100 Syringe for insufflation (left) and for insertion of Floseal (right) 
6.6 Test sessions 
A device like Floseal GI cath. doesn’t need preclinical testing to enter the EC market, because 
its risk class is IIa (see 0) and from the analysis of commercial similar devices and medical 
background it has been possible to achieve the CE without clinical evaluation tests (pg.118). 
In order to test the usefulness of the device before its possible marketing, the device has been 
tested several times and with different procedures. In Annex IX the test done are fully 
reported. 
The test sessions can be divided into test with different prototypes, which have been dove in 
order to find the right configuration for the device, and control test, done to demonstrate the 
efficacy of the manufactured device and the compliance to regulations. 
6.6.1 In vitro tests 
This first series of tests have been done using several subsequent prototypes of the catheter 
(all listed in Annex VIII). Starting from the test of the first prototype (vers. 1.0), very soon the 
critical feature of the device have been identified and corrective actions were taken. 
For the first session of trials, the test procedure was as follows: 
 Step 1: Block the catheter on the table making an "S”, medium radius of curvature of the 
Beam 30 cm 
 Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according to the catheter IFU  
 Step 4: Expulsion of Floseal 
 Step 5: Repeat steps 3 and 4 to 2 times. 
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The first big problem encountered was the impossibility of extruding Floseal , so several 
hypothesis followed regarding possible solutions( see 6.5.2.). Possible causes can be (in order 
of importance): 
Cause 
Degree of concern 
(1-small, 5-extremely difficult) 
1. storage temperature of Floseal 5 
2.dosage of Floseal 5 
3. shape of the tip 3 
4.dimensions of guide wire 2 
5. material of the oversheath 5 
6. gap between catheter and oversheath 5 
Table 40 Possible causes of inefficient extrusion. 
An analysis of possible solutions with the correspondent degree of importance has been 
reported in Table 41. 
Solution 
Difficulty of solution 
(1-easy, 5-hard) 
Probable effect 
Require the proper 
conservation 
3, it is not only a problem 
in Baxter but also in 
hospitals 
Probably decisive 
Reduce the dosage 
3, it depends on the 
surgeons’ opinion 
Decisive 
Reduce the gap between 
the tip and catheter 
4 It can help 
Hardening of the guide 
wire 
1 It can help 
Use of lubricants 1 
It can help, but it would be difficult to prove the 
complete compatibility with the materials used and in 
particular with the Floseal 
Material change 
(use of Teflon) 
5 (the subcontractor 
doesn’t use Teflon) 
Probably decisive 
Table 41 Possible solutions 
Hence decision has been undertaken: 
4. implementation of miniseries (2.0) with steel tip and sleeve micro-striped 
5. solicitation to Baxter about the verification of the conditions of conservation of Floseal 
6. request to the clinicians in touch with Baxter on the possibility of extruding a quantity 
of less than 2 CC of Floseal per time. 
After the acceptance of the third condition the following tests worked very good so it has 
been decided to reduce the dosage of Floseal to 0.5cc per application. 
Other considerations can be done about the small syringe for Floseal which crashed and bent 
(it was too small), so it was changed with a stiffer one. The safety valve was more comfortable 
than the stopcock than it has been chosen. The hemostatic valve was good as adaptor 
between the oversheath and the syringe. The balloon was good for transparency and volume. 
6.6.2 Ex-vivo tests 
The catheter  for the application of endoscopic Floseal through a flexible endoscope, was 
tested ex-vivo in an isolated pig stomach (mod. Erlangen) at the EETC (European Endoscopy 
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Training Centre) of the Università del Sacro Cuore in Rome, laboratory for the simulation of 
multiple endoscopic hemostasis interventions. 
 
Figure 101 Erlangen model of stomach 
The procedure and the results of test are illustrated in Table 42 as in Annex IX. 
Date: 
20/10/2009 
Place: EETC (European Endoscopy Training Centre) of the Università Cattolica del 
Sacro Cuore, Rome 
People involved in 
the test session 
Doc. Gianluca Spera (Università Cattolica del Sacro Cuore - Rome) 
Catheter version N. 4.0 Description: see Annex VIII N. tested cath. (same 
version): 2 
Batch Floseal  n.  
Test Procedure Step 1: Block the catheter on an  Erlangen model of a pig stomach 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 0.5 cc of Floseal 
according to the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results and 
problems 
encountered 
Test n.: 1 Cath. vers. : 4.0 The catheter work properly 
Test n.: 2 Cath. vers. : 4.0 the catheter works properly 
Test n.: 3 Cath. vers. : 4.0 the catheter works properly 
Corrective Actions 
taken 
 
Results of actions Device ready for the market 
Test  Responsible  Spera  Signature 
Table 42 Final ex vivo tests 
In this experiment the catheter has demonstrated efficacy and ease of use; it has revealed a 
remarkable handling also using a diagnostic endoscope with an operative channel of 2.8mm 
diameter . 
The catheter is optimal for the purpose, both for the easiness of introducing the Floseal, both 
in its introduction and subsequent use with the endoscope. 
Doctor Spera was impressed by the device that, to date , was the only system capable of 
allowing the use of Floseal in the digestive endoscopy and  in his view, it could allow good 
results in the techniques of hemostasis. 
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6.6.3 Control tests 
6.6.3.1 Physical controls 
Physical controls, including visual checks, dimensional and functional, for the medical device " 
Floseal GI catheter ", are performed on every batch of raw material and finished product, 
prior to sending the same to sterilize, as required by the Qualitative Contract with the 
contractor company (which manages the production process from raw materials to 
packaging). 
6.6.3.2 Floseal GI Catheter Balloon Control Procedure 
After the assembling of the balloon on the catheter, the following control is performed to 
ensure the accuracy and especially the safety of the catheter itself. 
First, during the prototyping phase, the limits of inflation and useful expansion of the balloon 
have been established. Therefore the syringe is prepared, making a groove in the body of the  
5cc syringe, so that during inflation doctor does not enter into the balloon over 4cc of air. The 
syringe is connected to the catheter and then the balloon is inflated; it is left inflated for 20 
minutes to verify that the diameter of the balloon just inflated remains unchanged even after 
20min. The expansion of the balloon is 11mm. After the control is found to be positive, the 
sheath, on which is mounted the balloon, is brought within allowing the return to zero of the 
balloon and the complete adhesion of the balloon to the sheath itself. Thanks to the 
procedure showed the balloon cannot block somehow the reintegration of the sheath in the 
catheter itself. 
Also a Break test of balloon is done: it is broken with a double delivery of the syringe kit for 
the pump (10ml).The material of the balloon does not divide up during the break. 
6.6.3.3 Chemical controls 
The components used for the device are made with own moulds or purchased on the market 
from certified manufacturers; all materials used are suitable for specific use both for purely 
structural aspects (compliance with harmonized standards) both in terms of chemical 
composition. The input materials are checked for the presence of the certificate that ensures 
compliance. In addition, a test of release of chemicals ( Italian Official Pharmacopoeia; ISO 
15747:2003 Plastics containers for intravenous injection) has been conducted in order to 
verify the compliance of the device as a whole. 
6.6.3.4 Biological Control 
The tests Bioburden pre-sterilization (conducted in accordance with the guidelines of ISO 
11737-1 and EN 1174-1, uses the methods provided by the Italian Official Pharmacopoeia) are 
performed regularly (a fixed date is that which corresponds with the periodic validation of 
sterilization) by accredited laboratories. 
Search of endotoxin (LAL Test- Pyrogen Test ) and the absence of abnormal toxicity 
(performed according to Italian Official Pharmacopoeia)are carried out regularly by accredited 
laboratories. 
Verification of sterility (performed according to current Italian Official Pharmacopoeia )is 
performed on each batch of sterilization by an external certified laboratory. 
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All the tests reports are kept by the Quality Assurance Manager of the producer company 
(MicroTech). 
In addition, the tests of hemolysis (UNI EN ISO 10993-4, "Biological evaluation of medical 
devices - Part 4: Selection of tests for interactions with blood") and the cytotoxicity test (UNI 
EN ISO 10993-5 "Evaluation biological medical devices - Part 5: Test for cytotoxicity in vitro) 
were conducted in order to verify the compliance of the device as a whole. 
6.7 Risk Management 
6.7.1 Risk assessment 
6.7.1.1 Risk analysis 
Floseal GI catheter intended use 
The Floseal GI Catheter has been designed, tested and, above all, CE labelled uniquely for a 
clinical use with Floseal Haemostatic Matrix. The Catheter is indicated in endoscopic surgical 
procedures of Gastrointestinal (GI) tract, when it allows to deliver and apply 0,5 cc of Floseal 
for each application. During the same surgical procedure, up to 5 total Floseal applications (of 
0,5 cc) are allowed. The gastroscope working channel is 8 French (2.97 mm) minimum. 
There are very similar products on the market, they all have the purpose or to seal tissues 
(cyano-n-butyl-cyano-acrylate) or to facilitate hemostasis (gel / fibrin glues) ; as accessories to 
these products there are medical devices that fulfill the need to affix and / or spread glue on 
the tissues in various ways. There is an established use of such devices, conceptually very 
similar to Floseal GI cath.: in open surgery and laparoscopy, both disposable and reusable, 
working with the same principle of the piston and using a syringe to make pressure on 
endoscopic applications. 
A research carried out in collaboration with Studio Ambiente Srl and with Baxter (who already 
use other medical device having the same intended purpose - "to distribute glue") showed 
that at least one endoscopic application that works exactly with the same principle of the 
piston exists on the market. In this case the Floseal is applied in situ with the help of a gauze 
instead of the balloon, but purpose and effect are exactly the same. In Table 43 a list of 
medical devices similar in intended use. 
Device Company 
Floseal endoscopic applicator Baxter 
49
. 
SurgiFlo endoscopic applicator Ethicon
50
 
Vivostat endoscopic applicator Vivostat
51
 
Glubran endoscopic  applicator Gem Italy
52
 
Table 43 Similar devices 
                                                     
49
 http://www.baxterbiosurgery.com/us/products/Floseal/accessories.html 
http://www.eaumilan2008.org/typo3conf/ext/eau_abstracts/abstracts/Poster%20session%2045/746-Wille.pdf 
50
 http://www.stopcrbsi.com/biosurgicals/surgiflo/surgiflo_FB_tip_options.html 
http://www.ethicon360.com/sites/default/files/userfiles/Evithrom%20Surgiflo%20pocket%20folder%20w_PI.pdf 
51
 http://www.vivostat.com/composite-61.htm 
52
 http://www.gemitaly.it/cms/index.php?option=com_content&task=view&id=54&Itemid=18 
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Even if the Floseal GI cath. has some differences from the mentioned devices it is very similar 
in intended use( a glue applicator). Hence it can be considered of established use and clinical 
validation hasn’t been necessary to reach the CE label.  
Although a clinical study is not needed for regulatory purposes, it is important to establish a 
proof of concept that Floseal is a safe and efficacious treatment for bleeding in GI endoscopy. 
Therefore the company decided to conduct a technical assessment by two independent 
specialists to check the ergonomics of the product. For marketing reasons also a multicenter 
study is started, involving centers throughout Italy.  
Classification 
The medical device "FLOSEAL GI CATHETER", subject of this Ph.D. thesis, has been classified in 
accordance with Rule 6, paragraph 2.2 "Invasive devices" of Annex IX of EC Directive 
2007/47/EEC as a Class IIa medical device, sterile.  
Application of the rule: 
 The family of medical device  FLOSEAL GI CATHETER, Class IIa, must meet the essential 
requirements set out in Annex I and be produced in compliance with the Annexes V + VII 
of the European Directive 2007/47/EC 
 The medical device, covered by a technical brochure, is intended to be used in endoscopic 
surgical procedures of the digestive system, where, at the time of bleeding, it is able to  
carry, release and apply following amounts of 0.5 cc of Floseal 
 The line of medical devices "FLOSEALTM GI CATHETER" consists of medical devices that 
incorporate medicines and contain no animal tissue. These devices are supplied 
individually wrapped and sterile 
 The application was submitted in accordance with the appropriate Annexes V + VII, 
according to paragraph 1 of Article 11 of European Directive 2007/47/EC to the notified 
Body, Cermet53. 
Functional analysis 
Question Answer 
What is the intended use and how 
is the medical device to be used? 
this medical device is intended to be used in surgical endoscopic 
procedures, where, in case of bleedings, it allows to carry, release amount 
and apply subsequent doses of 0.5 cc of Floseal; device for an invasive 
limited time complying with regulation 6 of the classifications provided in 
annex IX of EEC 2007/47). 
Is the device intended to be 
implanted? 
no 
Will the device be in (direct) 
contact whit patient or other 
persons? 
Yes: direct contact with the patient (the device is invasive in phase of 
surgical endoscopic interventions),direct contact with the surgeon but  
only in phase of preparation and use. 
What are the materials or 
components used ? 
the medical device is manufactured with plastic materials, in contact with 
them there is Floseal ™ to be used on the patient in the area affected by 
bleeding  
Is Some kind of energy given or 
detracted to the patient? 
No 
                                                     
53
 CERMET Soc. Cons. srl Via Cadriano, 23-40057 Cadriano – Granarolo E. (BO) 
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Is Some kind of matter given or 
detracted to the patient? 
Yes: the device is used for the application of Floseal on GI bleeedings 
Does the device manage some 
biological material for a 
subsequent use? 
No 
Is the device sterile or is it 
sterilised by the end user? 
Yes, It is single used, sterilized with ETO by the manufacturer. It cannot be 
re sterilized. 
Is the medical device intended to 
be routinely cleaned and 
disinfected by the user? 
No 
Does the device modify the 
environmental conditions of the 
patient? 
No  
Is a measurement device? No 
Can the device make an 
interpretation? 
No 
Can the device control or is it in 
connection with other devices?  
Yes, it is used with Floseal in GI endoscopic surgical procedures 
Can the device be subject at 
unexpected leak of energy or 
matter? 
No, the eventual unwanted leakage of Floseal is due to a wrong use of the 
device  
Can the device be subjected by 
ambient conditions?  
No 
Does the medical device influence 
the environment? 
No 
Are there some consumables or 
accessory associated to the 
devices?  
The device is complete with all the accessories needed for its use, all the 
connections are luer  
Are periodical set-up or re-
conditioning necessary? 
No 
Does the device use a software? No 
Has the device an expiration date? Yes, expiration date depends on sterilization process and level of 
bioburden 
Can the device produce some 
delay effects due to the long-term 
use? 
No 
To what mechanical forces will the 
medical device be subjected? 
The device and, in particular the balloon  in the distal part, can be forced 
during the insufflations phase  
What determines the lifetime of 
the medical device?  
For a new device, the lifetime of the medical device is driven by the 
sterilization process and its level of Bioburden; during use, life span 
depends on the need of medical / other person carrying the protocol, in 
any way is a limited time. 
Is the medical device intended for 
single use? 
Yes 
Is safe decommissioning or 
disposal of the medical device 
necessary? 
Yes, it is a special hospital hazardous disposal 
Does installation or use of the 
medical device require special 
training or special skills? 
The installation and use of the device requires specialized knowledge and 
the following of IFU 
How will information for safe use 
be provided? 
Through the label and the IFU leaflet 
Will new manufacturing processes 
need to be established or 
introduced? 
No 
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Is successful application of the 
medical device critically 
dependent on human factors such 
as the user interface? 
No 
Does the medical device use an 
alarm system? 
No 
In what way(s) might the medical 
device be deliberately misused? 
Not following the IFU 
Does the medical device hold data 
critical to patient care? 
No 
Is the medical device intended to 
be mobile or portable? 
no 
Does the use of the medical device 
depend on essential performance? 
no 
Table 44 Questionnaire for functional analysis (annex C , ISO 14971) 
Identification of dangerous phenomena 
Following there is a list of dangerous phenomena, known or predicted, identified following 
analysis of the Floseal GI cath.: 
 energy factors  
o force applied during use 
 chemical  and biological factors  
o bio contamination; bio incompatibility; toxicity; pyrogenicity; 
o failure to maintain sterility (break packaging); 
o degradation; 
 factors due to way of use 
o incompatibility with other devices with which it is intended to be used; 
o accidental mechanical. Damage 
o leakage of hemostatic Floseal . 
 information 
o improper labelling; 
o inadequate instructions; 
o use by personnel without skills / untrained. 
o inadequate packaging; 
o  re-use. 
Risk estimation for each hazardous event 
Starting from the list of dangerous phenomena identified in the previous chapter, in Table 45, 
the sequence of predictable events and dangerous situations are identified. For each 
identified hazard situation one or more hazards will be joined, which will be evaluated using 
information and data obtained from: 
 Published Standards  
 Information and scientific literature 
 Data collected by the use of the device and user feedback 
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 Data collected by the use of similar devices already in service, including reports of 
accidents that have been published 
 Results of studies specifically conducted  
 Clinical Evidence 
 Review of use 
 Evaluations by experts  
 Other possible. 
Dangerous phenomena Sequence of probable events 
Dangerous 
condition 
Unwanted event 
Force applied during use 
The device is subjected to 
forces which do not correspond 
to those expected in the 
activities for which it is intended 
The device deforms, 
kinks and can break 
during its use (i.e. 
the balloon cannot 
be inflated and it 
cannot  spread 
Floseal) 
Leakage of Floseal 
Contamination of the 
patient 
Contamination of the 
operator 
Bio contamination; bio 
incompatibility; toxicity; 
pyrogenicity 
The device hasn’t been 
manufactured in a controlled 
environment or with a wrong 
sterilization method 
Unnoticed 
contamination 
Infections to patie 
nts, allergies, irritations 
Failure to maintain sterility 
(break packaging) 
Contamination of the product 
during all the phases of 
transport of the device 
Unnoticed 
contamination 
Infections to patients, 
allergies, irritations 
Degradation 
unsuitable materials, submitted 
to several sterilization cycles 
and uses 
Degradation of the 
device with release 
of chemicals 
Intoxication 
Allergies, irritations 
Incompatibility with other 
devices with which it is 
intended to be used 
Component aren’t adequate for 
the intended use and aren’t 
compliant to regulations 
Partial and unclear 
connections 
Impossible use 
Accidental mechanical 
damage 
The device has fallen or has 
been broken during its use 
The device doesn’t 
work correctly 
during use 
Impossible use 
Leakage of hemostatic 
Floseal 
The device has fallen or has 
been broken during its use 
The device doesn’t 
work correctly 
during use 
Loss of Floseal 
Contamination of the  
patient 
Contamination of the 
environment, of the 
operator with 
subsequent need of 
decontamination 
Improper labelling 
Not sufficient transmitted 
information 
Wrong use 
Mistakes in the 
manipulation of the 
devices 
infection of the patient 
for the use after  
sterility period 
Inadequate instructions 
Not sufficient transmitted 
information 
Wrong use of the 
device 
Mistakes in the 
manipulation of the 
devices 
Use by without skills / 
untrained personnel. 
Not sufficient transmitted 
information 
Wrong Use of the 
device 
Mistakes in the 
manipulation of the 
devices 
Inadequate packaging; 
Contamination of the product 
during all the phases of 
Unnoticed 
contamination 
Infection for the use of a 
non sterile device 
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transport of the device 
Re-use 
Contamination of the product 
or stress for an additional 
sterilization process 
Unnoticed 
contamination or 
loss of technical 
properties 
Infection for the use of a 
contaminated device 
Loss of mechanical 
properties 
Table 45 List of identified hazards on the product (ref.: Annex E, Table E3 UNI CEI EN ISO 14971:2009) 
6.7.2 Risk evaluation and control  
The manufacturer has decided to accept a probability of a residual risk equal to or less than 
10-4 (Equal to 1 for the alternative scale(see Annex III)) 
Eventual analysis of the benefit-risk relationship (ref. section 6.4 of the UNI CEI EN ISO 
14971:2009): If the index of the residual risk is judged unacceptable on the basis of the fixed 
criteria, the manufacturer can collect and review information and documentation showing 
whether the medical benefits are greater than the residual risk. If even these tests do not 
confirm that medical benefits are greater than the residual risk, the risk is unacceptable. 
In Table 46 some examples of risk evaluation and corrective actions, for the analyzed device, 
are reported. The full documentation is filed in the technical file of the product. 
 
Unwanted event-
hazard 
Harm 
Descripti
on 
IL 
Causes 
and its 
occurrenc
e 
P RE 
Technical 
solution 
(Measures 
and 
contingency) 
EI 
Document
al 
measures 
AEI RRE 
ENERGY Force 
applied 
Floseal 
leakage 
(3) 
10
4 
rare 
(2) 
10
-5 
(6) 
10
-1 
Test of good 
functioning 
during 
production; 
controls on 
scrap 
materials and 
finished 
products 
(0.1
) 
10-
6 
  
(0.6
) 
10-
7 
CHEMICAL bio 
contamination; 
bio 
incompatibility; 
toxicity; 
pyrogenicity 
Infection 
of the 
patient 
(4) 
10
6 
Extremely 
rare 
(remote) 
(1) 
10
-6 
(4) 
10 
Use of 
biocompatibl
e materials; 
Sterilization; 
Manufacturin
g in 
controlled 
environment 
(0.3
) 
10-
4 
  
(1.2
) 
10-
4 
WAY OF USE 
incompatibility 
with other 
devices with 
which it is 
intended to be 
used 
Impossibi
lity to use 
the 
device 
(3) 
10
4 
Extremely 
rare 
(remote) 
(1) 
10
-6 
(3) 
10
-2 
Controls in 
process and 
of final 
product 
before 
release; 
validation of 
the 
components 
on the device 
(Regulation); 
Certificates of 
(0.3
) 
10-
4 
  
(0.9
) 
10-
6 
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Compliance 
issued by the 
suppliers of 
materials 
INFORMATION 
improper 
labelling 
Mistakes 
in the 
manipula
tion of 
the 
devices 
(4) 
10
6 
rare 
(2) 
10
-5 
(8) 
10 
  
Labelling 
validation 
compliant 
to 
regulation 
(0.1
) 
10-
6 
(0.8
) 
10-
5 
Table 46 Risk evaluation and management (see annex III for definitions) 
6.7.3 Sterilisation method 
The purpose of the sterilization process is to inactivate the microbiological contaminants 
which may be present on the device and then turn a NON STERILE product in STERILE. Since 
the effectiveness of sterilization cannot be verified by checking all products processed in each 
cycle, it is necessary to validate, monitor and control the process (as from European Directive 
2007/47/EC on medical devices).  
The curve of inactivation of a culture of microorganisms, through the action of a chemical or 
physical agent used to sterilize medical products, is often similar to an exponential 
relationship, which means that there is always a finite probability that a microorganism may 
survive regardless the extent of treatment applied. For a given treatment, the probability of 
survival is determined by the number and strength of micro-organisms and the environmental 
conditions to which the bodies have undergone during the treatment. From this it follows that 
the sterility of any piece in a lot of products subjected to sterilization cannot be guaranteed 
and the sterility of that production batch must be defined in terms of probability that a not 
sterile product is in that lot. 
The validation of the sterilization process is used to determine the values of some physical 
parameters (e.g.: Temperature, humidity, pressure, gas concentration, treatment time, etc..) 
necessary to transform, with a margin of warranty, the product from non-sterile to STERILE. A 
medical device is considered sterile when the probability of finding a sample with a living 
organism is equal to or less than 1x10-6 (due to the exponential relationship between the 
inactivation of microorganisms and sterilizing agents).  
To ensure the validation of a sterilization process is extremely important that the level of 
bacterial contamination of the products before sterilization is maintained constantly at the 
minimum, and that the type of contaminant doesn’t have particular strength to inactivating 
agent.  
To demonstrate the effectiveness of sterilization, which is being validated during routine 
sterility control, specific, high resistant to ethylene oxide, biomarkers are used.  
It is necessary to get a validation process of the sterilization treatment of the product 
(systematic analysis of the production phases) to get accurate and reliable indication on the 
physical, microbiological, chemical and biological state of the product prior to sterilization. 
These factors serve to make reliable the validation process and to ensure repeatability in time 
of the sterilization conditions guaranteeing a standard initial condition. 
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Hence the manufacturer (MicroTech srl) took steps to validate its sterilization with EtO 
(ethylene oxide) at the company SterilVerona Ltd. The details of the sterilization cycle can be 
found in the "VALIDATION OF STERILIZATION" filed in the Quality office of the manufacturer. 
In Annex X the parameters of the sterilization process are briefly reported. 
6.7.4 Instruction for Use – IFU 
 Each device is accompanied by instructions, complete with warnings, also in accordance to 
what is expressly stated in the Directive 2007/47/EC, Annex I - paragraph 13. Following a short 
description of the IFU (instruction of Use). 
 
Figure 102 Device main components: 1-Case,2-catheter,3-Haemostatic valve,4-Floseal syringe,5-Balloon syringe 
Step 1: Floseal preparation according to Floseal’ s IFU (no difference) 
Step 2: Charge of Floseal into the catheter 
 remove the catheter from the case and take away the orange cup 
 transfer 0,5 cc of Floseal in the Floseal syringe (comp. # 4) 
 connect the haemostatic valve (comp. # 3) to the distal part of the catheter and lock it 
 
Figure 103 insertion of hemostatic valve 
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 connect (Figure 104) the Floseal syringe with 0,5 cc of Floseal to the haemostatic valve and 
lock it 
 push the Floseal syringe in order to transfer the Floseal into the catheter.  
Remark: it is very important that the quantity of Floseal delivered into the catheter doesn’t 
exceed 0,5 cc. Check if the Floseal (that is visible in transparence) reaches the second 
reference54 on the catheter (see Figure 103) 
  
 
Figure 104 Connection of syringe and pushing of Floseal 
 remove the Floseal syringe and the haemostatic valve. 
Now the Floseal GI Catheter is ready to be used. 
Step 3: Floseal delivery and application on the surgical site: 
 introduce the Costamagna – Spera Floseal GI Catheter into the gastroscope through the 
working channel (8 French - size) 
 once the catheter is completely outside the gastroscope, push the blue catheter part. The 
Floseal is forced outside the catheter  
 using the balloon syringe (comp. #5), inflate the balloon 
 using the gastroscope handles, apply the Floseal Haemostatic Matrix on the bleeding 
 at the end of the procedure, using the balloon syringe (comp. #5), deflate the balloon 
 remove the catheter form the gastroscope for a further application, following the same 
entire procedure. 
                                                     
54
 the sheath of the catheter has 2 references in black: 
the first is useful to verify that the haemostatic valve reaches the correct position in order to be correctly locked 
the second is the reference for the correct quantity of Floseal: 0,5 cc 
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All the procedure seems very long, but after a little training it is very easy. It is important to 
use a Floseal in the correct storage conditions (temperature in particular). A temperature 
storage low than 2°C can make the Floseal difficult to be delivered: in this  case, a retraction of 
about 20 cm and a further introduction of the blue part of the catheter is advisable. During 
the “pushing” of the Floseal, in order to avoid the kink (permanent deformation) of the blue 
part of the catheter,  the hands of the surgeon must be at the distance  of 10 cm maximum 
(see Figure 105). 
 
Figure 105 Distance for good handling 
6.7.5 Packaging 
The final packaging of the product should be able to keep it intact until use. The Floseal GI 
cath. is packaged in a single envelope, consisting of medical paper  coupled with 
polypropylene / polyester. The bags are then packed in special boxes and prepared for 
shipment to sterilization on special pallets. Each box is marked with a label (Figure 106) 
identifying the product, with the following information (UNI EN 1041 and BS EN 980): 
 • indication of the manufacturer (MicroTech Srl) 
 • indication of the CE mark and number 
 • code of the finished product 
 • a description of the product 
 • batch production 
 • expiry date (valid for 5 years). 
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Figure 106 Label for the box with 5 units 
Next to the label is affixed a strip of tape "ethylene oxide" required to verify the sterilization 
of the product. The strip will change color after they have been sterilized. Before shipping 
each pallet is wrapped with "Estenpack"55 so as not to allow the movement of the boxes 
during transport. 
  
                                                     
55
 http://www.akroflex.it/english/estenpack_R-eng.htm 
United States Patent Application n. 20070106213 
0476
•Non utilizzare se la confezione o il prodotto risultano danneggiati
•Do not use if the package or the product has been damaged
Costamagna – Spera FloSealTM GI Catheter 
5 unità REF 002-09
Via Boccioni,2
56037 Peccioli (Pi)
Distribuito da: 
Piazzale dell'Industria, 20 
00144 ROMA
LATEX
Contenuto: 1 catetere con introduttore
1 custodia
1 siringa per gonfiaggio palloncino
1 siringa per introduzione FloSeal
1 valvola di tipo emostatico
Ed. 2010/01
2
STERILIZE 2i STERILE EO
LOT 0002 2010/01 2015/12
Baxter
micr tech
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7 Conclusions 
Medical device design methodology is a very attractive field of work, from basic research to 
the market profitability evaluation. Several variables have to be evaluated within all the 
phases, from the concept to the market roll-out, in order to ensure safety and effectiveness. 
The real innovation in medicine is represented by an improvement of patients’ quality of life. 
Minimally invasive surgery and therapies move toward this direction, enabling less pain, 
smaller incisions and a fast post operative course, over an augmented precision and control in 
the interventions.  
For achieving effective results it is fundamental, that the idea is born and supported by the 
real user of the medical devices: the surgeon. 
An analytical study of the idea must be approached and the entire creative process must be 
sustained by the production of prototypes, with various level of accuracy, in order to help the 
creation of a common language between researchers and surgeons. Hence a co-inventive 
iterative process of design, prototyping and tests can start. 
During the entire design course, evaluation of potential hazards, both mechanical and 
chemical, biological or electrical, associated to the use of the device must be analyzed and 
early solved, in order to avoid errors and possible risk to the final users. 
A complete methodology for the development of innovative medical devices has been studied 
and presented. Three examples of research and design of innovative devices in minimally 
invasive surgery are fully reported in this Ph.D. work. All the phases of the design process have 
been implemented in order to achieve different level of results, depending on the complexity 
on the device. 
The Muneretto Beam navigation device is a new system for magnetic guidance of electrodes 
for ablation of atrial fibrillation. The design starts from a commercially available device for 
minimally invasive ablation for cardiac surgery, which has been modified to enhance its 
easiness of use and mini-invasiveness. Other available systems are very expensive (robots) or 
too invasive (open surgery).  
The critical concern in the design of the Muneretto Beam Catheter has been the magnetic 
coupling and the friction with biological tissues. Various configurations and prototypes have 
been evaluated and tested; the best magnetic coupling has been obtained and the final 
configuration chosen. It will be a fixed one, as described previously, so the friction between 
tissues and catheter and the shape of the tip are not big issues. In this work only a proof of 
concept has been completed, thus a lot of work has still to be done. The next steps are the 
development of preindustrial prototypes and the deployment of in vivo and in vitro tests in 
order to assess its efficiency and safety. 
The VideoDrain is a new device for the monitoring of liquids and viscera in the post-operative 
phase, especially in case of huge interventions, where it allows the avoidance of a second-look 
invasive intervention. The main features of the device are: a balloon, from which it is possible 
to see the abdominal cavity, and a tube, for the insertion of a commercial fiberscope. A series 
of valves ensure the insulation from the external environment. A pre-industrial prototype has 
been developed and tested in vivo with medical personnel. An evaluation of regulatory issues 
and functional analysis have been deployed. The final industrial prototype must be developed 
and the certification process must start. 
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The FloSeal GI catheter is a novel device for the release of a commercial, gold standard, 
haemostatic matrix in the gastrointestinal tract. The entire process of invention, design, test, 
production and certification have been completed.  
The critical issue in the deployment of the device has been the extrusion of Floseal, an high 
viscous and granulose substance. Several prototypes and tests have been developed in order 
to understand which would better fit the efficacy and ergonomics of the whole procedure. 
The device has been fully tested with surgeons and is now CE labelled. Future work will 
include a post-market surveillance and possible design modifications owing to difficulties 
found during the use of the device 
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10 Annex I 
Classification of Medical devices 
TYPE OF 
CLASSIFICATION 
DEFINITION MEANING Rules 
Time- Duration Transient Normally intended for continuous use for less than 60 minutes.  
Time- Duration Short term 
Normally intended for continuous use for not more than 30 
days. 
 
Time- Duration Long term Normally intended for continuous use for more than 30 days.  
Invasiveness 
Non invasive 
devices 
 1.2.3.4 
Invasiveness 
Invasive 
devices 
A device which, in whole or in part, penetrates inside the body, 
either through a body orifice or through the surface of the body 
5, 6, 7, 
8 
Invasiveness 
Surgically 
invasive device 
An invasive device which penetrates inside the body through the 
surface of the body, with the aid or in the context of a surgical 
operation. 
 
Invasiveness 
Implantable 
device 
Any device which is intended: 
-to be totally introduced into the human body or, 
- to replace an epithelial surface or the surface of the eye, 
by surgical intervention which is intended to remain in place 
afterthe procedure. Any device intended to be partially 
introduced into the human body through surgical intervention 
and intended to remain in place after the procedure for at least 
30 days is also considered an implantable device. 
 
 
Reusable 
surgical 
instrument 
Instrument intended for surgical use by cutting, drilling, sawing, 
scratching, scraping, clamping, retracting, clipping or similar 
procedures, without connection to any active medical device 
and which can be reused after appropriate procedures have 
been carried out. 
 
 Active devices 
Any medical device the operation of which depends on a source 
of electrical energy or any source of power other than that 
directly generated by the human body or gravity and which acts 
by converting this energy. Medical devices intended to transmit 
energy, substances or other elements between an active 
medical device and the patient, without any significant change, 
are not considered to be active medical devices 
9, 10, 
11, 12 
 
Active 
therapeutical 
device 
Any active medical device, whether used alone or in 
combination with other medical devices, to support, modify, 
replace or restore biological functions or structures with a view 
to treatment or alleviation of an illness, injury or handicap. 
 
 
Active device 
for diagnosis 
Any active medical device, whether used alone or in 
combination with other medical devices, to supply information 
for detecting, diagnosing, monitoring or treating physiological 
conditions, states of health, illnesses or congenital deformities. 
 
 
Central 
circulatory 
system 
arteriae pulmonales, aorta ascendens, arcus aorta, aorta 
descendens to the bifurcatio aortae, arteriae coronariae, arteria 
carotis communis, arteria carotis externa, arteria carotis interna, 
arteriae cerebrales, truncus brachio-cephalicus, venae cordis, 
venae pulmonales, vena cava superior, vena cava inferior 
 
 
Central 
nervous 
system 
brain, meninges and spinal cord.  
Table 47 Definitions for classification of medical devices (Annex IX of directive) 
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CLASS Devices included 
I 
All non-invasive devices 
Non-invasive devices which come into contact with injured skin if they are intended to be used as a 
mechanical barrier, for compression or for absorption of exudates 
All invasive devices with respect to body orifices other than surgically invasive devices and which are not 
intended for connection to an active medical device if they are intended for transient use 
Reusable surgical instruments for transient use 
II a 
Non-invasive devices: for channelling or storing blood 
if they may be connected to an active medical device in Class IIa 
for filtration, centrifugation or exchanges of gas, heat 
which come into contact with injured skin manage the micro-environment of a wound 
All invasive devices with respect to body orifices: 
than surgically invasive devices if they are intended for short-term use 
other than surgically invasive devices, intended for connection to an active medical device in Class IIa or 
a higher class 
All surgically invasive devices intended for transient use  
All surgically invasive devices intended for short-term use 
Implantable devices and long-term surgically invasive devices placed in teeth 
All active therapeutic devices intended to administer or exchange energy 
Active devices intended for diagnosis: 
intended to supply energy which will be absorbed by the human body 
to image in vivo distribution of radiopharmaceuticals 
intended to allow direct diagnosis or monitoring of vital physiological processes 
All active devices intended to administer and/or remove medicine 
Devices for disinfecting medical devices except for invasive devices (IIb) 
Devices specifically intended for recording of X-ray diagnostic images 
II b 
Non-invasive devices: 
 intended for modifying the biological or chemical composition of blood 
which come into contact with injured skin if they are intended to be used principally with wound 
All invasive devices with respect to body orifices than surgically invasive devices if they are intended for 
long-term use except if they are used in the oral cavity as far as the pharynx (IIa) 
Surgically invasive devices for transient use intended to: 
supply energy in the form of ionising radiation 
have a biological effect or to be wholly or mainly absorbed 
administer medicines by means of a delivery system, if this is done in a manner that is potentially 
hazardous 
Surgically invasive devices intended for short-term use: 
 to supply energy in the form of ionizing radiation 
to undergo chemical change in the body, except if the devices are placed in the teeth (IIa) 
All implantable devices and long-term surgically invasive devices 
Active therapeutic devices intended to administer or exchange energy in a hazardous way 
All active devices intended to control or monitor the performance of active therapeutic devices 
Active devices intended for diagnosis  
of vital physiological parameters 
intended to emit ionizing radiation 
Active devices intended to administer and/or remove medicine in a potentially hazardous way 
All devices used for contraception unless they are implantable or long term invasive devices(III) 
Devices intended specifically to be used for disinfecting, cleaning,rinsing or, when appropriate, 
hydrating contact lenses 
Blood bags 
III 
Surgically invasive devices for transient use: 
 intended specifically to control, diagnose, monitor or correct a defect of the heart or of the central 
circulatory system through direct contact with these parts of the body 
in direct contact with the central nervous 
Surgically invasive devices intended for short-term use: 
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 to control, diagnose, monitor or correct a defect of the heart or of the central circulatory 
in direct contact with the central nervous system 
to have a biological effect or to be wholly or mainly absorbed 
Implantable devices and long-term surgically invasive devices: 
to be used in direct contact with the heart, the central circulatory system or the central nervous system 
to have a biological effect or to be wholly or mainly absorbed 
to undergo chemical change in the body 
All devices incorporating, as an integral part, a human blood derivative or a medicine 
All devices manufactured utilizing animal tissues or derivatives 
Table 48 Classification rules from article 9 and annex IX -2007/47 
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11 Annex II 
Biocompatible materials properties 
Material PU PTFE PVC  Silicone Latex 
Tensile strength 
(psi) 
4000-10000 5500-7000 2000-6000 800–1500 4400–4900 
Flexural 
modulus(psi) 
400000 100000 200000 30000 low 
Ultimate 
elongation(%) 
250-700 350/550 450% 600–1100 800–1200+ 
Durometer 
72 ShA- 
84ShD 
60 ShD 70-90 ShD 
10 ShA-60 
ShA 
35 ShA 
Biocompatibility good good medium optimal weak 
Abrasion 
resistance 
high high good low good 
Sterilization 
technique 
ETO, gamma 
ETO, 
Autoclave 
ETO, gamma 
ETO, 
Autoclave, 
gamma 
ETO, 
Autoclave 
Table 49 Principal characteristic of materials used 
 
Table 50 A list f steam sterilizable materials 
 
Table 51 Some gamma sterilizable materials 
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12 Annex III 
 
Flow Chart – Risk Management Activities in Design and Development 
 
 
Grids for Risk and Measures Assessment 
Risk Assessment Criteria 
Impact Level (IL) (Table 52) scale measures the level of danger of each risk starting form no 
risk level to the maximum potential risk (death).  
100 102 104 106 108 1010 
(1) (2) (3) (4) (5) (6) 
No Influence Low 
(Damage slight 
and subjective to 
the persons or 
things) 
Moderate 
(Slight damage 
and objective 
people or 
things) 
High 
(Injury or 
impairment in 
mild / 
temporary) 
Critical 
(Serious injury 
or disability 
/permanent) 
Very High 
(Death) 
Table 52 Impact Level scale (between brackets an alternative scale) 
The Probability Scale (P) measures the probability that a event occurs, from “incredible” to 
“frequent”.  
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10
-6
 10
-5
 10
-4
 10
-3
 10
-2
 10
-1
 
(1) (2) (3) (4) (5) (6) 
Extremely rare Rare Occasional Moderate 
Probability 
High Probability Frequent 
Table 53 Probability Scale(between brackets an alternative scale) 
Risk Estimation RE (Equation 15) should be less than 10-4(or fall in the green part of the Table 
54). 
IL*P=RE 
Equation 15 Risk Estimation 
Measures Assessment Criteria 
 
 
No Influence Low Moderate High Critical Very High 
  (1) (2) (3) (4) (5) (6) 
Frequent (6) 6 12 18 24 30 36 
High Probability (5) 5 10 15 20 25 30 
Moderate Probability (4) 4 8 12 16 20 24 
Occasional (3) 3 6 9 12 15 18 
Remote (2) 2 4 6 8 10 12 
Extremely rare (1) 1 2 3 4 5 6 
Table 54 three region risk char (it refers to alternative scale) 
It is often very difficult to assign a value for each parameters: some indications can be 
obtained by previous analysis, post market surveillance and clinical studies. 
Risk reduction:  
Technical measures (efficacy index EI) 
Effect of additional documentation (additional efficacy index AEI) 
 
Not present  (1 ) 10
0
 
Limited  (0.8) 10
-1
 
Fair (0.5) 10
-2
 
Good or Effective  (0.3)  10
-4
 
Safe-compliant harmonized (0.1) 10
-6
 
Table 55 Measures efficacy scale  
Risk Estimation after Measures or Residual Risk (RRE, Equation 16) must fall in the green area 
(less than 10-4). 
RE*IE*IUE=RRE 
Equation 16 Residual Risk Estimation 
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13 Annex IV 
Magnetization Pole Configuration 
Axial 
 
Multipolar on both end planes 
 
Diametral 
 
Radial 
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14 Annex V 
Results of  FE model validation 
Comparison with datasheets 
For the magnets used refer to table: 
 
Ø (mm) H (mm) Mdir Grade Brmax(T) 
Sphere s3 4.76 - 
 
N42 1.32 
Cylinder D22 3.175 3.175 
 
N52 1.48 
Cylinder D24 3.175 6.35 
 
N50 1.45 
Disk S09 9 2.50 
 
N52 1.45 
 
(magn_perm) d22_d22 axially56 
 
Figure 107 Comsol visualization of Magnetic flux density 
Δx(mm) 
57
 0.11  0.3  1  2  
F(N)  4.52  3.53  1.53  0.46  
Fdatasheet  3.34  2.44  1.11  0.53  
ΔF 1.18 1.09 0.42 0.07 
Table 56 Comparison of Forces evaluated 
                                                     
56
 Axially stands for axially magnetized. 
57
 Distance between the external surfaces of magnets in the direction of magnetization 
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(magn_perm) d24_d24 axially 
 
Figure 108 Magnetic flux density (B) between two d24 axially magnetized 
Δx (mm)  0.1  0.5  1  2  
F (N)  4.9  2.62  1.39  0.48  
Fdatasheet  4.4  2.89  1.77  0.84  
ΔF 0.5 0.27 0.38 0.36 
Table 57 Comparison of Forces 
(t.l.v.) d24_d24 diametrically58 
In this case the procedure followed for the evaluation of forces is different from the one 
described in 4.5.3.  
 
Figure 109 Magnetic flux density (B) between two d24 diametrically magnetized 
Δx (mm)  0.1  0.5  1  2  
F (N)  5.6  3.75  2.33  1.15  
Fdatasheet  4.88  3.63  1.77  0.97  
ΔF 0.72 0.12 0.56 0.18 
Table 58 Comparison of Forces 
Comparison with tests 
Δx (mm) 0.04 0.24 1 2 
F s3_s3
59
 3.95 3.5 1.88 0.99 
F D24_s09   2.48 1.9 
F D22_s3_axially   7.9 5.0 
F D22_d24_axially 4.9  1.86 0.75 
Table 59 First couplings analyzed for the validation of the model with tests 
                                                     
58
 Magnetization of magnets is diametral 
59
 All forces are in Newton 
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F  (N)  (no tissue) ΔF1 
F (N)  (with tissue, 
distance =1mm) 
ΔF2 
 
s3-s3 3.93±0.04    (3.95) 0.02 3.8±0.04   (1.88) 1.92 
 
S09-S09 6.74±0.10  6.2±0.11  
 
d22-d22 3.79±0.25   (4.52) 0.73 1.78±0.14     (1.53) 0.25 
 
d24-d24 4.53±0.27     (4.9) 0.37 2.0±0.14     (1.39) 0.61 
 
s3-d22 3.60±0.06  2.2±0.04     (7.9) 5.7 
 
s3-d24 4.03±0.03  2.18±0.15  
 
s3-S09 4.64±0.06  2.35±0.09  
 
d22-d24 4.04±0.25    (5.1) 1.06 0.71±0.07     (1.86) 1.15 
 
d22-S09 4.20±0.10  3.0±0.11  
 
d24-S09 4.57±0.19  2.38±0.02     (2.48) 0.1 
Table 60 Results of the validation. In bracket the correspondent results of FEA 
148 
 
Validation tests with hkcm60 magnets 
 
Table 61 Magnets  
Magnet-Cylinder Z02x02ND-48H with iron plate 
 
Figure 110 Magnetic flux density between magnet and a iron plate 
Δx(mm) 0 1 
F(N) 1.3  0.59  
Fdatasheet  1.26 0.63  
ΔF 0.04 0.04 
Table 62   
  
                                                     
60
 https://www.hkcm.de 
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15 Annex VI 
Tests results-September 2010 
Configuration 1  
 
TYPE  Number Magnets  Type Magnets  Code  Note  
EXTERNAL  2  Cylindrical  Z03.5x10GD-N35  No sliding up 
No sliding down  
INTERNAL  5  Ring  R03x01x015ND-N35  
Configuration 2  
 
TYPE  Number Magnets  Type Magnets  Code  Note  
EXTERNAL  2  Cylindrical  Z03.5x10GD-N35  No sliding up 
No sliding down 
INTERNAL  7  Ring  R03x01x015ND-N35  
Configuration 3 
 
TYPE Number Magnets Type Magnets Code Note 
EXTERNAL 4 Cylindrical Z03.5x09GD-N35 Sliding down ok 
Sliding up no 
Bad coupling 
INTERNAL 4 Ring R03x01x03Cr-N35 
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Configuration 4 
 
TYPE  Number 
Magnets  
Type 
Magnets  
Code  Note  
EXTERNAL  3  Disc  Z03.5x10GD-N35  The inner one has an external shell (in 
Medical PVC from a suction catheter 61)  
Good coupling  
INTERNAL  2 
2  
Cylindrical  
Cylindrical  
S03x01.4 ND-35EHT 
Z3.5x10GD-N35  
Configuration 5 
 
TYPE  Number Magnets  Type Magnets  Code  Note  
EXTERNAL  3  Ball  K04.76Au-N35  No sliding  
INTERNAL  3  Cylindrical  Z02.5x12ED-N35  
Configuration 6 
TYPE  Number Magnets  Type Magnets  Code  Note  
EXTERNAL  3  Cylindrical  Z03.5x10GD-N35  Sliding down ok 
No sliding up  
INTERNAL  3  Cylindrical  R03x01x015ND-N35  
October 2010 
Configuration 1  
 
 
 
                                                     
61
 * http://www.dmwood.com  
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TYPE 
Number 
Magnets 
Type 
Magnets 
Code 
Tube material 
(Øe, Øi)[mm] 
Note 
EXTERNAL 4 Cylindrical 
Z03.5x10GD-
N35 
Frosted PVC 
(4.6,3.1) Good coupling 
No cutted 
Round shape for the tip 
suggested 
INTERNAL 4 Cylindrical Z02x10ND-N35 
Pellethane 2363-
80AE 
(2.7,2.2) 
Configuration2 
 
TYPE 
Number 
Magnets 
Type 
Magnets 
Code Tube Note 
EXTERNAL 4 Disc MPI 
Frosted PVC 
(8.4,6.4) 
External cutted 
External is too rigid 
Good but worst than the 
first 
INTERNAL 4 Cylindrical 
Z02x10ND-
N35 
Pellethane 2363-80AE 
(2.7,2.2) 
 Configuration3 
 
TYPE 
Number 
Magnets 
Type 
Magnets 
Code Tube Note 
EXTERNAL 4 Disc MPI 
Frosted PVC 
(8.4,6.4) 
Both too rigid 
Axial magnets are not 
stable INTERNAL 4 Cylindrical 
D24 (K&J) 
Ø 
3.175x6.35 
Frosted PVC 
(4.6,3.1) 
Configuration 4  
 
TYPE 
Number 
Magnets 
Type 
Magnets 
Code Tube Note 
EXTERNAL 
3 
1 
Cylindrical 
Cylindrical 
Z04x04ND-N35 
Z03x14N52-GD 
Frosted 
PVC 
(6.6,4.4) 
Bad coupling 
External cutted, too rigid 
Internal magnets too small in 
lenght 
INTERNAL 11 Cylindrical Z01.2x03ND- PVC 
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N35 (2.4,1.4) 
 
Configuration 5 
 
TYPE 
Number 
Magnets 
Type 
Magnets 
Code Tube Note 
EXTERNAL 4 Cylindrical 
D24 (K&J)Ø 
3.175x6.35 
Frosted PVC 
(4.6,3.1) No good (axial 
magnetization) 
INTERNAL 4 Cylindrical Z02x10ND-N35 
Pellethane 2363-80AE 
(2.7,2.2) 
Configuration 6 
 
TYPE Number Magnets Type Magnets Code Tube Note 
EXTERNAL 4 Cylindrical Z03.5x10GD-N35 
Frosted PVC 
(4.6,3.1) 
Very Bad coupling 
INTERNAL 11 Cylindrical Z01.2x03ND-N35 
PVC 
(2.7,2.2) 
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16 Annex VII  
Drawings VideoDrain 
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17 Annex VIII 
FloSeal GI cath. prototypes 
Version Manufactured 
by 
General features Status 
1.0 External 
subcontractor 
See 1.1  
Oversheath material more transparent but with morefriction 
respect to vers.1.1 
Existent 
1.1 A External 
subcontractor 
Lenght oversheat: 173cm 
lenght Cath: 179 cm 
diam. Est. Oversheat:2.7mm(8fr) 
diam. Int  oversheat 2.1mm 
thickness 0.3mm 
diam. Cath  2.0mm 
diam int. cath. 1.0mm 
mandrel da 0.4 double until 700mm 
stopcock 
Existent 
1.1 B External 
subcontractor  
Lenght. oversheat: 173cm, 
lenght. Cath:179 
diam. Est. Oversheat:2.7mm(8fr) 
diam. Int  oversheat 2.1mm 
thickness 0.3mm 
diam. Cath  2.0mm 
diam int. cath. 1.0mm 
mandrel 0.7 corto (per una lenght di 700mm), stopcock 
Destroyed 
1.1 C External 
subcontractor  
Lenght oversheat: 173cm 
lenght Cath:179 
diam. Est. Oversheat:2.7mm(8fr) 
diam. Int  oversheat 2.1mm 
thickness 0.3mm 
diam. Cath  2.0mm 
diam int. cath. 1.0mm 
mandrel da 0.4 double 
one way valve 
Destroyed 
1.1 D External 
subcontractor  
Lenght oversheat: 173cm 
lenght Cath:179 
diam. Est. Oversheat:2.7mm(8fr) 
diam. Int  oversheat 2.1mm 
thickness 0.3mm 
diam. Cath  2.0mm 
diam int. cath. 1.0mm 
mandrel 0.7 corto 
one way valve 
Destroyed 
Baxter Baxter Lenght Oversheat :180 cm 
diam. Est.oversheat:2.45mm 
diam. Int oversheat: 1.82mm 
diam. Cath: 1.7mm 
diam tip cath:1.5mm 
Partially 
modified 
1.2 MicroTech (MT) Uguale a 1.1 con mandrel Ø 0.75mm Destroyed 
1.3 MT Uguale a 1.1 con mandrel Ø 0.6mm Destroyed 
1.4 MT as version 1.1 with glued tip of 2 mm in diameter and lenght of 
11mm ,soldered mandrel with 2 different diameter(0.8-0.55) 
Destroyed 
1.5 MT As version 1.4 1 with glued tip of 1.8 mm in diameter and lenght 
of 11mm 
Existent 
2.0 External 
subcontractor 
Lenght oversheat: 173cm 
lenght Cath:179 
Existent 
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diam. Est. Oversheat:3.00(+0,-0.05)mm(8fr) 
diam. Int  oversheat: 2.5(+0.03,-0)mm 
thickness 0.25mm 
diam. Cath  2.2mm 
metallic tip 
insufflation valve 
3.0 MT As version 1.1 but with different diameter soldered mandrel  Existent 
4.0 External 
subcontractor 
Lenght oversheat: 220 cm 
lenght Cath:227 cm 
diam. Est. Oversheat: 2.7mm(8fr) 
diam. Int  oversheat: 2.1mm 
thickness 0.3mm 
diam. Cath  2.0mm 
insufflation one way valve 
spiraled guide wire 
CE device-
batch 002 
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18 Annex IX 
Floseal GI cath tests 
Date: 
10/10/2008 
Place: ENKI, Concesio Brescia 
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Mario Di Cecio (ENKI), Elena Raza (ENKI), Lidia Bonazza (ENKI) 
Vers. Cath. 
N. 1.0 Description: lenght 175 N. tested 
cath.: 2 
N. Baxter Description: lenght 180 N. tested 
cath.: 1 
Batch Floseal Not inserted 
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of 
the Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according 
to the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results 
Test n.: 1 Cath. vers. : 1.0 Result: the catheter works properly 
Test n.: 2 Cath. vers. : 1.0 Result: the catheter works properly 
Test n.: 3 Cath. vers. : 
Baxter 
Result: the catheter works properly 
Following 
actions 
Order for the production of 20 catheters with features of version 1.0 
Results of 
actions 
Production of 2 catheters (version named 1.1) 
Test 
Responsable  
 Signature 
 
Date: 
01/11/2008 
Place: Ospedale del Sacro Cuore, Campobasso 
People involved 
in the test 
session 
Doc. Gianluca Spera (Ospedale del Sacro Cuore) 
Catheter version 
N. 1.1 A  N. tested cath.: 
1 
N. 1.1 B  N. tested cath.: 
1 
N.1.1 C  N. tested cath.: 
1 
Batch Floseal  unknown 
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of 
the Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according 
to the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results  
Test n. 1 
N. 1.1 A the catheter doesn’t work, impossible extrusion of 
Floseal 
Test n. 2 N. 1.1 B the catheter doesn’t work correctly, difficult extrusion  
Test n. 3 N.1.1 C the catheter doesn’t work, impossible extrusion of 
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Floseal  
General 
comments 
Following 
actions 
Doc. Spera was unable to extrude Floseal; the syringe for Floseal crashed and bent 
(too small); version 1.0 B with a more rigid guide wire was better than the other two; 
the safety valve was more comfortable than the stopcock: 
• Choice of one way valve for inflating balloon 
• Hemostatic valve is ok 
• preferred transparency of the outer sheath of version 1.0 
• the need for more rigid and / or longer metal guidewire   
• The balloon is good for transparency and volume 
it is necessary to increase the length of leakage of the catheter compared to the 
sheath of at least 4.5 cm ( lenght of catheter~ 1725mm) 
Results of 
actions 
Planning of additional tests 
Responsabile 
Test 
Doc. Gianluca Spera Signature 
 
Date: 
24/11/2008 
Place:MicroTech Peccioli (Pi) 
 
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Elena Troia (MT) 
Catheter version 
N. 1.1 Description: modified guidewire. Diam. 0.75mm or the 
entire catheter length 
N. tested cath. 
(same version): 
2 
N. 1.3 modified guidewire: diam 0.6 mm for the entire catheter 
length 
N. tested cath. 
(same version): 
1 
Batch Floseal n. HA080515 
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of 
the Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according 
to the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results 
Test n. 1 
Cath. vers. : 
1.2 
Floseal extruded 
Test n. 2 
Cath. vers. : 
1.2 
Phase 1a: Floseal extruded with a little difficulty; 
hardly bendable catheter in the distal part 
Test n. 3 
Cath. vers. : 
1.3 
Floseal extruded with greater difficulty 
Test n. 4 
Cath. vers. : 
1.3 
Phase 1bis:  Floseal extruded with greater difficulty 
hardly bendable catheter in the distal part 
Corrective 
Actions taken 
Evaluation of the length and diameter of the guidewire, evaluation of the procedure. 
catheter guidewire should be shorter or at least with a smaller diameter in the distal 
part because of the need to make a 90°curve  
Correction guidewire diameter 
Results of 
actions 
1. final notch in the distal part of the sheath for better positioning hemostasis valve  
2. Guidewire dimensions are important for extrusion 
3. In the instructions for use state: 
• use of gloves to improve grip, 
• recover drawn product bringing back catheter 
4. bring back the catheter to better push Floseal 
Test  
Responsable  
 Signature 
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Date: 
25/11/2008 
Place: Ospedale del Sacro Cuore, Campobasso 
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Paolo Passi (Baxter) 
Doc. Gianluca Spera (Ospedale del Sacro Cuore) 
Catheter version 
N. 1.2 View the list of prototypes for the features 
N. 1.3   
Baxter   “ 
Batch Floseal  n. HA080515 
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of 
the Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according to 
the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results and 
encountered 
problems  
Test n.: 1 Cath. vers. : 1.2 
the catheter doesn’t work, impossible extrusion of 
Floseal 
Test n. 2 Cath. vers. : 1.3 
the catheter doesn’t work, impossible extrusion of 
Floseal 
Test n. 3 
Cath. vers. : 
Baxter 
the catheter doesn’t work correctly, very difficult but 
possible extrusion of Floseal  
Corrective 
Actions taken 
Verify Floseal batch e storage 
Identification of the cause for no extrudability :the low storage temperature 
Results of 
actions 
The Floseal was actually delivered to the hospital in containers at -20 ° C, which 
determines the crystallization of the gelatinous matrix and hence the difficulty of 
extruding the Floseal. 
Planning further tests 
Test Responsable 
 
 Signature 
 
Date: 
28/11/08 
Place: ENKI, Concesio Brescia 
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Elena Troia (MT) 
Mario di cecio(Enki) 
Lidia Bonazza(Enki) 
Catheter 
version  
N. 1.2  N. tested cath. 
(same version): 2 
Catheter 
version 
N. Baxter  N. tested cath. 
(same version):  
Batch Floseal  n. HA080515 
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of the 
Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according to 
the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results and 
encountered 
Test 
n.:1 
Cath. vers. : 1.2 
Floseal frozen at -20 °, but thawed after 3 days 
Lubricated catheter: Floseal extruded but with difficulty 
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problems  Test 
n.2 
Cath. vers. :  
Baxter 
Floseal frozen at -20 °, but thawed after 3 days 
Better extrusion of Floseal but not optimal 
Test 
n.3 
Cath. vers. :  
1.2 
Floseal not frozen, difficoult extrusion  
Test 
n.4 
Cath. vers. :  
Baxter 
Floseal not frozen, difficoult extrusion 
Test 
n.5 
Cath. vers. : 2 
precedenti con 
guaine scambiate 
Floseal not frozen, used for the second time 
Baxter catheter with sheath of Vers. 1.1 is better than 1.1 
catheter in Baxter sheath 
Test 
n.6 
Cath. vers. : 1.3 
With coating NUSIL-MED 420-12500: Floseal easily 
extruded 
Test 
n.7 
Cath. vers. : 1.3 
 
lubricated with fluid silicone 
Floseal easily extruded 
Test 
n.8 
Cath. vers. : 1.2 e 
Baxter 
Both lubricated 
Floseal easily extruded with Baxter’s 
Corrective 
Actions taken 
Evaluation of problems encountered in previous tests with bad stored product and search 
for solutions 
Rating balloon material 
Rating balloon / sheath coupling materials 
Check possibility of using lubricants 
Results of 
actions 
Further tests need to establish the causes of difficult extrusion 
Test  
Responsable  
 Signature 
 
Date: 
2-3/12/08 
Place: MicroTech Peccioli (Pi) 
 
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Elena Troia (MT) 
Catheter version 
N. Baxter Description:  N. tested cath. 
(same version): 1 
N.1.2 modificato Description: guidewire 0.75 fino in punta N. tested cath. 
(same version): 1 
N. 1.1 con 
guidewire saldato  
Description: welded guidewire,(two different 
diameters 0.75/0.55 mm on the tip) 
N. tested cath. 
(same version): 1 
N.1.1 D Description: see annex VI N. tested cath. 
(same version): 1 
Batch Floseal  n. HA080515 
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of the 
Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according to 
the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results and 
encountered 
problems  
Test n.: 
1 
Cath. vers. : 1.2 
modif. 
The catheter works enought properly 
Test n.: 
2 
Cath. vers. : 1.1 D the catheter doesn’t work properly 
Test n.: 
3 
Cath. vers. : Baxter the catheter works properly, good extrusion of Floseal 
Test n.: 
4 
Cath. vers. : 1.1 con  
guidewire  saldato 
the catheter works properly, good extrusion of Floseal 
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Corrective 
Actions taken 
Check the shape and diameter of the Guidewire 
Finding cause no extrudability 
Results of 
actions 
Welded Guidewire is preferred to the others; so a difference in diameter between the 
distal and proximal part of the Guidewireis needed , the Guidewire has to reach the 
distal end of the catheter 
Test  
Responsable  
 Signature 
 
Date: 
23/01/2009 
Place: MicroTech Peccioli (Pi) 
 
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Elena Troia (MT) 
Catheter version 
N. 1.4 Description:  N. tested cath. 
(same version): 1 
Catheter version 
N. 1.5 Description:  N. tested cath. 
(same version): 1 
Catheter version 
N. Baxter Description:  N. tested cath. 
(same version): 1 
Batch Floseal  n.  
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of the 
Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according to 
the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results and 
encountered 
problems  
Test n.: 
1 
Cath. vers. : 
1.4 
The catheter works enought properly, extrusion of Floseal 
Test n. 2 
Cath. vers. : 
1.5 
The catheter works enought properly, extrusion of Floseal 
but previous version is better 
Test n. 3 
Cath. vers. : 
Baxter 
the catheter doesn’t work properly, difficoult but possible 
extrusion  
Corrective 
Actions taken 
Check Floseal batch Preservation 
Check possibility of using lubricants 
Finding cause no extrudability 
Manufacturing of tips with strict tolerances to avoid excessive lateral leakage of the drug 
Results of 
actions 
The Floseal was actually stored at improper temperature 
Realization sets of tips to be glued to existing catheters (version 1.1) 
Planning further tests 
Test  
Responsable  
 Signature 
Date: 
6/5/09 
Place: centro sperimentazione endoscopica Ospedale Gemelli, Roma  
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Elena Troia (MT) 
Doc. Gianluca Spera 
Laura Caliari (Baxter) 
Catheter version 
N. 1.4 Description:  N. tested cath. 
(same version): 1 
Catheter version 
N.1.5 with teflon 
sheath 
Description:  N. tested cath. 
(same version): 1 
Batch Floseal 
used 
n. HA090407 
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Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of the 
Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 2 cc of Floseal according to 
the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results and 
encountered 
problems  
Test n.: 1 Cath. vers. : 1.4 
The catheter works enought properly, extrusion of 
Floseal 
Test n. 2 
Cath. vers. : 1.5 
modif. 
The catheter doesn’t work 
Corrective 
Actions taken 
Verify catheter tip shape and diameter 
Check sheath material 
Administration of 1cc max 
Results of 
actions 
Leakage almost canceled due to the reduction of the gap between the catheter and 
sheath. 
The sheath material impacts on the operation less than the gap 
Test  
Responsable  
 Signature 
 
SUMMARY PROGRESS N. 1 
It is sometimes difficult to understand how the Floseal extrude properly or it blocks. Possible 
causes are considered to be (in order of importance): 
Cause Degree of concern 
(1-small, 5-extremely difficult) 
1. Storage temperature of Floseal 5 
2.dosage of Floseal 5 
3. shape of the tip 3 
4.dimensions of guide wire 2 
5. material of the oversheath 5 
6. gap between catheter and oversheath 5 
 
Summary of possible solutions 
 
Solution Difficulty of solution 
(1-easy, 5-hard) 
Probable effect 
Require the proper conservation 3, it is not only a problem in 
Baxter but also in hospitals 
Probably decisive 
Reduce the dosage 3, it depends on the surgeons’ 
opinion  
Decisive 
Reduce the gap between the tip 
and catheter 
4 It can help 
Hardening of the guide wire 1 It can help 
Use of lubricants 1 It can help, but it would be difficult to 
prove the complete compatibility with 
the materials used and in particular 
with the Floseal 
Material change (use of Teflon) 5 (ENKI doesn’t use Teflon) Probably decisive 
 
Undertaken decisions: 
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 implementation of miniseries (2.0) with steel tip and sleeve micro-striped  
 solicitation to Baxter on the verification of the conditions of conservation of Floseal 
 request to the clinicians in touch with Baxter on the possibility of extruding a 
quantity of less than 2 CC of Floseal per time. 
NOTE: REQUEST No 3 ACCEPTED, CC introduced a time: 0.5. 
 
Date: 
22/06/2008 
Place: MicroTech, Peccioli 
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Elena Troia (MT) 
Catheter version 
N. 2.0 Description N. tested cath. (same version): 
1 
N. 3.0 Description:  N. tested cath. (same version): 
1 
Batch Floseal  n. HA081010 
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of the 
Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 1cc of Floseal according to 
the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results and 
encountered 
problems  
Test n.: 1 Cath. vers. :  2.0 e 3.0 
The catheters work properly; the 2.0 works 
perfectly well without guidewire  
Test n.: 2 Cath. vers. : 2.0 e 3.0 The catheters work properly 
Corrective 
Actions taken 
Verify new prototyping 
Check old and new prototype with taper guide wire and new dosage of Floseal 
Results of 
actions 
Verification of catheters to be subjected to medical personnel 
Test  
Responsable  
 Signature 
 
Date: 
13/07/2008 
Place: centro sperimentazione endoscopica Ospedale Gemelli, Rome 
People involved 
in the test 
session 
Bernardo Magnani (MT) 
Elena Troia (MT) 
Prof. Claudio Costamagna (Università Cattolica del Sacro Cuore Roma) 
Doc. Gianluca Spera (Università Cattolica del Sacro Cuore - Roma) 
Doc. Rita Conigliaro (Nuovo Ospedale S. Agostino Estense - Modena) 
Laura Caliari (Baxter) 
Paolo Passi (Baxter) 
Catheter version 
N. 3.0 Description:  N. tested cath. 
(same version): 3 
Batch Floseal  n.  
Test Procedure 
Step 1: Block the catheter on the  table making an "S”, medium radius of curvature of the 
Beam 30 cm 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 0.5 cc of Floseal according to 
the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
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Test results and 
problems 
encountered 
Test n.: 1 
Cath. vers. : 
3.0 
the catheter is working properly; the oversheath needs to 
be shortened of 10mm and cutted at the distal end to 
facilitate the insertion hemostatic valve 
Test n.: 2 
Cath. vers. : 
3.0 
the catheter works properly 
Test n.: 3   
Corrective 
Actions taken 
CE labelling starts 
Manufacturing of version for the entire GI tract (lenght 2.4m) 
Results of 
actions 
Under development 
Test  
Responsable  
 Signature 
 
Date: 
20/10/2009 
Place: EETC (European Endoscopy Training Centre) dell’Università Cattolica del Sacro 
Cuore, Rome 
People involved 
in the test 
session 
Doc. Gianluca Spera (Università Cattolica del Sacro Cuore - Rome) 
Catheter version 
N. 4.0 Description:  N. tested cath. 
(same version): 2 
Batch Floseal  n.  
Test Procedure 
Step 1: Block the catheter on an  Erlangen model of a suine stomach 
Step 2: Preparation of Floseal according to IFU 
Step 3: Assemble the hemostatic valve and introduction of 0.5 cc of Floseal according 
to the catheter IFU  
Step 4: Expulsion of Floseal 
Step 5: Repeat steps 3 and 4 to 2 times 
Test results and 
problems 
encountered 
Test n.: 1 
Cath. vers. : 
4.0 
The catheter work properly 
Test n.: 2 
Cath. vers. : 
4.0 
the catheter works properly 
Test n.: 3  the catheter works properly 
Corrective 
Actions taken 
 
Results of 
actions 
Device ready for the market 
Test  
Responsable  
Spera  Signature 
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19 Annex X 
ETO Sterization process parameters 
Preconditioning period    14 h min 
Preconditioning temparature   45°C +/- 5°C 
Preconditioning relative umidity   45% +/- 5 % 
Initial vacuum (-950 +/- 20mbar)  
  
-722 +/- 15 mmHg 
 
Steam immission     23 mmHg (30 mbar) 
Steam stabilization time    20 min 
Humidity in sterilization chamber  45% +/- 5 % 
Sterilization temperature   45°C +/- 5°C 
EtO mixture concentration   (15% EtO + 
85% CO2) 
 235 mg/Lt 
Sterilization initial pressure  
(-20 +/- 13mbar) 
 
-15 +/- 10 mmHg 
Sterilization time    18h 
Washings pressure (-800 +/- 26mbar) 
  
-608 +/- 20 mmHg 
Number of washing cycles    5 
 
